


**CUMULATIVE
SUPPLEMENT 5
May 2023**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2023

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

**Cumulative Supplement 5
May 2023**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
DRUG PRODUCT LISTS		
	Prescription Drug Product List.....	1-1
	OTC Drug Product List.....	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List.....	3-1
	Orphan Products Designations and Approvals List.....	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution.....	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists.....	A-1
B.	Patent and Exclusivity Terms.....	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

**CUMULATIVE SUPPLEMENT 5
MAY 2023**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ALEOR DERMACEUTICALS LTD (ALEOR DERMACEUTICALS)	ALEMBIC PHARMACEUTICALS LTD (ALEMBIC)
ALLERGAN (ALLERGAN)	ABBVIE INC (ABBVIE)
ALLERGAN HOLDINGS UNLTD CO (ALLERGAN HOLDINGS)	ABBVIE INC (ABBVIE)
ALLERGAN INC (ALLERGAN)	ABBVIE INC (ABBVIE)
ALLERGAN SALES LLC (ALLERGAN)	ABBIE (ABBVIE)

ALLERGAN SALES LLC (ALLERGAN)	ABBVIE INC (ABBVIE)
EMCURE PHARMACEUTICALS LTD (EMCURE PHARMS)	AVET LIFESCIENCES LTD (AVET LIFESCIENCES)
EMCURE PHARMACEUTICALS LTD (EMCURE PHARMS LTD)	AVET LIFESCIENCES LTD (AVET LIFESCIENCES)
EPIC PHARMA INC (EPIC PHARMA)	EPIC PHARMA LLC (EPIC PHARMA LLC)
EPIC PHARMA INC (EPIC PHARMA INC)	EPIC PHARMA LLC (EPIC PHARMA LLC)
HERITAGE PHARMA LABS INC (HERITAGE PHARMA)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
HERITAGE PHARMA LABS INC DBA AVET PHARMACEUTICALS LABS INC (HERITAGE PHARMA AVET)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
MAYNE PHARMA INC (MAYNE PHARMA INC)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA INTERNATIONAL PTY LTD (MAYNE PHARMA)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA INTERNATIONAL PTY LTD (MAYNE PHARMA INTL)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA LLC (MAYNE PHARMA)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent

² Please consult the Active Section of the Orange Book for information on other strengths.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2022</u>	<u>MAR</u> <u>2023</u>	<u>JUN</u> <u>2023</u>	<u>SEP</u> <u>2023</u>	<u>DEC</u> <u>2024</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	21983	22398			
	2718 (12.4%)	2759 (12.3%)			
MULTISOURCE	19265 (87.6%)	19639 (87.7%)			
THERAPEUTICALLY EQUIVALENT	19165 (87.2%)	19554 (87.3%)			
NOT THERAPEUTICALLY EQUIVALENT	100 (0.5%)	85 (0.4%)			
EXCEPTIONS ⁴	46 (0.2%)	46 (0.2%)			
NEW MOLECULAR ENTITIES APPROVED	8	19			
NUMBER OF APPLICANTS	1211	1222			

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABIRATERONE ACETATE

TABLET; ORAL		ABIRATERONE ACETATE					
AB	FLORIDA	500MG		A215086	001	Mar 23, 2023	Mar NEWA
AB	TEVA PHARMS USA	500MG		A210726	001	Jan 26, 2023	Jan NEWA

ACARBOSE

TABLET; ORAL		ACARBOSE					
	@ DASH PHARMS	25MG		A091053	001	Jan 06, 2011	Feb CAHN
	@	50MG		A091053	002	Jan 06, 2011	Feb CAHN
	@	100MG		A091053	003	Jan 06, 2011	Feb CAHN

ACETAMINOPHEN

SOLUTION; INTRAVENOUS		ACETAMINOPHEN					
AP	HQ SPCLT PHARMA	1GM/100ML (10MG/ML)		A215403	001	May 03, 2023	Apr NEWA
AP	WOCKHARDT BIO AG	1GM/100ML (10MG/ML)		A205746	001	Apr 18, 2023	Apr NEWA
	@ ZYDUS PHARMS	1GM/100ML (10MG/ML)		A216467	001	Oct 25, 2022	Mar DISC

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET; ORAL		APADAZ					
	+ @ KVK TECH INC	325MG;EQ 4.08MG BASE		N208653	002	Jan 04, 2019	Mar DISC
	+ @	325MG;EQ 6.12MG BASE		N208653	001	Feb 23, 2018	Mar DISC
	+ @	325MG;EQ 8.16MG BASE		N208653	003	Jan 04, 2019	Mar DISC

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL		BUTALBITAL AND ACETAMINOPHEN					
AA	SENORES PHARMS	300MG;50MG		A214088	001	Apr 07, 2022	Jan CAHN
AA		325MG;25MG		A214088	002	Apr 07, 2022	Jan CAHN
AA		325MG;50MG		A214088	003	Apr 07, 2022	Jan CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL		ACETAMINOPHEN AND CODEINE PHOSPHATE					
	@ NOSTRUM LABS INC	300MG;15MG		A088629	002	Mar 06, 1985	Apr DISC
	@	300MG;30MG		A088629	003	Mar 06, 1985	Apr DISC
	+ @	300MG;60MG		A088629	001	Mar 06, 1985	Apr DISC

ACETAMINOPHEN; IBUPROFEN

TABLET; ORAL		COMBOGESIC					
	+! AFT PHARMS LTD	325MG;97.5MG		N209471	001	Mar 01, 2023	Mar NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL		OXYCODONE AND ACETAMINOPHEN					
	@ DR REDDYS LABS SA	325MG;2.5MG		A090177	001	Oct 20, 2008	Apr CAHN
	@	325MG;5MG		A090177	002	Oct 20, 2008	Apr CAHN
	@	325MG;7.5MG		A090177	003	Oct 20, 2008	Apr CAHN
	@	325MG;10MG		A090177	004	Oct 20, 2008	Apr CAHN
	@	500MG;7.5MG		A090177	005	Oct 20, 2008	Apr CAHN
	@	650MG;10MG		A090177	006	Oct 20, 2008	Apr CAHN
	@ MAYNE PHARMA INC	325MG;2.5MG		A090177	001	Oct 20, 2008	Apr DISC
	@	325MG;5MG		A090177	002	Oct 20, 2008	Apr DISC
	@	325MG;7.5MG		A090177	003	Oct 20, 2008	Apr DISC
	@	325MG;10MG		A090177	004	Oct 20, 2008	Apr DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL		TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN					
AB	! AMNEAL PHARMS	325MG;37.5MG		A090485	001	Dec 09, 2009	Mar CHRS
	ULTRACET						
	+ @ JANSSEN PHARMS	325MG;37.5MG		N021123	001	Aug 15, 2001	Mar DISC

ACETAZOLAMIDE

	CAPSULE, EXTENDED RELEASE;ORAL						
	ACETAZOLAMIDE						
AB	INDICUS PHARMA	500MG	A090779	001	Jul 14, 2011	Feb	CMFD
	TABLET;ORAL						
	ACETAZOLAMIDE						
AB	AARKISH PHARMS NJ	125MG	A217197	001	May 09, 2023	Apr	NEWA
AB		250MG	A217197	002	May 09, 2023	Apr	NEWA
	@ BRECKENRIDGE	125MG	A207503	001	Apr 30, 2020	Jan	DISC
	@	250MG	A207503	002	Apr 30, 2020	Jan	DISC
AB	ZYDUS	125MG	A211069	001	Apr 04, 2023	Mar	NEWA
AB		250MG	A211069	002	Apr 04, 2023	Mar	NEWA

ACETIC ACID, GLACIAL

	SOLUTION/DROPS;OTIC						
	ACETIC ACID						
	@ CHARTWELL RX	2%	A040166	001	Jul 26, 1996	Jan	CAHN

ACETYLCYSTEINE

	INJECTABLE;INTRAVENOUS						
	ACETYLCYSTEINE						
AP	STERISCIENCE	6GM/30ML (200MG/ML)	A217182	001	Apr 19, 2023	Apr	NEWA

ACYCLOVIR

	CAPSULE;ORAL						
	ACYCLOVIR						
>A>	@ AUROBINDO PHARMA USA	200MG	A074727	001	Apr 22, 1997	May	CAHN
>D>	@ MYLAN	200MG	A074727	001	Apr 22, 1997	May	CAHN
	CREAM;TOPICAL						
	ACYCLOVIR						
AB	ZYDUS LIFESCIENCES	5%	A206770	001	Feb 28, 2023	Feb	NEWA
	SUSPENSION;ORAL						
	ACYCLOVIR						
AB	MSN	200MG/5ML	A217393	001	Mar 09, 2023	Mar	NEWA
>D>	AB	NOVITIUM PHARMA	A212252	001	Jul 10, 2020	May	CHRS
>A>	AB	!	A212252	001	Jul 10, 2020	May	CHRS
>D>		ZOVIRAX					
>D>	AB	+!	N019909	001	Dec 22, 1989	May	DISC
>A>		+ @	N019909	001	Dec 22, 1989	May	DISC
	TABLET;ORAL						
	ACYCLOVIR						
	@ AUROBINDO PHARMA USA	400MG	A075211	001	Sep 28, 1998	Apr	CAHN
	@	800MG	A075211	002	Sep 28, 1998	Apr	CAHN

ADAPALENE

	GEL;TOPICAL						
	ADAPALENE						
AB	ENCUBE ETHICALS	0.3%	A200298	001	Jun 14, 2012	Apr	CMFD

ALBENDAZOLE

	TABLET;ORAL						
	ALBENDAZOLE						
>A>	@ CHARTWELL RX	200MG	A211636	001	Jun 10, 2020	May	CAHN
>D>	@ LUPIN LTD	200MG	A211636	001	Jun 10, 2020	May	CAHN

ALBUTEROL SULFATE

	TABLET;ORAL						
	ALBUTEROL SULFATE						
AB	DASH PHARMS NATCO	EQ 2MG BASE	A072894	002	Jan 17, 1991	Feb	CAHN
AB	!	EQ 4MG BASE	A072894	001	Jan 17, 1991	Feb	CAHN

ALBUTEROL SULFATE; BUDESONIDE

	AEROSOL, METERED;INHALATION						
	AIRSUPRA						
	+!	ASTRAZENECA	N214070	001	Jan 10, 2023	Feb	CAHN
	+!	BOND	N214070	001	Jan 10, 2023	Jan	NEWA

ALENDRONATE SODIUMSOLUTION;ORAL
ALENDRONATE SODIUM

>D>	!	HIKMA	EQ 70MG BASE/75ML	A 090520	001	Feb 25, 2013	May CTEC
>A>	AA	!	EQ 70MG BASE/75ML	A 090520	001	Feb 25, 2013	May CTEC
>A>	AA	NOVITIUM PHARMA	EQ 70MG BASE/75ML	A 214512	001	May 11, 2023	May NEWA

ALVIMOPANCAPSULE;ORAL
ALVIMOPAN

AB		PAR PHARM	12MG	A 216843	001	Jan 24, 2023	Jan NEWA
----	--	-----------	------	----------	-----	--------------	----------

AMANTADINE HYDROCHLORIDECAPSULE;ORAL
AMANTADINE HYDROCHLORIDE

AB		STRIDES PHARMA	100MG	A 209047	001	Jun 07, 2017	Feb CTEC
----	--	----------------	-------	----------	-----	--------------	----------

TABLET;ORAL
AMANTADINE HYDROCHLORIDE

AB		STRIDES PHARMA	100MG	A 209035	001	Jun 09, 2017	Feb CTEC
----	--	----------------	-------	----------	-----	--------------	----------

AMIKACIN SULFATEINJECTABLE;INJECTION
AMIKACIN SULFATE

@	FRESENIUS KABI USA	EQ 50MG BASE/ML	A 205605	001	Dec 09, 2015	Feb DISC
!	HIKMA	EQ 50MG BASE/ML	A 063313	001	Apr 11, 1994	Feb CTEC

AMINO ACIDSINJECTABLE;INJECTION
FREAMINE HBC 6.9%

@	B BRAUN	6.9% (6.9GM/100ML)	N 016822	006	May 17, 1983	Jan DISC
---	---------	--------------------	----------	-----	--------------	----------

FREAMINE III 10%

@	B BRAUN	10% (10GM/100ML)	N 016822	005		Jan DISC
---	---------	------------------	----------	-----	--	----------

FREAMINE III 8.5%

@	B BRAUN	8.5% (8.5GM/100ML)	N 016822	004		Jan DISC
---	---------	--------------------	----------	-----	--	----------

HEPATAMINE 8%

@	B BRAUN	8% (8GM/100ML)	N 018676	001	Aug 03, 1982	Jan DISC
---	---------	----------------	----------	-----	--------------	----------

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDEINJECTABLE;INJECTION
PROCALAMINE

@	B BRAUN	3%;26MG/100ML;3GM/100ML;54MG/100ML ;41MG/100ML;150MG/100ML;200MG/100M L;120MG/100ML	N 018582	001	May 08, 1982	Jan DISC
---	---------	---	----------	-----	--------------	----------

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE;INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES

@	B BRAUN	8.5%;110MG/100ML;230MG/100ML;10MG/ 100ML;440MG/100ML;690MG/100ML	N 016822	007	Jul 01, 1988	Jan DISC
---	---------	---	----------	-----	--------------	----------

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

FREAMINE III 3% W/ ELECTROLYTES

@	B BRAUN	3%;54MG/100ML;40MG/100ML;150MG/100 ML;200MG/100ML;120MG/100ML	N 016822	003		Jan DISC
---	---------	--	----------	-----	--	----------

AMINOCAPROIC ACIDSOLUTION;ORAL
AMINOCAPROIC ACID

>A>	AA	TARO	0.25GM/ML	A 214458	001	Mar 24, 2023	May CAHN
>D>	AA	TARO PHARMS	0.25GM/ML	A 214458	001	Mar 24, 2023	May CAHN
	AA		0.25GM/ML	A 214458	001	Mar 24, 2023	Mar NEWA
		@ VISTAPHARM	0.25GM/ML	A 212814	001	Feb 26, 2020	Mar DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

>A>	AB	GRAVITI PHARMS	10MG	A217411	001	May 19, 2023	May	NEWA
>A>	AB		25MG	A217411	002	May 19, 2023	May	NEWA
>A>	AB		50MG	A217411	003	May 19, 2023	May	NEWA
>A>	AB		75MG	A217411	004	May 19, 2023	May	NEWA
>A>	AB		100MG	A217411	005	May 19, 2023	May	NEWA
>A>	AB		150MG	A217411	006	May 19, 2023	May	NEWA
	AB	RUBICON	10MG	A215376	001	May 01, 2023	Apr	NEWA
	AB		25MG	A215376	002	May 01, 2023	Apr	NEWA
	AB		50MG	A215376	003	May 01, 2023	Apr	NEWA
	AB		75MG	A215376	004	May 01, 2023	Apr	NEWA
	AB		100MG	A215376	005	May 01, 2023	Apr	NEWA
	AB		150MG	A215376	006	May 01, 2023	Apr	NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

LIMBITROL

+	@	CHARTWELL RX	EQ 12.5MG BASE;5MG	N016949	001		Mar	CAHN
		LIMBITROL DS						
+	@	CHARTWELL RX	EQ 25MG BASE;10MG	N016949	002		Mar	CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

	AB	COREPHARMA	EQ 2.5MG BASE	A076719	001	May 23, 2007	Feb	CAHN
	AB		EQ 5MG BASE	A076719	002	May 23, 2007	Feb	CAHN
	AB		EQ 10MG BASE	A076719	003	May 23, 2007	Feb	CAHN

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

>D>	AP	@ ESSENTIAL ISOTOPES	3.75mCi-260mCi/ML	A205687	001	Dec 17, 2015	Apr	DISC
		SOFIE	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	May	DISC
>A>		@	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	May	DISC
		@ WISCONSIN	3.75mCi-260mCi/ML	A204356	001	Dec 18, 2014	Feb	DISC

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

	@	CHARTWELL RX	125MG/5ML	A062059	001		Jan	CAHN
	@		250MG/5ML	A062059	002		Jan	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

	AB	ANI PHARMS	2.5MG; 2.5MG; 2.5MG; 2.5MG	A205401	002	Jan 22, 2019	Feb	CMFD
	AB	ASCENT PHARMS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A214959	001	Sep 29, 2021	Feb	CTNA
	AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A214959	002	Sep 29, 2021	Feb	CTNA
	AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A214959	003	Sep 29, 2021	Feb	CTNA
	AB		5MG; 5MG; 5MG; 5MG	A214959	004	Sep 29, 2021	Feb	CTNA
	AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A214959	005	Sep 29, 2021	Feb	CTNA
	AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A214959	006	Sep 29, 2021	Feb	CTNA
	AB	GRANULES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A217027	001	Jan 23, 2023	Feb	CTNA
	AB		1.25MG; 1.25MG; 1.25MG; 1.25MG	A217027	001	Jan 23, 2023	Jan	NEWA
	AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A217027	002	Jan 23, 2023	Feb	CTNA
	AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A217027	002	Jan 23, 2023	Jan	NEWA
	AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A217027	003	Jan 23, 2023	Feb	CTNA
	AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A217027	003	Jan 23, 2023	Jan	NEWA
	AB		5MG; 5MG; 5MG; 5MG	A217027	004	Jan 23, 2023	Feb	CTNA
	AB		5MG; 5MG; 5MG; 5MG	A217027	004	Jan 23, 2023	Jan	NEWA
	AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A217027	005	Jan 23, 2023	Feb	CTNA
	AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A217027	005	Jan 23, 2023	Jan	NEWA
	AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A217027	006	Jan 23, 2023	Jan	NEWA
	AB	LANNETT CO INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A214403	001	Nov 26, 2021	Feb	CMFD
	@		1.25MG; 1.25MG; 1.25MG; 1.25MG	A214403	001	Nov 26, 2021	Feb	CTNA
	AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A214403	002	Nov 26, 2021	Feb	CMFD
	@		2.5MG; 2.5MG; 2.5MG; 2.5MG	A214403	002	Nov 26, 2021	Feb	CTNA
	AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A214403	003	Nov 26, 2021	Feb	CMFD

CAPSULE, EXTENDED RELEASE;ORAL

		DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE				
	@	3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	Feb CTNA
AB		5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	Feb CMFD
	@	5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	Feb CMFD
	@	6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	Feb CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	Feb CMFD
	@	7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	Feb CTNA

TABLET;ORAL

		DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE				
AB	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A215565	001	Jul 08, 2022	Feb CMFD
AB		1.875MG;1.875MG;1.875MG;1.875MG	A215565	002	Jul 08, 2022	Feb CMFD
AB		2.5MG;2.5MG;2.5MG;2.5MG	A215565	003	Jul 08, 2022	Feb CMFD
AB		3.125MG;3.125MG;3.125MG;3.125MG	A215565	004	Jul 08, 2022	Feb CMFD
AB		3.75MG;3.75MG;3.75MG;3.75MG	A215565	005	Jul 08, 2022	Feb CMFD
AB		5MG;5MG;5MG;5MG	A215565	006	Jul 08, 2022	Feb CMFD
AB		7.5MG;7.5MG;7.5MG;7.5MG	A215565	007	Jul 08, 2022	Feb CMFD

AMPICILLIN SODIUM

		INJECTABLE;INJECTION				
		AMPICILLIN SODIUM				
	@	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Jan CAHN
	@	EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Jan CAHN
AP		EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Jan CAHN
AP		EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Jan CAHN
AP		EQ 10GM BASE/VIAL	A202198	001	Apr 07, 2014	Jan CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

		INJECTABLE;INJECTION				
		AMPICILLIN AND SULBACTAM				
AP	STERISCIENCE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A201024	001	Apr 07, 2014	Jan CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A201024	002	Apr 07, 2014	Jan CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A202197	001	Apr 07, 2014	Jan CAHN

APALUTAMIDE

		TABLET;ORAL				
		ERLEADA				
	+ JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Feb CHRS
	+!	240MG	N210951	002	Feb 17, 2023	Feb NEWA

APIXABAN

		TABLET;ORAL				
		APIXABAN				
>A>	AB AUROBINDO PHARMA LTD	2.5MG	A210026	001	May 26, 2023	May NEWA
>A>	AB	5MG	A210026	002	May 26, 2023	May NEWA
	AB ZYDUS PHARMS	2.5MG	A210185	001	Feb 27, 2023	Feb NEWA
	AB	5MG	A210185	002	Feb 27, 2023	Feb NEWA

APRACLONIDINE HYDROCHLORIDE

		SOLUTION/DROPS;OPHTHALMIC				
		IOPIDINE				
>A>	AT +! HARROW EYE	EQ 0.5% BASE	N020258	001	Jul 30, 1993	May CAHN
>A>	AT +!	EQ 1% BASE	N019779	001	Dec 31, 1987	May CAHN
>D>	AT +! IMPRIMIS PHARMS USA	EQ 0.5% BASE	N020258	001	Jul 30, 1993	May CAHN
>D>	AT +!	EQ 1% BASE	N019779	001	Dec 31, 1987	May CAHN

APREMILAST

		TABLET;ORAL				
		APREMILAST				
AB	SHILPA	10MG	A211774	001	Apr 07, 2023	Mar NEWA
AB		20MG	A211774	002	Apr 07, 2023	Mar NEWA
AB		30MG	A211774	003	Apr 07, 2023	Mar NEWA
	@ TEVA PHARMS USA INC	10MG	A211897	001	Aug 18, 2022	Feb DISC
	@	20MG	A211897	002	Aug 18, 2022	Feb DISC
	@	30MG	A211897	003	Aug 18, 2022	Feb DISC

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION
 ARFORMOTEROL TARTRATE
 AN RITEDOSE CORP EQ 0.015MG BASE/2ML A214736 001 Mar 02, 2022 Feb CMFD

ARGATROBAN

INJECTABLE; INJECTION
 ARGATROBAN
 >D> AP +! NOVARTIS 250MG/2.5ML (100MG/ML) N020883 001 Jun 30, 2000 May CAHN
 >A> AP +! SANDOZ 250MG/2.5ML (100MG/ML) N020883 001 Jun 30, 2000 May CAHN

ARIPIPRAZOLE

SOLUTION; ORAL
 ARIPIPRAZOLE
 >A> AA CHARTWELL RX 1MG/ML A215595 001 Oct 25, 2022 May CAHN
 >D> AA GLASSHOUSE PHARMS 1MG/ML A215595 001 Oct 25, 2022 May CAHN
 SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
 ABILIFY ASIMTUFI
 + OTSUKA 720MG/2.4ML (300MG/ML) N217006 001 Apr 27, 2023 Apr NEWA
 +! 960MG/3.2ML (300MG/ML) N217006 002 Apr 27, 2023 Apr NEWA

ARMODAFINIL

TABLET; ORAL
 ARMODAFINIL
 @ COREPHARMA 50MG A201514 001 Mar 25, 2019 Feb CAHN
 @ 150MG A201514 002 Mar 25, 2019 Feb CAHN
 @ 250MG A201514 003 Mar 25, 2019 Feb CAHN

ARSENIC TRIOXIDE

INJECTABLE; INJECTION
 ARSENIC TRIOXIDE
 AP ORBICULAR 1MG/ML A217413 001 Apr 20, 2023 Apr NEWA
 AP 2MG/ML A217413 002 Apr 20, 2023 Apr NEWA
 >A> AP PENN LIFE 1MG/ML A209873 001 May 06, 2019 May CAHN
 >D> AP STI PHARMA LLC 1MG/ML A209873 001 May 06, 2019 May CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
 @ DR REDDYS LABS SA 325MG; 50MG; 40MG; 30MG A203335 001 Oct 30, 2015 Apr CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL
 CARISOPRODOL AND ASPIRIN
 @ CHARTWELL RX 325MG; 200MG A089594 001 Mar 31, 1989 Mar CAHN

ASPIRIN; METHOCARBAMOL

TABLET; ORAL
 ROBAXISAL
 + @ ROBINS AH 325MG; 400MG N012281 001 Mar CRLD

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL
 OXYCODONE AND ASPIRIN
 @ DR REDDYS LABS SA 325MG; 4.8355MG A091670 001 Mar 16, 2011 Apr CAHN

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL
 ATENOLOL AND CHLORTHALIDONE
 @ AUROBINDO PHARMA USA 50MG; 25MG A074203 001 Oct 31, 1993 Apr CAHN
 @ 100MG; 25MG A074203 002 Oct 31, 1993 Apr CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL
 ATOMOXETINE HYDROCHLORIDE
 AB ZYDUS PHARMS USA INC 10MG A079017 007 Apr 05, 2023 Mar NEWA

ATORVASTATIN CALCIUM

SUSPENSION;ORAL

ATORVALIQ

+! CMP DEV LLC 20MG/5ML N213260 001 Feb 01, 2023 Feb NEWA

TABLET;ORAL

ATORVASTATIN CALCIUM

>D>	AB	BIOCON PHARMA	EQ 10MG BASE	A216436	001	Nov 23, 2022	May DISC
>A>		@	EQ 10MG BASE	A216436	001	Nov 23, 2022	May DISC
>D>	AB		EQ 20MG BASE	A216436	002	Nov 23, 2022	May DISC
>A>		@	EQ 20MG BASE	A216436	002	Nov 23, 2022	May DISC
>D>	AB		EQ 40MG BASE	A216436	003	Nov 23, 2022	May DISC
>A>		@	EQ 40MG BASE	A216436	003	Nov 23, 2022	May DISC
>D>	AB		EQ 80MG BASE	A216436	004	Nov 23, 2022	May DISC
>A>		@	EQ 80MG BASE	A216436	004	Nov 23, 2022	May DISC
		@ LEPU PHARM	EQ 10MG BASE	A216848	001	Nov 03, 2022	Apr DISC
		@	EQ 20MG BASE	A216848	002	Nov 03, 2022	Apr DISC
		@	EQ 40MG BASE	A216848	003	Nov 03, 2022	Apr DISC
		@	EQ 80MG BASE	A216848	004	Nov 03, 2022	Apr DISC

>D> ATROPINE

SOLUTION;INTRAMUSCULAR

>D>		ATROPEN					
>D>	+!	MMT	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004	May DISC
>A>	+ @		EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004	May DISC
>D>	+!		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003	May DISC
>A>	+ @		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003	May DISC
>D>	+!		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003	May DISC
>A>	+ @		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003	May DISC
>D>	+!		EQ 2MG SULFATE/0.7ML	N017106	001		May DISC
>A>	+ @		EQ 2MG SULFATE/0.7ML	N017106	001		May DISC

AZELAIC ACID

AEROSOL, FOAM;TOPICAL

FINACEA

+! LEO PHARMA AS 15% N207071 001 Jul 29, 2015 Feb CTEC

AZITHROMYCIN

TABLET;ORAL

AZITHROMYCIN

		@ ACI	EQ 250MG BASE	A215772	001	Jul 15, 2022	Jan DISC
		@	EQ 500MG BASE	A215773	001	Jul 12, 2022	Jan DISC
>A>		@ AUROBINDO PHARMA USA	EQ 600MG BASE	A065360	001	Jan 08, 2007	May CAHN
>D>		@ MYLAN	EQ 600MG BASE	A065360	001	Jan 08, 2007	May CAHN
AB		ZYDUS PHARMS	EQ 250MG BASE	A213275	001	Apr 11, 2023	Mar NEWA
AB			EQ 500MG BASE	A213056	001	Apr 07, 2023	Mar NEWA

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

		@ AKORN	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213	001	Jul 25, 2012	Jan DISC
	!	BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068	001	Oct 30, 1995	Jan CTEC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

		@ AKORN	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065088	001	Feb 06, 2004	Jan DISC
--	--	---------	--	---------	-----	--------------	----------

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

AP		RUBICON	0.5MG/ML	A217324	001	Feb 22, 2023	Feb NEWA
AP			1MG/ML	A217324	002	Feb 22, 2023	Feb NEWA
AP			2MG/ML	A217324	003	Feb 22, 2023	Feb NEWA

TABLET;ORAL

BACLOFEN

AB		UNICHEM	5MG	A212067	003	Mar 09, 2023	Mar NEWA
----	--	---------	-----	---------	-----	--------------	----------

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

@ DASH PHARMS NATCO

750MG

A 077807 001 Dec 28, 2007 Feb CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB COREPHARMA

5MG

A 077128 001 Mar 08, 2006 Mar CAHN

AB 10MG

A 077128 002 Mar 08, 2006 Mar CAHN

AB 20MG

A 077128 003 Mar 08, 2006 Mar CAHN

AB 40MG

A 077128 004 Mar 08, 2006 Mar CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D> @ APOTEX

5MG; 6.25MG

A 078794 001 Aug 21, 2014 May CMFD

>A> AB 5MG; 6.25MG

A 078794 001 Aug 21, 2014 May CMFD

>D> @ 10MG; 12.5MG

A 078794 002 Aug 21, 2014 May CMFD

>A> AB 10MG; 12.5MG

A 078794 002 Aug 21, 2014 May CMFD

>D> @ 20MG; 12.5MG

A 078794 003 Aug 21, 2014 May CMFD

>A> AB 20MG; 12.5MG

A 078794 003 Aug 21, 2014 May CMFD

>D> @ 20MG; 25MG

A 078794 004 Aug 21, 2014 May CMFD

>A> AB 20MG; 25MG

A 078794 004 Aug 21, 2014 May CMFD

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

>A> AP APOTEX

25MG/VIAL

A 204230 001 Jun 05, 2023 May NEWA

>A> AP 100MG/VIAL

A 204230 002 Jun 05, 2023 May NEWA

AP BRECKENRIDGE

25MG/VIAL

A 205447 001 Feb 14, 2023 Feb NEWA

AP 100MG/VIAL

A 205447 002 Feb 14, 2023 Feb NEWA

>A> AP EUGIA PHARMA

25MG/VIAL

A 214739 001 Jun 05, 2023 May NEWA

>A> AP 100MG/VIAL

A 214739 002 Jun 05, 2023 May NEWA

>A> AP KINDOS

25MG/VIAL

A 211001 001 Jun 05, 2023 May NEWA

>A> AP 100MG/VIAL

A 211001 002 Jun 05, 2023 May NEWA

>D> AP MYLAN LABS LTD

25MG/VIAL

A 204104 001 Apr 28, 2023 May DISC

>A> @ 25MG/VIAL

A 204104 001 Apr 28, 2023 May DISC

AP 25MG/VIAL

A 204104 001 Apr 28, 2023 Apr NEWA

>D> AP 100MG/VIAL

A 204104 002 Apr 28, 2023 May DISC

>A> @ 100MG/VIAL

A 204104 002 Apr 28, 2023 May DISC

AP 100MG/VIAL

A 204104 002 Apr 28, 2023 Apr NEWA

>A> AP NANG KUANG PHARM CO

25MG/VIAL

A 206554 001 Jun 07, 2023 May NEWA

>A> AP 100MG/VIAL

A 206554 002 Jun 07, 2023 May NEWA

SOLUTION; INTRAVENOUS

BENDAMUSTINE HYDROCHLORIDE

+ @ HOSPIRA 25MG/ML (25MG/ML)

N 211530 001 Dec 15, 2022 Jan DISC

+ @ 100MG/4ML (25MG/ML)

N 211530 002 Dec 15, 2022 Jan DISC

+ @ 200MG/8ML (25MG/ML)

N 211530 003 Dec 15, 2022 Jan DISC

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA CHARTWELL RX

100MG

A 040682 001 Jul 30, 2007 Feb CAHN

AA 200MG

A 040682 002 Jul 30, 2007 Feb CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZAFLIN

+ @ BAUSCH 5%;EQ 1% BASE

N 050756 001 Dec 21, 2000 Feb DISC

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB ! GLENMARK PHARMS 5%;EQ 1% BASE

A 209252 001 Mar 14, 2019 Feb CHRS

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPOTASTINE BESILATE

AT ALEMBIC

1.5%

A 214588 001 Apr 05, 2023 Mar NEWA

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

AB HIKMA 3MG/ML;EQ 3MG BASE/ML A077838 001 Jan 17, 2023 Jan NEWA

BETAMETHASONE DIPROPIONATE

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

>D> AB PAI HOLDINGS PHARM EQ 0.05% BASE A206389 001 Feb 13, 2018 May DISC

>A> @ EQ 0.05% BASE A206389 001 Feb 13, 2018 May DISC

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

>D> AB PAI HOLDINGS PHARM EQ 0.05% BASE A206118 001 Nov 09, 2017 May DISC

>A> @ EQ 0.05% BASE A206118 001 Nov 09, 2017 May DISC

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB GLENMARK PHARMS LTD 0.064%;0.005% A214688 001 Mar 21, 2023 Mar NFTG

ENSTILAR

AB +! LEO PHARMA AS 0.064%;0.005% N207589 001 Oct 16, 2015 Mar CFTG

OINTMENT; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

@ TOLMAR 0.064%;0.005%

A201615 001 Jan 14, 2013 Feb DISC

SUSPENSION; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB COSETTE 0.064%;0.005% A210765 001 May 11, 2020 Feb CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

>D> AB TARO EQ 0.05% BASE;1% A075673 001 May 29, 2001 May CHRS

>A> AB ! EQ 0.05% BASE;1% A075673 001 May 29, 2001 May CHRS

>D> LOTRISONE

>D> AB +! ORGANON EQ 0.05% BASE;1% N018827 001 Jul 10, 1984 May DISC

>A> + @ EQ 0.05% BASE;1% N018827 001 Jul 10, 1984 May DISC

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

BETAMETHASONE VALERATE

AB XIROMED 0.12% A210639 001 Apr 18, 2023 Apr NEWA

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

@ AKORN EQ 0.5% BASE

A075386 001 Jun 30, 2000 Feb DISC

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

>D> AA AIPING LIFE SCI 5MG A040728 002 Oct 26, 2007 May CAHN

>D> AA 10MG A040728 003 Oct 26, 2007 May CAHN

>D> AA 25MG A040728 004 Oct 26, 2007 May CAHN

>D> AA 50MG A040728 001 Oct 26, 2007 May CAHN

>A> AA CHARTWELL RX 5MG A040728 002 Oct 26, 2007 May CAHN

>A> AA 10MG A040728 003 Oct 26, 2007 May CAHN

>A> AA 25MG A040728 004 Oct 26, 2007 May CAHN

>A> AA 50MG A040728 001 Oct 26, 2007 May CAHN

BEXAGLIFLOZIN

TABLET; ORAL

BRENZAVVY

+! THERACOSBIO 20MG N214373 001 Jan 20, 2023 Jan NEWA

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB PINNACLE LIFE SCI 50MG A079089 001 Jul 06, 2009 Jan CAHN

BIMATOPROST

IMPLANT;OPHTHALMIC
DURYSTA

+! ABBVIE 10MCG N211911 001 Mar 04, 2020 Jan CAHN

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

AB PAR PHARM 140MG;125MG;125MG A205770 001 Mar 06, 2023 Feb NFTG
 PYLEERA
 AB +! ABBVIE 140MG;125MG;125MG N050786 001 Sep 28, 2006 Mar CAHN
 AB +! ALLERGAN 140MG;125MG;125MG N050786 001 Sep 28, 2006 Feb CFTG

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB ALEMBIC 5MG A204891 001 Jan 11, 2017 Feb CAHN
 AB 10MG A204891 002 Jan 11, 2017 Feb CAHN
 @ DASH PHARMS NATCO 5MG A075831 001 Dec 14, 2005 Feb CAHN
 @ 10MG A075831 002 Dec 14, 2005 Feb CAHN

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
BORTEZOMIB

@ ACCORD HLTHCARE 3.5MG/VIAL

A204405 001 Jul 26, 2022 Feb DISC

POWDER;INTRAVENOUS

BORTEZOMIB

>D> DR REDDYS 3.5MG/VIAL N206927 001 Oct 04, 2019 May DISC
 >A> @ 3.5MG/VIAL N206927 001 Oct 04, 2019 May DISC
 >D> FRESENIUS KABI USA 3.5MG/VIAL N205004 001 Nov 06, 2017 May DISC
 >A> @ 3.5MG/VIAL N205004 001 Nov 06, 2017 May DISC

SOLUTION;INTRAVENOUS

BORTEZOMIB

+ @ ACCORD HLTHCARE 2.5MG/ML (2.5MG/ML) N215441 001 Jul 26, 2022 Feb DISC
 + @ 3.5MG/1.4ML (2.5MG/ML) N215441 002 Jul 26, 2022 Feb DISC

BOSENTAN

TABLET;ORAL

BOSENTAN

@ PAR PHARM INC 62.5MG A205699 001 Apr 26, 2019 Apr DISC
 @ 125MG A205699 002 Apr 26, 2019 Apr DISC

BRETYLIUM TOSYLATE

INJECTABLE;INJECTION

BRETYLIUM TOSYLATE

@ BRECKENRIDGE 50MG/ML A204386 001 Dec 21, 2018 Feb DISC

BREXPIPIRAZOLE

TABLET;ORAL

BREXPIPIRAZOLE

AB AJANTA PHARMA LTD 0.25MG A213718 001 Feb 03, 2023 Jan NEWA
 AB 0.5MG A213718 002 Feb 03, 2023 Jan NEWA
 AB 1MG A213718 003 Feb 03, 2023 Jan NEWA
 AB 2MG A213718 004 Feb 03, 2023 Jan NEWA
 AB 3MG A213718 005 Feb 03, 2023 Jan NEWA
 AB 4MG A213718 006 Feb 03, 2023 Jan NEWA
 @ AMNEAL 0.25MG A213562 001 Jan 31, 2023 Mar DISC
 AB 0.25MG A213562 001 Jan 31, 2023 Jan NEWA
 @ 0.5MG A213562 002 Jan 31, 2023 Mar DISC
 AB 0.5MG A213562 002 Jan 31, 2023 Jan NEWA
 @ 1MG A213562 003 Jan 31, 2023 Mar DISC
 AB 1MG A213562 003 Jan 31, 2023 Jan NEWA
 @ 2MG A213562 004 Jan 31, 2023 Mar DISC
 AB 2MG A213562 004 Jan 31, 2023 Jan NEWA
 @ 3MG A213562 005 Jan 31, 2023 Mar DISC
 AB 3MG A213562 005 Jan 31, 2023 Jan NEWA
 @ 4MG A213562 006 Jan 31, 2023 Mar DISC
 AB 4MG A213562 006 Jan 31, 2023 Jan NEWA
 >D> AB LUPIN LTD 0.25MG A213512 001 Mar 17, 2023 May DISC
 >A> @ 0.25MG A213512 001 Mar 17, 2023 May DISC
 AB 0.25MG A213512 001 Mar 17, 2023 Mar NEWA

TABLET;ORAL

BREXPIPIRAZOLE

>D>	AB		0.5MG	A213512	002	Mar 17, 2023	May	DISC
>A>	@		0.5MG	A213512	002	Mar 17, 2023	May	DISC
	AB		0.5MG	A213512	002	Mar 17, 2023	Mar	NEWA
>D>	AB		1MG	A213512	003	Mar 17, 2023	May	DISC
>A>	@		1MG	A213512	003	Mar 17, 2023	May	DISC
	AB		1MG	A213512	003	Mar 17, 2023	Mar	NEWA
>D>	AB		2MG	A213512	004	Mar 17, 2023	May	DISC
>A>	@		2MG	A213512	004	Mar 17, 2023	May	DISC
	AB		2MG	A213512	004	Mar 17, 2023	Mar	NEWA
>D>	AB		3MG	A213512	005	Mar 17, 2023	May	DISC
>A>	@		3MG	A213512	005	Mar 17, 2023	May	DISC
	AB		3MG	A213512	005	Mar 17, 2023	Mar	NEWA
>D>	AB		4MG	A213512	006	Mar 17, 2023	May	DISC
>A>	@		4MG	A213512	006	Mar 17, 2023	May	DISC
	AB		4MG	A213512	006	Mar 17, 2023	Mar	NEWA
	@	TEVA PHARMS USA INC	0.25MG	A213692	001	Aug 11, 2022	Feb	DISC
	@		0.5MG	A213692	002	Aug 11, 2022	Feb	DISC
	@		1MG	A213692	003	Aug 11, 2022	Feb	DISC
	@		2MG	A213692	004	Aug 11, 2022	Feb	DISC
	@		3MG	A213692	005	Aug 11, 2022	Feb	DISC
	@		4MG	A213692	006	Aug 11, 2022	Feb	DISC

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

AT	ALEMBIC		0.15%	A215225	001	Mar 29, 2023	Mar	NEWA
----	---------	--	-------	---------	-----	--------------	-----	------

BRIVARACETAM

TABLET;ORAL

BRIVARACETAM

	@	AUROBINDO PHARMA LTD	50MG	A214848	001	Jan 06, 2023	Mar	DISC
	@		100MG	A214848	002	Jan 06, 2023	Mar	DISC
	@	LUPIN LTD	10MG	A214918	001	Dec 20, 2022	Mar	DISC
	@		25MG	A214918	002	Dec 20, 2022	Mar	DISC
	@		50MG	A214918	003	Dec 20, 2022	Mar	DISC
	@		75MG	A214918	004	Dec 20, 2022	Mar	DISC
	@		100MG	A214918	005	Dec 20, 2022	Mar	DISC

BRIVIACT

+		UCB INC	10MG	N205836	001	May 12, 2016	Mar	CTEC
+			25MG	N205836	002	May 12, 2016	Mar	CTEC
+			50MG	N205836	003	May 12, 2016	Mar	CTEC
+			75MG	N205836	004	May 12, 2016	Mar	CTEC
+	!		100MG	N205836	005	May 12, 2016	Mar	CTEC

BROMOCRIPTINE MESYLATE

TABLET;ORAL

BROMOCRIPTINE MESYLATE

	@	AUROBINDO PHARMA USA	EQ 2.5MG BASE	A076962	001	Sep 24, 2004	Apr	CAHN
--	---	----------------------	---------------	---------	-----	--------------	-----	------

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

	@	BRECKENRIDGE	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	Jan	DISC
--	---	--------------	---------------------------	---------	-----	--------------	-----	------

BUDESONIDE

AEROSOL, FOAM;RECTAL

BUDESONIDE

AB		PADAGIS ISRAEL	2MG/ACTUATION	A215328	001	Apr 12, 2023	Mar	NFTG
AB	+	SALIX	2MG/ACTUATION	N205613	001	Oct 07, 2014	Mar	CFTG

BUDESONIDE; FORMOTEROL FUMARATE

AEROSOL, METERED;INHALATION

SYMBICORT AEROSPHERE

+	!	ASTRAZENECA	0.16MG/INH;0.0048MG/INH	N216579	001	Apr 28, 2023	Apr	NEWA
---	---	-------------	-------------------------	---------	-----	--------------	-----	------

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL
BUPRENORPHINE

AB	ALVOGEN	7.5MCG/HR	A207490	005	Mar 21, 2023	Mar	NEWA
>A>	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS						
>A>	BRIXADI						
>A>	+	BRAEBURN	8MG/0.16ML (50MG/ML)	N210136	001	May 23, 2023	May NEWA
>A>	+		16MG/0.32ML (50MG/ML)	N210136	002	May 23, 2023	May NEWA
>A>	+		24MG/0.48ML (50MG/ML)	N210136	003	May 23, 2023	May NEWA
>A>	+		32MG/0.64ML (50MG/ML)	N210136	004	May 23, 2023	May NEWA
>A>	+		64MG/0.18ML (356MG/ML)	N210136	005	May 23, 2023	May NEWA
>A>	+		96MG/0.27ML (356MG/ML)	N210136	006	May 23, 2023	May NEWA
>A>	+	!	128MG/0.36ML (356MG/ML)	N210136	007	May 23, 2023	May NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE
@ DR REDDYS LABS SA EQ 2MG BASE;EQ 0.5MG BASE
@ EQ 8MG BASE;EQ 2MG BASE

A206953	001	Jul 17, 2020	Apr	CAHN
A206953	002	Jul 17, 2020	Apr	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

>A>	AB1	ANNORA PHARMA	100MG	A216800	001	May 31, 2023	May	NEWA
>A>	AB1		150MG	A216800	002	May 31, 2023	May	NEWA
>A>	AB1		200MG	A216800	003	May 31, 2023	May	NEWA

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL
BUSPIRONE HYDROCHLORIDE
@ GRAVITI PHARMS 5MG
@ 10MG
@ 15MG
AB ZYDUS PHARMS 7.5MG

A075413	001	Mar 19, 2002	Feb	CAHN
A075413	002	Mar 19, 2002	Feb	CAHN
A075413	003	Mar 19, 2002	Feb	CAHN
A078888	005	Mar 21, 2023	Mar	NEWA

BUSULFAN

INJECTABLE;INJECTION
BUSULFAN
@ AM REGENT 6MG/ML
@ ARTHUR GRP 6MG/ML

A202259	001	Dec 22, 2015	Jan	DISC
A205106	001	Sep 21, 2018	Mar	DISC

CABAZITAXEL

SOLUTION;INTRAVENOUS
CABAZITAXEL

+	!	ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021	Feb	CMFD
AP		APOTEX	60MG/1.5ML (40MG/ML)	A207736	001	Feb 10, 2023	Feb	NEWA
AP		DR REDDYS	60MG/1.5ML (40MG/ML)	A207718	001	Feb 10, 2023	Feb	NEWA
+	!	SANDOZ	45MG/4.5ML (10MG/ML)	N208715	001	Jan 05, 2023	Jan	NEWA
+	!		60MG/6ML (10MG/ML)	N208715	002	Jan 05, 2023	Jan	NEWA

CALCIPOTRIENE

CREAM;TOPICAL
CALCIPOTRIENE
@ TOLMAR 0.005%
SOLUTION;TOPICAL
CALCIPOTRIENE

AT	!	COSETTE	0.005%	A078468	001	Mar 24, 2011	Feb	CHRS
		@ TOLMAR	0.005%	A077029	001	Nov 20, 2009	Feb	DISC

CALCITRIOL

CAPSULE;ORAL
CALCITRIOL

>D>	AB	STRIDES PHARMA	0.5MCG	A091356	002	Dec 12, 2014	May	CHRS	
>A>	AB	!	0.5MCG	A091356	002	Dec 12, 2014	May	CHRS	
		ROCALTROL							
>D>	AB	+	VALIDUS PHARMS	0.5MCG	N018044	002		May	CHRS
>A>	AB	+		0.5MCG	N018044	002		May	CHRS

CALCIUM ACETATE

CAPSULE;ORAL
 CALCIUM ACETATE
 AB SQUARE PHARMS 667MG A217205 001 Mar 13, 2023 Mar NEWA

CANDESARTAN CILEXETIL

TABLET;ORAL
 CANDESARTAN CILEXETIL
 >A> AB ZYDUS LIFESCIENCES 4MG A091390 001 Aug 23, 2017 May CAHN
 >A> AB 8MG A091390 002 Aug 23, 2017 May CAHN
 >A> AB 16MG A091390 003 Aug 23, 2017 May CAHN
 >A> AB 32MG A091390 004 Aug 23, 2017 May CAHN
 >D> AB ZYDUS PHARMS 4MG A091390 001 Aug 23, 2017 May CAHN
 >D> AB 8MG A091390 002 Aug 23, 2017 May CAHN
 >D> AB 16MG A091390 003 Aug 23, 2017 May CAHN
 >D> AB 32MG A091390 004 Aug 23, 2017 May CAHN

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
 >A> AB ZYDUS LIFESCIENCES 16MG;12.5MG A203466 001 Nov 27, 2017 May CAHN
 >A> AB 32MG;12.5MG A203466 002 Nov 27, 2017 May CAHN
 >A> AB 32MG;25MG A203466 003 Nov 27, 2017 May CAHN
 >D> AB ZYDUS PHARMS 16MG;12.5MG A203466 001 Nov 27, 2017 May CAHN
 >D> AB 32MG;12.5MG A203466 002 Nov 27, 2017 May CAHN
 >D> AB 32MG;25MG A203466 003 Nov 27, 2017 May CAHN

CAPECITABINE

TABLET;ORAL
 XELODA
 AB + CHEPLAPHARM 150MG N020896 001 Apr 30, 1998 Apr CAHN
 AB +! 500MG N020896 002 Apr 30, 1998 Apr CAHN

CAPTOPRIL

TABLET;ORAL
 CAPTOPRIL
 >A> @ AUROBINDO PHARMA USA 12.5MG A074434 001 Feb 13, 1996 May CAHN
 >A> @ 25MG A074434 002 Feb 13, 1996 May CAHN
 >A> @ 50MG A074434 003 Feb 13, 1996 May CAHN
 >A> @ 100MG A074434 004 Feb 13, 1996 May CAHN
 AB CHANGZHOU PHARM 12.5MG A214442 001 Jan 27, 2023 Jan NEWA
 AB 25MG A214442 002 Jan 27, 2023 Jan NEWA
 AB 50MG A214442 003 Jan 27, 2023 Jan NEWA
 AB 100MG A214442 004 Jan 27, 2023 Jan NEWA
 AB COREPHARMA 12.5MG A074737 001 Oct 28, 1998 Mar CAHN
 AB 25MG A074737 002 Oct 28, 1998 Mar CAHN
 AB 50MG A074737 003 Oct 28, 1998 Mar CAHN
 AB 100MG A074737 004 Oct 28, 1998 Mar CAHN
 >D> @ MYLAN 12.5MG A074434 001 Feb 13, 1996 May CAHN
 >D> @ 25MG A074434 002 Feb 13, 1996 May CAHN
 >D> @ 50MG A074434 003 Feb 13, 1996 May CAHN
 >D> @ 100MG A074434 004 Feb 13, 1996 May CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE
 >D> @ RISING 25MG;15MG A074896 001 Dec 29, 1997 May CMFD
 >A> 25MG;15MG A074896 001 Dec 29, 1997 May CMFD
 >D> @ 25MG;25MG A074896 002 Dec 29, 1997 May CMFD
 >A> ! 25MG;25MG A074896 002 Dec 29, 1997 May CMFD
 >D> @ 50MG;15MG A074896 004 Dec 29, 1997 May CMFD
 >A> ! 50MG;15MG A074896 004 Dec 29, 1997 May CMFD
 >D> @ 50MG;25MG A074896 003 Dec 29, 1997 May CMFD
 >A> 50MG;25MG A074896 003 Dec 29, 1997 May CMFD

CARBAMAZEPINE

SUSPENSION;ORAL
 CARBAMAZEPINE
 AB CHARTWELL RX 100MG/5ML A075714 001 Jun 05, 2002 Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB	AJANTA PHARMA LTD	100MG	A216193	001	Mar 24, 2023	Mar	NEWA
AB		200MG	A216193	002	Mar 24, 2023	Mar	NEWA
AB		400MG	A216193	003	Mar 24, 2023	Mar	NEWA
AB	SCIECURE PHARMA INC	100MG	A216235	001	Mar 02, 2023	Feb	NEWA
AB		200MG	A216235	002	Mar 02, 2023	Feb	NEWA
AB		400MG	A216235	003	Mar 02, 2023	Feb	NEWA

CARBIDOPA; LEVODOPA

TABLET;ORAL

CARBIDOPA AND LEVODOPA

AB	ZYDUS PHARMS	10MG;100MG	A215999	001	Apr 04, 2023	Mar	NEWA
AB		25MG;100MG	A215999	002	Apr 04, 2023	Mar	NEWA
AB		25MG;250MG	A215999	003	Apr 04, 2023	Mar	NEWA

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

>D>	AB	SCIEGEN PHARMS INC	50MG;200MG	A214091	002	Oct 05, 2021	May	CHRS	
>A>	AB	!	50MG;200MG	A214091	002	Oct 05, 2021	May	CHRS	
>D>	AB	!	SUN PHARM INDS	50MG;200MG	A077828	002	Aug 23, 2007	May	CHRS
>A>	AB		50MG;200MG	A077828	002	Aug 23, 2007	May	CHRS	

TABLET, ORALLY DISINTEGRATING;ORAL

CARBIDOPA AND LEVODOPA

	SUN PHARM	10MG;100MG	A078690	001	Jul 31, 2009	Apr	CTEC
		25MG;100MG	A078690	002	Jul 31, 2009	Apr	CTEC

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

>D>		@ NOVAST LABS	450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	May	CMFD
>A>	AP		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	May	CMFD
>D>		@	600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	May	CMFD
>A>	AP		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	May	CMFD

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION

CARBOPROST TROMETHAMINE

AP	CAPLIN	EQ 0.25MG BASE/ML	A216882	001	Feb 13, 2023	Feb	NEWA	
>A>	AP	EUGIA PHARMA	EQ 0.25MG BASE/ML	A216939	001	May 25, 2023	May	NEWA
>A>	AP	WELDING	EQ 0.25MG BASE/ML	A216824	001	May 19, 2023	May	NEWA

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL

CARIPRAZINE HYDROCHLORIDE

>A>		@ ZYDUS	EQ 1.5MG BASE	A213984	001	Sep 09, 2022	May	CAHN
>A>		@	EQ 3MG BASE	A213984	002	Sep 09, 2022	May	CAHN
>A>		@	EQ 4.5MG BASE	A213984	003	Sep 09, 2022	May	CAHN
>A>		@	EQ 6MG BASE	A213984	004	Sep 09, 2022	May	CAHN
>D>		@ ZYDUS PHARMS	EQ 1.5MG BASE	A213984	001	Sep 09, 2022	May	CAHN
>D>		@	EQ 3MG BASE	A213984	002	Sep 09, 2022	May	CAHN
>D>		@	EQ 4.5MG BASE	A213984	003	Sep 09, 2022	May	CAHN
>D>		@	EQ 6MG BASE	A213984	004	Sep 09, 2022	May	CAHN
		VRAYLAR						
+!	ABBVIE	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Jan	CAHN	
+		EQ 3MG BASE	N204370	002	Sep 17, 2015	Jan	CAHN	
+		EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Jan	CAHN	
+		EQ 6MG BASE	N204370	004	Sep 17, 2015	Jan	CAHN	

CARMUSTINE

INJECTABLE;INJECTION

CARMUSTINE

AP	ACCORD HLTHCARE	100MG/VIAL	A214117	001	Dec 27, 2022	Mar	CTNA	
>A>	AP	MSN	100MG/VIAL	A214814	001	May 11, 2023	May	NEWA
		@ MYLAN LABS LTD	100MG/VIAL	A215368	001	Mar 03, 2023	Mar	DISC
AP			100MG/VIAL	A215368	001	Mar 03, 2023	Feb	NEWA
>A>	AP	PENN LIFE	100MG/VIAL	A209278	001	Apr 02, 2019	May	CAHN
>D>	AP	STI PHARMA LLC	100MG/VIAL	A209278	001	Apr 02, 2019	May	CAHN

CEFAZOLIN SODIUMPOWDER; INTRAVENOUS
CEFAZOLIN SODIUM

>A>	+	!	HQ SPCLT PHARMA	EQ 2GM BASE/VIAL	N211413	001	May 08, 2023	May	NEWA
-----	---	---	-----------------	------------------	---------	-----	--------------	-----	------

CEFOTAXIME SODIUMINJECTABLE; INJECTION
CEFOTAXIME

	@		HIKMA	EQ 500MG BASE/VIAL	A065072	001	Nov 20, 2002	Mar	DISC
	@			EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002	Mar	DISC
	@			EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002	Mar	DISC
	@			EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002	Mar	DISC

CEFOTETAN DISODIUMINJECTABLE; INJECTION
CEFOTAN

>D>	AP	+	PAI HOLDINGS PHARM	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	May	DISC
>A>		+	@	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	May	DISC
>D>	AP	+		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	May	DISC
>A>		+	@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	May	DISC
			CEFOTETAN						
>D>	AP	+	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065374	001	Aug 09, 2007	May	CTEC
>A>		!		EQ 1GM BASE/VIAL	A065374	001	Aug 09, 2007	May	CTEC
>D>	AP	+		EQ 2GM BASE/VIAL	A065374	002	Aug 09, 2007	May	CTEC
>A>		!		EQ 2GM BASE/VIAL	A065374	002	Aug 09, 2007	May	CTEC

CEFTAROLINE FOSAMILPOWDER; INTRAVENOUS
TEFLARO

>A>	+	!	ABBVIE	400MG/VIAL	N200327	001	Oct 29, 2010	May	CAHN
>A>	+	!		600MG/VIAL	N200327	002	Oct 29, 2010	May	CAHN
>D>	+	!	ALLERGAN	400MG/VIAL	N200327	001	Oct 29, 2010	May	CAHN
>D>	+	!		600MG/VIAL	N200327	002	Oct 29, 2010	May	CAHN

CEFTAZIDIMEINJECTABLE; INJECTION
CEFTAZIDIME

>D>	AP		ACS DOBFAR	1GM/VIAL	A062640	002	Nov 20, 1985	May	CHRS
>A>	AP	!		1GM/VIAL	A062640	002	Nov 20, 1985	May	CHRS
>D>	AP			2GM/VIAL	A062640	003	Nov 20, 1985	May	CHRS
>A>	AP	!		2GM/VIAL	A062640	003	Nov 20, 1985	May	CHRS
>D>	AP			6GM/VIAL	A062640	004	Feb 03, 1992	May	CHRS
>A>	AP	!		6GM/VIAL	A062640	004	Feb 03, 1992	May	CHRS
			FORTAZ						
>D>	AP	+	PAI HOLDINGS PHARM	500MG/VIAL	N050578	001	Jul 19, 1985	May	DISC
>A>		+	@	500MG/VIAL	N050578	001	Jul 19, 1985	May	DISC
>D>	AP	+	!	1GM/VIAL	N050578	002	Jul 19, 1985	May	DISC
>A>		+	@	1GM/VIAL	N050578	002	Jul 19, 1985	May	DISC
>D>	AP	+	!	2GM/VIAL	N050578	003	Jul 19, 1985	May	DISC
>A>		+	@	2GM/VIAL	N050578	003	Jul 19, 1985	May	DISC
>D>	AP	+	!	6GM/VIAL	N050578	004	Jul 19, 1985	May	DISC
>A>		+	@	6GM/VIAL	N050578	004	Jul 19, 1985	May	DISC
			TAZICEF						
>D>	AP		HOSPIRA	500MG/VIAL	A062662	001	Mar 06, 1986	May	DISC
>A>			@	500MG/VIAL	A062662	001	Mar 06, 1986	May	DISC

CEFUROXIME SODIUMINJECTABLE; INJECTION
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

>D>	AP	+	B BRAUN	EQ 750MG BASE/VIAL	N050780	001	Feb 21, 2001	May	CTEC
>A>		+	!	EQ 750MG BASE/VIAL	N050780	001	Feb 21, 2001	May	CTEC

CELECOXIBCAPSULE; ORAL
CELECOXIB

	@		MYLAN	100MG	A078857	002	Feb 11, 2015	Mar	DISC
AB			YABAO PHARM	100MG	A212564	001	Apr 10, 2023	Mar	NEWA
AB				200MG	A212564	002	Apr 10, 2023	Mar	NEWA
AB				400MG	A212564	003	Apr 10, 2023	Mar	NEWA

SOLUTION;ORAL
ELYXYB

+ @ SCILEX HLDG 25MG/ML N212157 001 May 05, 2020 Feb CAHN

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL
CEVIMELINE HYDROCHLORIDE

AB AUROBINDO PHARMA 30MG A215056 001 Apr 18, 2023 Apr NEWA
AB RUBICON 30MG A216682 001 Apr 06, 2023 Mar NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL
CHLORHEXIDINE GLUCONATE

AT CHARTWELL RX 0.12% A075006 001 Mar 03, 2004 Jan CAHN

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL
CHLORPROMAZINE HYDROCHLORIDE

AB AMNEAL PHARMS CO 10MG A209755 001 Sep 10, 2018 Apr CTEC
AB 25MG A209755 002 Sep 10, 2018 Apr CTEC
AB 50MG A209755 003 Sep 10, 2018 Apr CTEC
AB 100MG A209755 004 Sep 10, 2018 Apr CTEC
AB 200MG A209755 005 Sep 10, 2018 Apr CTEC

CHLORZOXAZONE

TABLET;ORAL
CHLORZOXAZONE

AA ACME LABS 500MG A214365 001 Apr 27, 2023 Apr NEWA
AB APPCO 375MG A212047 001 Jan 27, 2023 Jan NEWA
AB 750MG A212047 002 Jan 27, 2023 Jan NEWA
AA BELCHER 250MG A215540 001 Jan 24, 2023 Jan NEWA
AA COREPHARMA 250MG A214702 001 Apr 10, 2023 Mar NEWA

CICLOPIROX

SHAMPOO;TOPICAL
CICLOPIROX

>D> AT PAI HOLDINGS PHARM 1% A209975 001 Apr 05, 2018 May DISC
>A> @ 1% A209975 001 Apr 05, 2018 May DISC

SOLUTION;TOPICAL
CICLOPIROX

AT ! PADAGIS US 8% A077623 001 Sep 18, 2007 Jan CHRS
+ @ VALEANT BERMUDA 8% N021022 001 Dec 17, 1999 Jan DISC

CILOSTAZOL

TABLET;ORAL
CILOSTAZOL
@ AUROBINDO PHARMA USA 50MG
@ 100MG

A077019 001 Nov 23, 2004 Apr CAHN
A077019 002 Nov 23, 2004 Apr CAHN

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL
CIMETIDINE HYDROCHLORIDE

AA XTTRIUM LABS INC EQ 300MG BASE/5ML A074757 001 Oct 17, 1997 Mar CAHN

CIPROFLOXACIN

FOR SUSPENSION;ORAL
CIPRO

>D> + BAYER HLTHCARE 250MG/5ML N020780 001 Sep 26, 1997 May CTEC
>A> AB + 250MG/5ML N020780 001 Sep 26, 1997 May CTEC
>D> +! 500MG/5ML N020780 002 Sep 26, 1997 May CTEC
>A> AB +! 500MG/5ML N020780 002 Sep 26, 1997 May CTEC

CIPROFLOXACIN
@ CHARTWELL 250MG/5ML
@ 250MG/5ML
@ 500MG/5ML
@ 500MG/5ML

A200563 001 Mar 05, 2014 May CMFD
A200563 001 Mar 05, 2014 May CMFD
A200563 002 Mar 05, 2014 May CMFD
A200563 002 Mar 05, 2014 May CMFD

INJECTABLE, SUSPENSION;OTIC
OTIPRIO

+ @ ALK ABELLO 6% (60MG/ML) N207986 001 Dec 10, 2015 Jan DISC

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE
@ AKORN

EQ 0.3% BASE

A076555 001 Dec 11, 2008 Feb DISC

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION
CISATRACURIUM BESYLATE

AP HIKMA EQ 2MG BASE/ML

A203079 001 Apr 19, 2023 Apr NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL
CELEXA

AB + ABBVIE EQ 10MG BASE

N020822 001 Apr 27, 2000 Feb CAHN

AB + EQ 20MG BASE

N020822 002 Jul 17, 1998 Feb CAHN

AB +! EQ 40MG BASE

N020822 003 Jul 17, 1998 Feb CAHN

@ EQ 60MG BASE

N020822 004 Jul 17, 1998 Feb CAHN

CLARITHROMYCIN

FOR SUSPENSION;ORAL
CLARITHROMYCIN

>D> AB SANDOZ 125MG/5ML

A065283 002 Sep 04, 2007 May CTEC

>A> 125MG/5ML

A065283 002 Sep 04, 2007 May CTEC

>D> AB ! 250MG/5ML

A065283 003 Sep 04, 2007 May CTEC

>A> ! 250MG/5ML

A065283 003 Sep 04, 2007 May CTEC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL
CLINDAMYCIN HYDROCHLORIDE

AB GLENMARK PHARMS LTD EQ 75MG BASE

A216957 001 Mar 10, 2023 Mar NEWA

AB EQ 150MG BASE

A216957 002 Mar 10, 2023 Mar NEWA

AB EQ 300MG BASE

A216957 003 Mar 10, 2023 Mar NEWA

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL
CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA CHARTWELL RX EQ 75MG BASE/5ML

A206958 001 May 05, 2017 Feb CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

AP HIKMA EQ 6MG BASE/ML

A214401 001 Apr 05, 2023 Mar NEWA

AP EQ 12MG BASE/ML

A214401 002 Apr 05, 2023 Mar NEWA

AP EQ 18MG BASE/ML

A214401 003 Apr 05, 2023 Mar NEWA

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

>A> AT CHARTWELL RX EQ 1% BASE

A209846 001 Feb 08, 2018 May CAHN

>D> AT GLASSHOUSE PHARMS EQ 1% BASE

A209846 001 Feb 08, 2018 May CAHN

@ XTTRIUM LABS INC EQ 1% BASE

A063304 001 Jul 15, 1997 Jan CAHN

CLOBAZAM

SUSPENSION;ORAL
CLOBAZAM

@ ACCORD HLTHCARE 2.5MG/ML

A216008 001 Sep 06, 2022 Mar DISC

@ UPSHER SMITH LABS 2.5MG/ML

A210569 001 Oct 22, 2018 Mar DISC

CLOBETASOL PROPIONATE

CREAM;TOPICAL
CLOBETASOL PROPIONATE

>A> @ CHARTWELL RX 0.05%

A211207 001 Mar 26, 2021 May CAHN

>D> @ GLASSHOUSE PHARMS 0.05%

A211207 001 Mar 26, 2021 May CAHN

@ TORRENT 0.05%

A211836 001 Dec 30, 2019 Feb DISC

CLOBETASOL PROPIONATE (EMOLLIENT)

@ ANI PHARMS 0.05%

A075733 001 Aug 22, 2001 Apr DISC

CLOFARABINE

SOLUTION; INTRAVENOUS
CLOFARABINE

@ EUGIA PHARMA 20MG/20ML (1MG/ML) A212457 001 Oct 03, 2022 Mar DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
CLOMIPRAMINE HYDROCHLORIDE

AB AUROBINDO PHARMA 25MG A216440 001 Mar 20, 2023 Mar NEWA
AB 50MG A216440 002 Mar 20, 2023 Mar NEWA
AB 75MG A216440 003 Mar 20, 2023 Mar NEWA

CLONAZEPAM

TABLET; ORAL
CLONAZEPAM

AB AUROBINDO PHARMA USA 0.5MG A075150 001 Oct 05, 1998 Jan CMFD
AB 1MG A075150 002 Oct 05, 1998 Jan CMFD
AB 2MG A075150 003 Oct 05, 1998 Jan CMFD

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

@ DASH PHARMS 3.75MG A071509 001 Oct 19, 1987 Feb CAHN
@ 7.5MG A071510 001 Oct 19, 1987 Feb CAHN
@ 15MG A071511 001 Oct 19, 1987 Feb CAHN

CLOZAPINE

TABLET; ORAL
CLOZAPINE

@ DR REDDYS LABS SA 25MG A203807 001 Sep 17, 2015 Apr CAHN
@ 50MG A203807 003 Aug 22, 2017 Apr CAHN
@ 100MG A203807 002 Sep 17, 2015 Apr CAHN
@ 200MG A203807 004 Aug 22, 2017 Apr CAHN
@ MAYNE PHARMA 25MG A203807 001 Sep 17, 2015 Apr DISC
@ 50MG A203807 003 Aug 22, 2017 Apr DISC
@ 100MG A203807 002 Sep 17, 2015 Apr DISC
@ 200MG A203807 004 Aug 22, 2017 Apr DISC

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
TRIACIN-C

! ANIMA 10MG/5ML; 30MG/5ML; 1.25MG/5ML A088704 001 Mar 22, 1985 Mar CAHN

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL
COLESEVELAM HYDROCHLORIDE

AB IMPAX 3.75GM/PACKET A212886 001 Jan 18, 2023 Jan NEWA

TABLET; ORAL
COLESEVELAM HYDROCHLORIDE

>A> @ CHARTWELL RX 625MG A201354 001 Dec 17, 2020 May CAHN
>D> @ LUPIN LTD 625MG A201354 001 Dec 17, 2020 May CAHN

COLESTIPOL HYDROCHLORIDE

TABLET; ORAL
COLESTIPOL HYDROCHLORIDE

AB ANI PHARMS 1GM A216517 001 Mar 10, 2023 Apr CAHN
AB PRAXGEN 1GM A216517 001 Mar 10, 2023 Mar NEWA

CROMOLYN SODIUM

SOLUTION; INHALATION
CROMOLYN SODIUM

>A> @ EUGIA PHARMA 10MG/ML A074209 001 Apr 26, 1994 May CAHN
>D> @ MYLAN SPECIALITY LP 10MG/ML A074209 001 Apr 26, 1994 May CAHN
AN VIRTUS 10MG/ML A075437 001 Apr 21, 2000 Apr CAHN

SOLUTION/DROPS; OPHTHALMIC
CROMOLYN SODIUM

@ AKORN 4% A074706 001 Apr 29, 1998 Feb DISC
! SANDOZ 4% A075282 001 Jun 16, 1999 Feb CTEC
AT ! SANDOZ INC 4% A075282 001 Jun 16, 1999 Feb CHRS

CYCLOBENZAPRINE HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL						
	CYCLOBENZAPRINE HYDROCHLORIDE						
	@ APOTEX	15MG	A206703	001	Jul 24, 2018	Mar	DISC
	@	30MG	A206703	002	Jul 24, 2018	Mar	DISC
	TABLET;ORAL						
	CYCLOBENZAPRINE HYDROCHLORIDE						
AB	CHARTWELL RX	5MG	A078218	002	Jun 19, 2015	Feb	CAHN
AB		7.5MG	A078218	003	Nov 03, 2020	Feb	CAHN
AB		10MG	A078218	001	Apr 18, 2008	Feb	CAHN

CYCLOPENTOLATE HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC						
	CYCLOGYL						
	+! ALCON LABS INC	0.5%	A084109	001		Feb	CTEC
	CYCLOPENTOLATE HYDROCHLORIDE						
	@ AKORN	0.5%	A205937	001	Dec 09, 2015	Feb	DISC

CYCLOPHOSPHAMIDE

	INJECTABLE;INJECTION							
	CYCLOPHOSPHAMIDE							
>D>	AP	XELLIA PHARMS APS	500MG/VIAL	A211757	001	Oct 18, 2022	May	CAHN
>D>	AP		1GM/VIAL	A211757	002	Oct 18, 2022	May	CAHN
>D>	AP		2GM/VIAL	A211757	003	Oct 18, 2022	May	CAHN
>A>	AP	XGEN PHARMS	500MG/VIAL	A211757	001	Oct 18, 2022	May	CAHN
>A>	AP		1GM/VIAL	A211757	002	Oct 18, 2022	May	CAHN
>A>	AP		2GM/VIAL	A211757	003	Oct 18, 2022	May	CAHN

CYCLOSPORINE

	EMULSION;OPHTHALMIC						
	CYCLOSPORINE						
AB	APOTEX	0.05%	A207606	001	Jan 12, 2023	Jan	NEWA
	SOLUTION;OPHTHALMIC						
>A>	VEVYE						
>A>	+! NOVALIQ GMBH	0.1%	N217469	001	May 30, 2023	May	NEWA
	SOLUTION;ORAL						
	CYCLOSPORINE						
AB2	XTTRIUM LABS INC	100MG/ML	A065133	001	Sep 17, 2004	Jan	CAHN

CYPROHEPTADINE HYDROCHLORIDE

	TABLET;ORAL						
	CYPROHEPTADINE HYDROCHLORIDE						
AA	CHARTWELL RX	4MG	A088212	001	May 26, 1983	Mar	CMFD
>D>	AA	RISING	A207783	001	Dec 29, 2016	May	DISC
>A>	@	4MG	A207783	001	Dec 29, 2016	May	DISC

CYSTEINE HYDROCHLORIDE

	INJECTABLE;INJECTION						
	CYSTEINE HYDROCHLORIDE						
	@ HIKMA	7.25%	A213073	001	Jan 26, 2023	Apr	CAHN
	@ NIVAGEN PHARMS INC	7.25%	A213073	001	Jan 26, 2023	Apr	DISC
		7.25%	A213073	001	Jan 26, 2023	Jan	NFTG

DABRAFENIB MESYLATE

	TABLET, FOR SUSPENSION;ORAL						
	TAFINLAR						
	+! NOVARTIS	EQ 10MG BASE	N217514	001	Mar 16, 2023	Mar	NEWA

DAPRODUSTAT

	TABLET;ORAL						
	JESDUVROQ						
	+ GLAXOSMITHKLINE	1MG	N216951	001	Feb 01, 2023	Feb	NEWA
		2MG	N216951	002	Feb 01, 2023	Feb	NEWA
		4MG	N216951	003	Feb 01, 2023	Feb	NEWA
		6MG	N216951	004	Feb 01, 2023	Feb	NEWA
	+!	8MG	N216951	005	Feb 01, 2023	Feb	NEWA

DAPSONE

GEL; TOPICAL
DAPSONE

>A>	AB	ACRUX DDS	5%	A213907	001	Jun 06, 2023	May	NEWA
>A>	AB	AMNEAL	7.5%	A212701	001	May 31, 2023	May	NEWA

DAPTOMYCIN

POWDER; INTRAVENOUS
CUBICIN

>D>	AP	+	!	CUBIST PHARMS LLC	500MG/VIAL	N021572	002	Sep 12, 2003	May	DISC
>A>		+	@		500MG/VIAL	N021572	002	Sep 12, 2003	May	DISC

DAPTOMYCIN

		@		HAINAN POLY PHARM	500MG/VIAL	A215890	001	Aug 18, 2022	Feb	DISC
>D>	AP			QILU PHARM HAINAN	500MG/VIAL	A215316	001	Aug 24, 2021	May	CHRS
>A>	AP		!		500MG/VIAL	A215316	001	Aug 24, 2021	May	CHRS
		+	!	XELLIA PHARMS APS	350MG/VIAL	N217415	001	Jan 30, 2023	Jan	NEWA
		+	!		500MG/VIAL	N217415	002	Jan 30, 2023	Jan	NEWA

SOLUTION; INTRAVENOUS

DAPTOMYCIN IN 0.9% SODIUM CHLORIDE

		+	!	BAXTER HLTHCARE CORP	350MG/50ML (7MG/ML)	N213645	002	Feb 27, 2023	Mar	NEWA
		+	!		500MG/50ML (10MG/ML)	N213645	003	Feb 27, 2023	Mar	NEWA
		+	!		700MG/100ML (7MG/ML)	N213645	004	Feb 27, 2023	Mar	NEWA
		+	!		1GM/100ML (10MG/ML)	N213645	005	Feb 27, 2023	Mar	NEWA

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL
ENABLEX

		+	@	ABBVIE	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Apr	CAHN
		+	@		EQ 15MG BASE	N021513	002	Dec 22, 2004	Apr	CAHN

DEFERASIROX

GRANULE; ORAL
DEFERASIROX

AB				ANNORA PHARMA	90MG	A216229	003	Mar 16, 2023	Mar	NEWA
----	--	--	--	---------------	------	---------	-----	--------------	-----	------

TABLET; ORAL
DEFERASIROX

AB				CHARTWELL RX	90MG	A212669	001	May 27, 2021	Mar	CAHN
AB					180MG	A212669	002	May 27, 2021	Mar	CAHN
AB					360MG	A212669	003	May 27, 2021	Mar	CAHN
		@		CIPLA	90MG	A211852	001	Feb 11, 2020	Mar	DISC
		@			180MG	A211852	003	Jun 15, 2020	Mar	DISC
		@			360MG	A211852	002	Feb 11, 2020	Mar	DISC

TABLET, FOR SUSPENSION; ORAL

DEFERASIROX

		@		TEVA PHARMS USA	125MG	A207124	001	Sep 23, 2022	Mar	DISC
		@			250MG	A207124	002	Sep 23, 2022	Mar	DISC
		@			500MG	A207124	003	Sep 23, 2022	Mar	DISC

DEFERIPRONE

TABLET; ORAL
DEFERIPRONE

>D>	AB			HIKMA	1GM	A213239	002	Feb 08, 2022	May	CHRS
>A>	AB		!		1GM	A213239	002	Feb 08, 2022	May	CHRS

FERRIPROX

>D>	AB	+	!	CHIESI	1GM	N021825	002	Jul 25, 2019	May	CHRS
>A>	AB	+			1GM	N021825	002	Jul 25, 2019	May	CHRS

DESLORATADINE

TABLET; ORAL
DESLORATADINE
@ DASH PHARMS

					5MG	A078351	001	Feb 10, 2012	Feb	CAHN
--	--	--	--	--	-----	---------	-----	--------------	-----	------

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DESMOPRESSIN ACETATE

AP				GLAND	0.004MG/ML	A216904	001	Mar 20, 2023	Mar	NEWA
----	--	--	--	-------	------------	---------	-----	--------------	-----	------

DESONIDE

LOTION; TOPICAL
DESONIDE

>D>	AB	PAI HOLDINGS PHARM	0.05%	A207855	001	Sep 28, 2017	May DISC
>A>	@		0.05%	A207855	001	Sep 28, 2017	May DISC

DEUTETRABENAZINE

TABLET, EXTENDED RELEASE; ORAL
AUSTEDO XR

+	TEVA	6MG	N216354	001	Feb 17, 2023	Feb NEWA
+		12MG	N216354	002	Feb 17, 2023	Feb NEWA
+	!	24MG	N216354	003	Feb 17, 2023	Feb NEWA

DEXAMETHASONE

ELIXIR; ORAL
DEXAMETHASONE

+	@	XTTRIUM LABS INC	0.5MG/5ML	A088254	001	Jul 27, 1983	Jan CAHN
---	---	------------------	-----------	---------	-----	--------------	----------

SUSPENSION/DROPS; OPHTHALMIC
MAXIDEX

>A>	+	HARROW EYE	0.1%	N013422	001		May CAHN
>D>	+	NOVARTIS	0.1%	N013422	001		May CAHN

TABLET; ORAL

DEXAMETHASONE

AB		ALVOGEN	4MG	A088481	004	Apr 28, 1983	Apr CTEC
AB			6MG	A088481	001	Nov 28, 1983	Apr CTEC
AB		BIONPHARMA INC	2MG	A217538	001	Apr 26, 2023	Apr NEWA
AB			4MG	A217001	001	Apr 19, 2023	Apr NEWA
AB			6MG	A217001	002	Apr 19, 2023	Apr NEWA
AB		NOVITIUM PHARMA	2MG	A217696	001	May 09, 2023	Apr NEWA
AB		PRASCO	4MG	A080399	002	Apr 20, 2022	Apr CMFD
		@	4MG	A080399	002	Apr 20, 2022	Feb DISC

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

MAXITROL

>A>	AT	+	HARROW EYE	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002	May CAHN
>D>	AT	+	IMPRIMIS PHARMS USA	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002	May CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

>A>	AP		AMNEAL	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A216604	001	May 15, 2023	May NEWA
>A>	AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A216604	002	May 15, 2023	May NEWA
>A>	AP		MILLA PHARMS	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A217308	001	Jun 07, 2023	May NEWA
>A>	AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A217308	002	Jun 07, 2023	May NEWA

DEXTROAMPHETAMINE SULFATE

SOLUTION; ORAL

DEXTROAMPHETAMINE SULFATE

AA	!	PRASCO	5MG/5ML	A040776	001	Jan 29, 2008	Mar CAHN
----	---	--------	---------	---------	-----	--------------	----------

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA		ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011	Jan CTEC
AA			7.5MG	A090533	003	Oct 25, 2011	Jan CTEC
AA			15MG	A090533	005	Oct 25, 2011	Jan CTEC
AA			20MG	A090533	006	Oct 25, 2011	Jan CTEC
AA			30MG	A090533	007	Oct 25, 2011	Jan CTEC
AA		WINDER LABS LLC	2.5MG	A212160	001	Jun 07, 2021	Jan CMFD
AA			5MG	A212160	002	Jun 07, 2021	Jan CMFD
AA			7.5MG	A212160	003	Jun 07, 2021	Jan CMFD
AA			10MG	A212160	004	Jun 07, 2021	Jan CMFD
AA			15MG	A212160	005	Jun 07, 2021	Jan CMFD
AA			20MG	A212160	006	Jun 07, 2021	Jan CMFD
AA			30MG	A212160	007	Jun 07, 2021	Jan CMFD

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

		POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER						
AP		FRESENIUS KABI USA 5GM/100ML;149MG/100ML;225MG/100ML	A212348	001	Jul 30, 2021	Mar	CMFD	
		POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP		FRESENIUS KABI USA 5GM/100ML;74.5MG/100ML;450MG/100ML	A213523	001	Mar 09, 2021	Mar	CMFD	
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER						
AP		FRESENIUS KABI USA 5GM/100ML;149MG/100ML;225MG/100ML	A212348	002	Jul 30, 2021	Mar	CMFD	
AP	+	ICU MEDICAL INC 5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Mar	CHRS	
AP	+	5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Mar	CTEC	
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP		FRESENIUS KABI USA 5GM/100ML;149MG/100ML;450MG/100ML	A213523	002	Mar 09, 2021	Mar	CMFD	
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%						
AP		FRESENIUS KABI USA 5GM/100ML;149MG/100ML;900MG/100ML	A213445	001	Mar 09, 2021	Mar	CMFD	
		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP		FRESENIUS KABI USA 5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Mar	CMFD	
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP		FRESENIUS KABI USA 5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Mar	CMFD	
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%						
AP		FRESENIUS KABI USA 5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Mar	CMFD	

DIAZEPAM

GEL; RECTAL

DIASTAT ACUDIAL

>D>	+	BAUSCH 10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	May	CFTG	
>A>	AB	+	N020648	007	Sep 15, 2005	May	CFTG	
>D>	+	20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005	May	CFTG	
>A>	AB	+	N020648	006	Sep 15, 2005	May	CFTG	

DIAZEPAM

>A>	AB	NOVEL LABS INC 10MG/2ML (5MG/ML)	A091076	001	May 30, 2023	May	NFTG	
>A>	AB	20MG/4ML (5MG/ML)	A091076	002	May 30, 2023	May	NFTG	

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM

>A>		@ CHARTWELL RX 50MG	A075582	001	Feb 23, 2001	May	CAHN	
>D>		@ SANDOZ 50MG	A075582	001	Feb 23, 2001	May	CAHN	
AB		SENORES PHARMS 50MG	A215787	001	Mar 15, 2023	Mar	NEWA	

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AB		AMNEAL 3%	A200936	001	Oct 28, 2013	Feb	CAHN	
----	--	-----------	---------	-----	--------------	-----	------	--

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AB		AUROLIFE PHARMA LLC 2%	A213040	001	Feb 03, 2023	Jan	NEWA	
----	--	------------------------	---------	-----	--------------	-----	------	--

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

>A>	AB	RUBICON 25MG	A216548	001	May 11, 2023	May	NEWA	
>A>	AB	50MG	A216548	002	May 11, 2023	May	NEWA	
>A>	AB	75MG	A216548	003	May 11, 2023	May	NEWA	

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

		@ AUROBINDO PHARMA USA 100MG	A076152	001	Dec 13, 2001	Apr	CAHN	
--	--	------------------------------	---------	-----	--------------	-----	------	--

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HYDROCHLORIDE

AB		COREPHARMA 10MG	A216639	001	Mar 24, 2023	Mar	NEWA	
----	--	-----------------	---------	-----	--------------	-----	------	--

INJECTABLE; INJECTION

BENTYL

AP	+	ABBVIE 10MG/ML	N008370	001	Oct 15, 1984	Feb	CAHN	
----	---	----------------	---------	-----	--------------	-----	------	--

BENTYL PRESERVATIVE FREE

AP	+	ABBVIE 10MG/ML	N008370	002	Oct 15, 1984	Feb	CAHN	
----	---	----------------	---------	-----	--------------	-----	------	--

TABLET; ORAL

DICYCLOMINE HYDROCHLORIDE

AB		AUROBINDO PHARMA USA 20MG	A040317	001	Sep 07, 1999	Feb	CMFD	
>A>	AB	TWI PHARMS 20MG	A216782	001	Jun 01, 2023	May	NEWA	

DIETHYLPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
DIETHYLPROPION HYDROCHLORIDE
! LANNETT CO INC 75MG

A091680 001 Oct 24, 2011 Feb CTEC

DIFLORASONE DIACETATE

CREAM;TOPICAL
DIFLORASONE DIACETATE

>A> @ AVONDALE PHARMS 0.05%
>D> @ FOUGERA PHARMS 0.05%

A075187 001 Mar 30, 1998 May CAHN
A075187 001 Mar 30, 1998 May CAHN

OINTMENT;TOPICAL
DIFLORASONE DIACETATE

>A> AB AVONDALE PHARMS 0.05%
>D> AB FOUGERA PHARMS 0.05%

A075374 001 Apr 27, 1999 May CAHN
A075374 001 Apr 27, 1999 May CAHN

DIHYDROERGOTAMINE MESYLATE

SPRAY, METERED;NASAL
DIHYDROERGOTAMINE MESYLATE

AB AMNEAL 0.5MG/SPRAY

A214105 001 Jan 04, 2022 Apr CMFD

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB1 TWI PHARMS 60MG
AB1 90MG
AB1 120MG

A217377 001 Mar 01, 2023 Feb NEWA
A217377 002 Mar 01, 2023 Feb NEWA
A217377 003 Mar 01, 2023 Feb NEWA

INJECTABLE;INJECTION
DILTIAZEM HYDROCHLORIDE

AP EUGIA PHARMA 5MG/ML

A216552 001 Mar 29, 2023 Mar NEWA

TABLET, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB AMTA 120MG
AB 180MG
AB 240MG
AB 300MG
AB 360MG
AB 420MG
AB SCIEGEN PHARMS INC 120MG
AB 180MG
AB 240MG
AB 300MG
AB 360MG
AB 420MG

A216439 001 Mar 07, 2023 Feb NEWA
A216439 002 Mar 07, 2023 Feb NEWA
A216439 003 Mar 07, 2023 Feb NEWA
A216439 004 Mar 07, 2023 Feb NEWA
A216439 005 Mar 07, 2023 Feb NEWA
A216439 006 Mar 07, 2023 Feb NEWA
A216327 001 Apr 06, 2023 Mar NEWA
A216327 002 Apr 06, 2023 Mar NEWA
A216327 003 Apr 06, 2023 Mar NEWA
A216327 004 Apr 06, 2023 Mar NEWA
A216327 005 Apr 06, 2023 Mar NEWA
A216327 006 Apr 06, 2023 Mar NEWA

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL
DIMETHYL FUMARATE

AB SOLA PHARMS 120MG
AB 240MG

A210436 001 Mar 26, 2021 Feb CMFD
A210436 002 Mar 26, 2021 Feb CMFD

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR;ORAL
DIPHENHYDRAMINE HYDROCHLORIDE

+! PHARM ASSOC 12.5MG/5ML

A087513 001 Feb 10, 1982 Apr CRLD

DIPYRIDAMOLE

TABLET;ORAL
DIPYRIDAMOLE

@ ANI PHARMS 25MG
@ 50MG
@ 75MG

A086944 002 Apr 16, 1991 Apr DISC
A086944 001 Feb 25, 1992 Apr DISC
A086944 003 Feb 25, 1992 Apr DISC

DISULFIRAM

TABLET;ORAL
DISULFIRAM

@ DASH PHARMS 250MG
@ 500MG

A203916 001 Mar 04, 2015 Feb CAHN
A203916 002 Mar 04, 2015 Feb CAHN

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	ALEMVIC	20MG/2ML (10MG/ML)	A215744	001	Feb 28, 2023	Feb	NEWA
AP		80MG/8ML (10MG/ML)	A215744	002	Feb 28, 2023	Feb	NEWA
AP		160MG/16ML (10MG/ML)	A215744	003	Feb 28, 2023	Feb	NEWA
AP	MYLAN LABS LTD	20MG/ML (20MG/ML)	A203892	001	May 11, 2023	Apr	NEWA
AP		80MG/4ML (20MG/ML)	A203892	002	May 11, 2023	Apr	NEWA

SOLUTION; INTRAVENOUS

DOCETAXEL

>D>	+!	MERIDIAN LABS	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	May	DISC
>A>	+ @		20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	May	DISC
>D>	+!		80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	May	DISC
>A>	+ @		80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	May	DISC
>D>	+!		160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	May	DISC
>A>	+ @		160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	May	DISC

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

+ @	B BRAUN	80MG/100ML	N019099	002	Oct 15, 1986	Apr	DISC
+ @		320MG/100ML	N019099	004	Oct 15, 1986	Apr	DISC

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

+ @	B BRAUN	40MG/100ML	N019099	001	Oct 15, 1986	Apr	DISC
+ @		160MG/100ML	N019099	003	Oct 15, 1986	Apr	DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT

>D>	AT	+!	THEA PHARMA	EQ 2% BASE;EQ 0.5% BASE	N020869	001	Apr 07, 1998	May	CTEC
>A>	AT1	+!		EQ 2% BASE;EQ 0.5% BASE	N020869	001	Apr 07, 1998	May	CTEC

COSOPT PF

>D>	AT	+!	THEA PHARMA	EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012	May	CTEC
>A>	AT2	+!		EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012	May	CTEC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>D>	AT		AKORN	EQ 2% BASE;EQ 0.5% BASE	A077847	001	Oct 28, 2008	May	CTEC
>A>	AT1			EQ 2% BASE;EQ 0.5% BASE	A077847	001	Oct 28, 2008	May	CTEC
>D>	AT			EQ 2% BASE;EQ 0.5% BASE	A203058	001	Sep 22, 2014	May	CTEC
>A>	AT1			EQ 2% BASE;EQ 0.5% BASE	A203058	001	Sep 22, 2014	May	CTEC
>D>	AT		ALEMVIC	EQ 2% BASE;EQ 0.5% BASE	A213099	001	May 04, 2021	May	CTEC
>A>	AT1			EQ 2% BASE;EQ 0.5% BASE	A213099	001	May 04, 2021	May	CTEC
>D>	AT		BAUSCH AND LOMB	EQ 2% BASE;EQ 0.5% BASE	A090037	001	Jul 14, 2009	May	CTEC
>A>	AT1			EQ 2% BASE;EQ 0.5% BASE	A090037	001	Jul 14, 2009	May	CTEC
>D>	AT		EUGIA PHARMA	EQ 2% BASE;EQ 0.5% BASE	A207629	001	May 14, 2021	May	CTEC
>A>	AT1			EQ 2% BASE;EQ 0.5% BASE	A207629	001	May 14, 2021	May	CTEC
>D>	AT			EQ 2% BASE;EQ 0.5% BASE	A207630	001	Jul 24, 2018	May	CTEC
>A>	AT2			EQ 2% BASE;EQ 0.5% BASE	A207630	001	Jul 24, 2018	May	CTEC
>D>	AT		FDC LTD	EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13, 2019	May	CTEC
>A>	AT1			EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13, 2019	May	CTEC
>D>	AT		GLAND PHARMA LTD	EQ 2% BASE;EQ 0.5% BASE	A215520	001	Sep 19, 2022	May	CTEC
>A>	AT1			EQ 2% BASE;EQ 0.5% BASE	A215520	001	Sep 19, 2022	May	CTEC
>D>	AT		INDOCO	EQ 2% BASE;EQ 0.5% BASE	A202054	001	Sep 03, 2014	May	CTEC
>A>	AT1			EQ 2% BASE;EQ 0.5% BASE	A202054	001	Sep 03, 2014	May	CTEC
>D>	AT		INGENUS PHARMS LLC	EQ 2% BASE;EQ 0.5% BASE	A217260	001	May 01, 2023	May	CTEC
>A>	AT2			EQ 2% BASE;EQ 0.5% BASE	A217260	001	May 01, 2023	May	CTEC
>D>	AT			EQ 2% BASE;EQ 0.5% BASE	A217260	001	May 01, 2023	Apr	NEWA
>A>	AT		MICRO LABS	EQ 2% BASE;EQ 0.5% BASE	A204777	001	May 28, 2020	May	CTEC
>A>	AT1			EQ 2% BASE;EQ 0.5% BASE	A204777	001	May 28, 2020	May	CTEC
>D>	AT			EQ 2% BASE;EQ 0.5% BASE	A215936	001	Jan 25, 2022	May	CTEC
>A>	AT2			EQ 2% BASE;EQ 0.5% BASE	A215936	001	Jan 25, 2022	May	CTEC
>D>	AT		SANDOZ	EQ 2% BASE;EQ 0.5% BASE	A078749	001	Nov 06, 2008	May	CTEC
>A>	AT1			EQ 2% BASE;EQ 0.5% BASE	A078749	001	Nov 06, 2008	May	CTEC
>A>	AT1			EQ 2% BASE;EQ 0.5% BASE	A090604	001	Nov 18, 2009	May	CTEC
>D>	AT		SANDOZ INC	EQ 2% BASE;EQ 0.5% BASE	A090604	001	Nov 18, 2009	May	CTEC
>D>	AT		SOMERSET	EQ 2% BASE;EQ 0.5% BASE	A207523	001	Jun 25, 2019	May	CTEC
>A>	AT1			EQ 2% BASE;EQ 0.5% BASE	A207523	001	Jun 25, 2019	May	CTEC
>D>	AT		TEVA PHARMS	EQ 2% BASE;EQ 0.5% BASE	A078704	001	Sep 28, 2009	May	CTEC
>A>	AT1			EQ 2% BASE;EQ 0.5% BASE	A078704	001	Sep 28, 2009	May	CTEC

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB	ZYDUS LIFESCIENCES	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar CAHN
AB		EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar CAHN
AB		EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar CAHN
AB		EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar CAHN
AB		EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar CAHN
AB		EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar CAHN
AB	ZYDUS PHARMS	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar NEWA
AB		EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar NEWA
AB		EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar NEWA
AB		EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar NEWA
AB		EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar NEWA
AB		EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar NEWA

CREAM;TOPICAL

DOXEPIN HYDROCHLORIDE

AB	TEVA PHARMS	5%	A215408	001	Feb 17, 2023	Feb NFTG
	ZONALON					
AB	+! MYLAN	5%	N020126	001	Apr 01, 1994	Feb CFTG
	TABLET;ORAL					
	DOXEPIN HYDROCHLORIDE					
AB	MSN	EQ 3MG BASE	A214823	001	Apr 03, 2023	Mar NEWA
AB		EQ 6MG BASE	A214823	002	Apr 03, 2023	Mar NEWA

DOXYCYCLINE HYCLATE

INJECTABLE;INJECTION

DOXYCYCLINE HYCLATE

AP	GLAND PHARMA LTD	EQ 100MG BASE/VIAL	A215583	001	Apr 12, 2023	Mar NEWA
	TABLET;ORAL					
	DOXYCYCLINE HYCLATE					
	@ ORYZA PHARMS SHENZHN	EQ 100MG BASE	A213475	001	Mar 10, 2021	Feb CAHN
	TABLET, DELAYED RELEASE;ORAL					
	DOXYCYCLINE HYCLATE					
>A>	@ AUROBINDO PHARMA USA	EQ 150MG BASE	A091052	001	Feb 08, 2012	May CAHN
>D>	@ MYLAN PHARMS INC	EQ 150MG BASE	A091052	001	Feb 08, 2012	May CAHN

DROPERIDOL

INJECTABLE;INJECTION

DROPERIDOL

>D>	AP	EUROHLTH INTL SARL	2.5MG/ML	A208197	001	Dec 14, 2017	May CAHN
>A>	AP	HIKMA	2.5MG/ML	A208197	001	Dec 14, 2017	May CAHN

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

>D>	@	CELLTRION	100MG	A214217	001	May 05, 2022	May CAHN
>D>	@		200MG	A214217	002	May 05, 2022	May CAHN
>D>	@		300MG	A214217	003	May 05, 2022	May CAHN
>A>	@	CHARTWELL RX	100MG	A214217	001	May 05, 2022	May CAHN
>A>	@		200MG	A214217	002	May 05, 2022	May CAHN
>A>	@		300MG	A214217	003	May 05, 2022	May CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DRIZALMA SPRINKLE

	+ @	SUN PHARM	EQ 30MG BASE	N212516	002	Jul 19, 2019	Mar DISC
	+ @		EQ 40MG BASE	N212516	003	Jul 19, 2019	Jan DISC
	+ @		EQ 60MG BASE	N212516	004	Jul 19, 2019	Mar DISC
		DULOXETINE HYDROCHLORIDE					
AB	ZYDUS HLTHCARE	EQ 40MG BASE	A090739	004	Apr 18, 2023	Apr NEWA	

>A> DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM

>A>		POWDER;INTRAVENOUS					
>A>		XACDURO (COPACKAGED)					
>A>	+!	ENTASIS THERAP	EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL	N216974	001	May 24, 2023	May NEWA

DYCLONINE HYDROCHLORIDE

	SOLUTION; TOPICAL							
	DYCLOPRO							
>D>	!	NOVOCOL INC	0.5%	A200480	001	Nov 20, 2018	May	CAHN
>D>	!		1%	A200480	002	Nov 20, 2018	May	CAHN
>A>	!	SEPTODONT	0.5%	A200480	001	Nov 20, 2018	May	CAHN
>A>	!		1%	A200480	002	Nov 20, 2018	May	CAHN

ECONAZOLE NITRATE

	CREAM; TOPICAL							
	ECONAZOLE NITRATE							
>D>	AB	@ AUROBINDO PHARMA USA	1%	A210364	001	Apr 18, 2018	Apr	CAHN
>A>		PAI HOLDINGS PHARM	1%	A076574	001	Dec 17, 2004	May	DISC
>A>		@	1%	A076574	001	Dec 17, 2004	May	DISC

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION
CALCIUM DISODIUM VERSENATE

	+	@ BAUSCH	200MG/ML	N008922	001		Mar	DISC
	!	CASPER PHARMA LLC	200MG/ML	A216435	001	May 03, 2023	Apr	NFTG
			200MG/ML	A216435	001	May 03, 2023	Apr	NFTG

EFAVIRENZ

CAPSULE; ORAL
EFAVIRENZ

		AUROBINDO PHARMA	50MG	A078064	001	Dec 15, 2017	Mar	CTEC
	!		200MG	A078064	003	Dec 15, 2017	Mar	CHRS
			200MG	A078064	003	Dec 15, 2017	Mar	CTEC
	+	@ BRISTOL MYERS SQUIBB	50MG	N020972	001	Sep 17, 1998	Mar	DISC
	+	@	200MG	N020972	003	Sep 17, 1998	Mar	DISC

ELACESTRANT DIHYDROCHLORIDE

TABLET; ORAL
ORSERDU

	+	STEMLINE THERAP	EQ 86MG BASE	N217639	001	Jan 27, 2023	Jan	NEWA
	+	!	EQ 345MG BASE	N217639	002	Jan 27, 2023	Jan	NEWA

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

GRANULES; ORAL
TRIKAFTA (COPACKAGED)

	+	VERTEX PHARMS INC	80MG, 60MG, 40MG; 59.5MG	N217660	001	Apr 26, 2023	Apr	NEWA
	+	!	100MG, 75MG, 50MG; 75MG	N217660	002	Apr 26, 2023	Apr	NEWA

ELIGLUSTAT TARTRATE

CAPSULE; ORAL
ELIGLUSTAT TARTRATE

AB		ZENARA	EQ 84MG BASE	A212420	001	May 02, 2023	Apr	NEWA
----	--	--------	--------------	---------	-----	--------------	-----	------

EMPAGLIFLOZIN

TABLET; ORAL
EMPAGLIFLOZIN
@ ZYDUS PHARMS
@
JARDIANCE

	+	BOEHRINGER INGELHEIM	10MG	N204629	001	Aug 01, 2014	Jan	CTEC
	+	!	25MG	N204629	002	Aug 01, 2014	Jan	CTEC

EMTRICITABINE

CAPSULE; ORAL
EMTRICITABINE

AB		AUROBINDO PHARMA LTD	200MG	A079188	001	Mar 15, 2023	Mar	NEWA
----	--	----------------------	-------	---------	-----	--------------	-----	------

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

		@ APOTEX	200MG; 300MG	A208740	001	Jun 16, 2021	Apr	DISC
AB		AUROBINDO PHARMA LTD	100MG; 150MG	A211640	001	Mar 09, 2023	Mar	NEWA
AB			133MG; 200MG	A211640	002	Mar 09, 2023	Mar	NEWA
AB			167MG; 250MG	A211640	003	Mar 09, 2023	Mar	NEWA

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

>A>	@	CHARTWELL RX	2.5MG	A 075048	001	Aug 22, 2000	May	CAHN
>A>	@		5MG	A 075048	002	Aug 22, 2000	May	CAHN
>A>	@		10MG	A 075048	003	Aug 22, 2000	May	CAHN
>A>	@		20MG	A 075048	004	Aug 22, 2000	May	CAHN
>D>	@	SANDOZ	2.5MG	A 075048	001	Aug 22, 2000	May	CAHN
>D>	@		5MG	A 075048	002	Aug 22, 2000	May	CAHN
>D>	@		10MG	A 075048	003	Aug 22, 2000	May	CAHN
>D>	@		20MG	A 075048	004	Aug 22, 2000	May	CAHN

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP		DR REDDYS	1.25MG/ML	A 075578	001	Aug 22, 2000	Apr	CMFD
----	--	-----------	-----------	----------	-----	--------------	-----	------

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

>A>	AP	BE PHARMS	30MG/0.3ML (100MG/ML)	A 214646	001	Jun 06, 2023	May	NEWA
>A>	AP		40MG/0.4ML (100MG/ML)	A 214646	002	Jun 06, 2023	May	NEWA
>A>	AP		60MG/0.6ML (100MG/ML)	A 214646	003	Jun 06, 2023	May	NEWA
>A>	AP		80MG/0.8ML (100MG/ML)	A 214646	004	Jun 06, 2023	May	NEWA
>A>	AP		100MG/ML (100MG/ML)	A 214646	005	Jun 06, 2023	May	NEWA
>A>	AP		120MG/0.8ML (150MG/ML)	A 214646	006	Jun 06, 2023	May	NEWA
>A>	AP		150MG/ML (150MG/ML)	A 214646	007	Jun 06, 2023	May	NEWA
AP		SHENZHEN TECHDOW	30MG/0.3ML (100MG/ML)	A 205660	001	Mar 15, 2023	Mar	NEWA
AP			40MG/0.4ML (100MG/ML)	A 205660	002	Mar 15, 2023	Mar	NEWA
AP			60MG/0.6ML (100MG/ML)	A 205660	003	Mar 15, 2023	Mar	NEWA
AP			80MG/0.8ML (100MG/ML)	A 205660	004	Mar 15, 2023	Mar	NEWA
AP			100MG/ML (100MG/ML)	A 205660	005	Mar 15, 2023	Mar	NEWA
AP			120MG/0.8ML (150MG/ML)	A 205660	006	Mar 15, 2023	Mar	NEWA
AP			150MG/ML (150MG/ML)	A 205660	007	Mar 15, 2023	Mar	NEWA

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

EMERPHED

+!		NEXUS PHARMS	25MG/5ML (5MG/ML)	N 213407	002	Feb 28, 2023	Mar	NEWA
AP		SAGENT PHARMS INC	50MG/ML (50MG/ML)	A 214528	001	Mar 09, 2023	Feb	NEWA
>A>	AP	ZYDUS PHARMS	50MG/ML (50MG/ML)	A 217276	001	May 16, 2023	May	NEWA

EPINEPHRINE

SOLUTION; INTRAVENOUS

EPINEPHRINE IN 0.9% SODIUM CHLORIDE

+!		PAR STERILE PRODUCTS	2MG/250ML (8MCG/ML)	N 215875	001	Apr 21, 2023	Apr	NEWA
+!			4MG/250ML (16MCG/ML)	N 215875	002	Apr 21, 2023	Apr	NEWA
+!			5MG/250ML (20MCG/ML)	N 215875	003	Apr 21, 2023	Apr	NEWA
+!			8MG/250ML (32MCG/ML)	N 215875	004	Apr 21, 2023	Apr	NEWA
+!			10MG/250ML (40MCG/ML)	N 215875	005	Apr 21, 2023	Apr	NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

!		HOSPIRA	0.01MG/ML; 2%	A 089646	001	Jun 21, 1988	Apr	CTEC
>D>	AP	+!	FRESENIUS KABI USA	0.02MG/ML; 2%	N 006488	005		May
>A>		+!		0.02MG/ML; 2%	N 006488	005		May

EPLERENONE

TABLET; ORAL

EPLERENONE

>A>	AB	ANNORA PHARMA	25MG	A 213812	001	Jun 02, 2023	May	NEWA
>A>	AB		50MG	A 213812	002	Jun 02, 2023	May	NEWA

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION
EPOPROSTENOL SODIUM

AP2	!	SUN PHARM	EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Feb	CHRS
		VELETRI						
AP2	+	ACTELION	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb	CHRS

ERGOCALCIFEROL

CAPSULE; ORAL
DRISDOL

AA	+	VALIDUS PHARMS	50,000 IU	N003444	001		Feb	CHRS
		ERGOCALCIFEROL						
AA		CHARTWELL RX	50,000 IU	A040833	001	May 20, 2009	Feb	CAHN
AA	!	STRIDES PHARMA	50,000 IU	A090455	001	Aug 03, 2010	Feb	CHRS

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL
ERLOTINIB HYDROCHLORIDE

AB	!	ZYDUS PHARMS	EQ 150MG BASE	A213065	003	Apr 16, 2020	Apr	CHRS
		TARCEVA						
	+	@ OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	Apr	DISC
	+	@	EQ 100MG BASE	N021743	002	Nov 18, 2004	Apr	DISC
	+	@	EQ 150MG BASE	N021743	003	Nov 18, 2004	Apr	DISC

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
ERTAPENEM SODIUM

AP		SUN PHARM	EQ 1GM BASE/VIAL	A209145	001	May 02, 2023	Apr	NEWA
----	--	-----------	------------------	---------	-----	--------------	-----	------

ERYTHROMYCIN

GEL; TOPICAL
ERYTHROMYCIN

>D>	AT	PAI HOLDINGS PHARM	2%	A208154	001	Jul 19, 2017	May	DISC
>A>		@	2%	A208154	001	Jul 19, 2017	May	DISC

TABLET; ORAL
ERYTHROMYCIN

AB		ARBOR PHARMS LLC	500MG	A061621	002		Jan	CHRS
AB	!	CADILA PHARMS LTD	500MG	A213628	002	Jun 28, 2021	Jan	CHRS
AB		ZYDUS	250MG	A212693	001	Mar 07, 2023	Feb	NEWA
AB			500MG	A212693	002	Mar 07, 2023	Feb	NEWA

ERYTHROMYCIN ETHYLSUCCINATE

TABLET; ORAL
ERYTHROMYCIN ETHYLSUCCINATE

		@ AUROBINDO PHARMA USA	EQ 400MG BASE	A062847	001	Sep 14, 1988	Apr	CAHN
--	--	------------------------	---------------	---------	-----	--------------	-----	------

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION
ERYTHROMYCIN LACTOBIONATE

>D>	AP	EXELA PHARMA	EQ 500MG BASE/VIAL	A211086	001	Sep 17, 2020	May	DISC
>A>		@	EQ 500MG BASE/VIAL	A211086	001	Sep 17, 2020	May	DISC

ESCITALOPRAM OXALATE

SOLUTION; ORAL
LEXAPRO

	+	@ ABBVIE	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Jan	CAHN
--	---	----------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL
ESCITALOPRAM OXALATE

	@	DASH PHARMS	EQ 5MG BASE	A077550	001	May 14, 2015	Feb	CAHN
	@		EQ 10MG BASE	A077550	002	May 14, 2015	Feb	CAHN
	@		EQ 20MG BASE	A077550	003	May 14, 2015	Feb	CAHN
>A>	AB	JUBILANT CADISTA	EQ 5MG BASE	A202280	001	Sep 12, 2012	May	CAHN
>A>	AB		EQ 10MG BASE	A202280	002	Sep 12, 2012	May	CAHN
>A>	AB		EQ 20MG BASE	A202280	003	Sep 12, 2012	May	CAHN
>D>	AB	JUBILANT GENERICS	EQ 5MG BASE	A202280	001	Sep 12, 2012	May	CAHN
>D>	AB		EQ 10MG BASE	A202280	002	Sep 12, 2012	May	CAHN
>D>	AB		EQ 20MG BASE	A202280	003	Sep 12, 2012	May	CAHN

LEXAPRO

AB	+	ABBVIE	EQ 5MG BASE	N021323	001	Aug 14, 2002	Jan	CAHN
AB	+		EQ 10MG BASE	N021323	002	Aug 14, 2002	Jan	CAHN
AB	+	!	EQ 20MG BASE	N021323	003	Aug 14, 2002	Jan	CAHN

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION		BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER					
AP	+!	BAXTER HLTHCARE	2GM/100ML	N019386	005	Jan 27, 2003	Jan CTEC
INJECTABLE; INJECTION		BREVIBLOC IN PLASTIC CONTAINER					
AP	+!	BAXTER HLTHCARE	1GM/100ML	N019386	004	Feb 16, 2001	Jan CTEC
ESMOLOL HYDROCHLORIDE							
AP		AMNEAL	1GM/100ML	A216603	001	Dec 13, 2022	Jan CPOT
AP			2GM/100ML	A216603	002	Dec 13, 2022	Jan CPOT
AP		EUGIA PHARMA	1GM/100ML	A216244	001	Mar 21, 2022	Jan CPOT
AP			2GM/100ML	A216244	002	Mar 21, 2022	Jan CPOT
AP		HQ SPCLT PHARMA	1GM/100ML	A214172	001	Dec 02, 2022	Jan CPOT
AP			2GM/100ML	A214172	002	Dec 02, 2022	Jan CPOT
AP		MYLAN LABS LTD	1GM/100ML	A206608	001	Jun 08, 2018	Jan CPOT
AP			2GM/100ML	A206608	002	Jun 08, 2018	Jan CPOT
AP		SAGENT PHARMS INC	1GM/100ML	A207107	001	Jun 08, 2018	Jan CPOT
AP			2GM/100ML	A207107	002	Jun 08, 2018	Jan CPOT

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL		ESOMEPRAZOLE MAGNESIUM					
AB		PRINSTON INC	EQ 20MG BASE	A214920	001	Mar 28, 2023	Mar NEWA
AB			EQ 40MG BASE	A214920	002	Mar 28, 2023	Mar NEWA
FOR SUSPENSION, DELAYED RELEASE; ORAL		ESOMEPRAZOLE MAGNESIUM					
>A>	AB	ZYDUS PHARMS	EQ 20MG BASE/PACKET	A206055	001	Jun 07, 2023	May NEWA
>A>	AB		EQ 40MG BASE/PACKET	A206055	002	Jun 07, 2023	May NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL		NAPROXEN AND ESOMEPRAZOLE MAGNESIUM					
	@	ACTAVIS LABS FL INC	EQ 20MG BASE; 375MG	A204470	001	Aug 24, 2022	Feb DISC
	@		EQ 20MG BASE; 500MG	A204470	002	Aug 24, 2022	Feb DISC

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS		ESOMEPRAZOLE SODIUM					
AP		EUGIA PHARMA	EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jan CHRS
		GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020	Apr CTEC

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL		ESTRADIOL					
AB2		ZYDUS NOVELTECH INC	0.025MG/24HR	A202985	001	Mar 29, 2023	Mar NEWA
AB2			0.0375MG/24HR	A202985	002	Mar 29, 2023	Mar NEWA
AB2			0.05MG/24HR	A202985	003	Mar 29, 2023	Mar NEWA
AB			0.06MG/24HR	A202985	004	Mar 29, 2023	Mar NEWA
AB2			0.075MG/24HR	A202985	005	Mar 29, 2023	Mar NEWA
AB2			0.1MG/24HR	A202985	006	Mar 29, 2023	Mar NEWA
AB2		ZYDUS PHARMS	0.025MG/24HR	A202985	001	Mar 29, 2023	Apr CAHN
AB2			0.0375MG/24HR	A202985	002	Mar 29, 2023	Apr CAHN
AB2			0.05MG/24HR	A202985	003	Mar 29, 2023	Apr CAHN
AB			0.06MG/24HR	A202985	004	Mar 29, 2023	Apr CAHN
AB2			0.075MG/24HR	A202985	005	Mar 29, 2023	Apr CAHN
AB2			0.1MG/24HR	A202985	006	Mar 29, 2023	Apr CAHN
INSERT; VAGINAL		IMVEXXY					
	+	MAYNE PHARMA	0.004MG	N208564	001	May 29, 2018	Jan CAHN
	+!		0.01MG	N208564	002	May 29, 2018	Jan CAHN
SYSTEM; TRANSDERMAL		ESTRADIOL					
>D>	AB	ZYDUS NOVELTECH INC	0.014MG/24HR	A204379	001	Apr 17, 2023	May CAHN
	AB		0.014MG/24HR	A204379	001	Apr 17, 2023	Apr NFTG
>D>	AB1		0.025MG/24HR	A206241	001	Dec 01, 2022	May CAHN
>D>	AB1		0.0375MG/24HR	A206241	002	Dec 01, 2022	May CAHN
>D>	AB1		0.05MG/24HR	A206241	003	Dec 01, 2022	May CAHN
>D>	AB1		0.075MG/24HR	A206241	004	Dec 01, 2022	May CAHN
>D>	AB1		0.1MG/24HR	A206241	005	Dec 01, 2022	May CAHN
>A>	AB	ZYDUS PHARMS	0.014MG/24HR	A204379	001	Apr 17, 2023	May CAHN
>A>	AB1		0.025MG/24HR	A206241	001	Dec 01, 2022	May CAHN
>A>	AB1		0.0375MG/24HR	A206241	002	Dec 01, 2022	May CAHN

SYSTEM; TRANSDERMAL
ESTRADIOL

>A>	AB1		0.05MG/24HR	A206241	003	Dec 01, 2022	May	CAHN	
>A>	AB1		0.075MG/24HR	A206241	004	Dec 01, 2022	May	CAHN	
>A>	AB1		0.1MG/24HR	A206241	005	Dec 01, 2022	May	CAHN	
		MENOSTAR							
	AB	+!	BAYER HLTHCARE	0.014MG/24HR	N021674	001	Jun 08, 2004	Apr	CFTG
		VIVELLE							
>D>		@	NOVARTIS	0.025MG/24HR	N020323	005	Aug 16, 2000	May	CAHN
>D>		@		0.0375MG/24HR	N020323	001	Oct 28, 1994	May	CAHN
>D>		@		0.05MG/24HR	N020323	002	Oct 28, 1994	May	CAHN
>D>		@		0.075MG/24HR	N020323	003	Oct 28, 1994	May	CAHN
>D>		@		0.1MG/24HR	N020323	004	Oct 28, 1994	May	CAHN
>A>		@	SANDOZ	0.025MG/24HR	N020323	005	Aug 16, 2000	May	CAHN
>A>		@		0.0375MG/24HR	N020323	001	Oct 28, 1994	May	CAHN
>A>		@		0.05MG/24HR	N020323	002	Oct 28, 1994	May	CAHN
>A>		@		0.075MG/24HR	N020323	003	Oct 28, 1994	May	CAHN
>A>		@		0.1MG/24HR	N020323	004	Oct 28, 1994	May	CAHN
		VIVELLE-DOT							
>D>	AB1	+	NOVARTIS	0.025MG/24HR	N020538	009	May 03, 2002	May	CAHN
>D>	AB1	+		0.0375MG/24HR	N020538	005	Jan 08, 1999	May	CAHN
>D>	AB1	+		0.05MG/24HR	N020538	006	Jan 08, 1999	May	CAHN
>D>	AB1	+		0.075MG/24HR	N020538	007	Jan 08, 1999	May	CAHN
>D>	AB1	+!		0.1MG/24HR	N020538	008	Jan 08, 1999	May	CAHN
>A>	AB1	+	SANDOZ	0.025MG/24HR	N020538	009	May 03, 2002	May	CAHN
>A>	AB1	+		0.0375MG/24HR	N020538	005	Jan 08, 1999	May	CAHN
>A>	AB1	+		0.05MG/24HR	N020538	006	Jan 08, 1999	May	CAHN
>A>	AB1	+		0.075MG/24HR	N020538	007	Jan 08, 1999	May	CAHN
>A>	AB1	+!		0.1MG/24HR	N020538	008	Jan 08, 1999	May	CAHN

ESTRADIOL VALERATE

INJECTABLE; INJECTION
ESTRADIOL VALERATE

AO			XIROMED	10MG/ML	A216656	001	Apr 28, 2023	Apr	NEWA
AO				20MG/ML	A216656	002	Apr 28, 2023	Apr	NEWA
AO				40MG/ML	A216656	003	Apr 28, 2023	Apr	NEWA

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

			LEVONORGESTREL AND ETHINYL ESTRADIOL						
		@	AMNEAL PHARMS	0.02MG; 0.1MG	A201108	001	Feb 05, 2014	Jan	DISC
		@		0.03MG; 0.15MG	A201095	001	Dec 08, 2014	Jan	DISC
AB1			HETERO LABS	0.02MG; 0.1MG	A212298	001	Feb 13, 2023	Feb	NEWA
AB			LUPIN LTD	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A200248	001	Nov 19, 2015	Jan	CTEC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

			RHUZDAH						
		@	AUROBINDO PHARMA	0.035MG; 0.4MG	A207585	001	Oct 11, 2022	Apr	DISC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

			HAILEY 24 FE						
AB		!	GLENMARK PHARMS LTD	0.02MG; 1MG	A204847	001	Nov 17, 2017	Feb	CTNA
			MINASTRIN 24 FE						
		+	@ APIL	0.02MG; 1MG	N203667	001	May 08, 2013	Apr	DISC
			NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB		!	GLENMARK PHARMS LTD	0.02MG; 1MG	A210369	001	Dec 26, 2017	Apr	CHRS

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

			NORGESTIMATE AND ETHINYL ESTRADIOL						
		@	AMNEAL PHARMS	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG	A203870	001	Nov 12, 2015	Jan	DISC

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

RING; VAGINAL
ANNOVERA

		+	MAYNE PHARMA	0.013MG/24HR; 0.15MG/24HR	N209627	001	Aug 10, 2018	Jan	CAHN
--	--	---	--------------	---------------------------	---------	-----	--------------	-----	------

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

@ DASH PHARMS	20MG/ML	A204927	001	Oct 31, 2017	Mar CAHN
@ DASH PHARMS NATCO	20MG/ML	A203507	001	Nov 20, 2017	Feb CAHN

EVEROLIMUS

TABLET; ORAL
EVEROLIMUS

AB	TEVA PHARMS USA	10MG	A210050	004	Dec 09, 2019	Apr CMFD
----	-----------------	------	---------	-----	--------------	----------

EXEMESTANE

TABLET; ORAL
EXEMESTANE

@ ALVOGEN	25MG	A200898	001	Jul 28, 2014	Feb DISC
-----------	------	---------	-----	--------------	----------

EZETIMIBE

TABLET; ORAL
EZETIMIBE

@ ORIENT PHARMA	10MG	A215693	001	Sep 13, 2022	Mar DISC
-----------------	------	---------	-----	--------------	----------

FAMOTIDINE

FOR SUSPENSION; ORAL
FAMOTIDINE

>A> AB	ALKEM LABS LTD	40MG/5ML	A216400	001	May 15, 2023	May NEWA
--------	----------------	----------	---------	-----	--------------	----------

INJECTABLE; INJECTION
FAMOTIDINE

@ ZYDUS PHARMS	10MG/ML	A215828	001	Nov 22, 2022	Apr DISC
----------------	---------	---------	-----	--------------	----------

TABLET; ORAL
FAMOTIDINE

AB	ALKEM LABS LTD	20MG	A217375	001	Apr 24, 2023	Apr NEWA
AB		40MG	A217375	002	Apr 24, 2023	Apr NEWA
AB	VKT PHARMA	20MG	A215630	001	Jan 07, 2022	Jan CAHN
AB		40MG	A215630	002	Jan 07, 2022	Jan CAHN

FAMOTIDINE; IBUPROFEN

TABLET; ORAL
IBUPROFEN AND FAMOTIDINE

AB	ASCENT PHARMS INC	26.6MG; 800MG	A216814	001	Mar 15, 2023	Mar NEWA
----	-------------------	---------------	---------	-----	--------------	----------

FEBUXOSTAT

TABLET; ORAL
FEBUXOSTAT

AB	ZYDUS LIFESCIENCES	40MG	A205443	001	Jan 09, 2023	Jan CAHN
AB		80MG	A205443	002	Jan 09, 2023	Jan CAHN

FENOFIBRATE

TABLET; ORAL
FENOFIBRATE

AB	CHARTWELL RX	54MG	A209660	001	Feb 11, 2019	Feb CAHN
AB		160MG	A209660	002	Feb 11, 2019	Feb CAHN

FENOPROFEN CALCIUM

CAPSULE; ORAL
FENOPROFEN CALCIUM

>A> AB	MISEMER	EQ 200MG BASE	A215548	001	May 16, 2023	May NEWA
>A>		EQ 300MG BASE	A215548	002	May 16, 2023	May NEWA
>A> AB		EQ 400MG BASE	A215548	003	May 16, 2023	May NEWA
>D>	+ XSPIRE PHARMA	EQ 200MG BASE	N017604	003		May CTEC
>A> AB	+	EQ 200MG BASE	N017604	003		May CTEC

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL
FENTANYL-100

>D> AB	ZYDUS NOVELTECH INC	100MCG/HR	A209655	008	Jan 24, 2023	May CAHN
AB		100MCG/HR	A209655	008	Jan 24, 2023	Jan NEWA
>A> AB	ZYDUS PHARMS	100MCG/HR	A209655	008	Jan 24, 2023	May CAHN
>D> AB	ZYDUS NOVELTECH INC	12.5MCG/HR	A209655	001	Jan 24, 2023	May CAHN

FILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-12

AB		12.5MCG/HR	A209655	001	Jan 24, 2023	Jan NEWA
>A>	AB	ZYDUS PHARMS 12.5MCG/HR	A209655	001	Jan 24, 2023	May CAHN
FENTANYL-25						
>D>	AB	ZYDUS NOVELTECH INC 25MCG/HR	A209655	002	Jan 24, 2023	May CAHN
	AB	25MCG/HR	A209655	002	Jan 24, 2023	Jan NEWA
>A>	AB	ZYDUS PHARMS 25MCG/HR	A209655	002	Jan 24, 2023	May CAHN
FENTANYL-37						
>D>	AB	ZYDUS NOVELTECH INC 37.5MCG/HR	A209655	003	Jan 24, 2023	May CAHN
	AB	37.5MCG/HR	A209655	003	Jan 24, 2023	Jan NEWA
>A>	AB	ZYDUS PHARMS 37.5MCG/HR	A209655	003	Jan 24, 2023	May CAHN
FENTANYL-50						
>D>	AB	ZYDUS NOVELTECH INC 50MCG/HR	A209655	004	Jan 24, 2023	May CAHN
	AB	50MCG/HR	A209655	004	Jan 24, 2023	Jan NEWA
>A>	AB	ZYDUS PHARMS 50MCG/HR	A209655	004	Jan 24, 2023	May CAHN
FENTANYL-62						
>D>	AB	ZYDUS NOVELTECH INC 62.5MCG/HR	A209655	005	Jan 24, 2023	May CAHN
	AB	62.5MCG/HR	A209655	005	Jan 24, 2023	Jan NEWA
>A>	AB	ZYDUS PHARMS 62.5MCG/HR	A209655	005	Jan 24, 2023	May CAHN
FENTANYL-75						
>D>	AB	ZYDUS NOVELTECH INC 75MCG/HR	A209655	006	Jan 24, 2023	May CAHN
	AB	75MCG/HR	A209655	006	Jan 24, 2023	Jan NEWA
>A>	AB	ZYDUS PHARMS 75MCG/HR	A209655	006	Jan 24, 2023	May CAHN
FENTANYL-87						
	AB	MYLAN TECHNOLOGIES 87.5MCG/HR	A076258	008	Dec 29, 2014	Jan CTEC
>D>	AB	ZYDUS NOVELTECH INC 87.5MCG/HR	A209655	007	Jan 24, 2023	May CAHN
	AB	87.5MCG/HR	A209655	007	Jan 24, 2023	Jan NEWA
>A>	AB	ZYDUS PHARMS 87.5MCG/HR	A209655	007	Jan 24, 2023	May CAHN

FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE

	+	HIKMA	EQ 0.025MG BASE/0.5ML	N019101	002	Jan 20, 2023	Jan NEWA
AP	+		EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Jan CTNA
SOLUTION; INTRAVENOUS							
FENTANYL CITRATE							
>D>	+	EXELA PHARMA	EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML)	N215870	001	Feb 08, 2023	May DISC
>A>	+	@	EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML)	N215870	001	Feb 08, 2023	May DISC
	+		EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML)	N215870	001	Feb 08, 2023	Feb NEWA
>D>	+		EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N215870	002	Feb 08, 2023	May DISC
>A>	+	@	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N215870	002	Feb 08, 2023	May DISC
	+		EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N215870	002	Feb 08, 2023	Feb NEWA

TABLET;BUCCAL, SUBLINGUAL
FENTANYL CITRATE

@	DR REDDYS LABS SA	EQ 0.1MG BASE	A206329	001	Aug 22, 2022	Apr CAHN
@		EQ 0.2MG BASE	A206329	002	Aug 22, 2022	Apr CAHN
@		EQ 0.3MG BASE	A206329	003	Aug 22, 2022	Apr CAHN
@		EQ 0.4MG BASE	A206329	004	Aug 22, 2022	Apr CAHN
@		EQ 0.6MG BASE	A206329	005	Aug 22, 2022	Apr CAHN
@		EQ 0.8MG BASE	A206329	006	Aug 22, 2022	Apr CAHN

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

@	LUPIN LTD	4MG	A204983	001	Jan 05, 2023	Feb DISC
@		8MG	A204983	002	Jan 05, 2023	Feb DISC

>A> FEZOLINETANT

>A>	TABLET;ORAL						
>A>	VEOZAH						
>A>	+	ASTELLAS	45MG	N216578	001	May 12, 2023	May NEWA

FINAFLOXACIN

SUSPENSION/DROPS;OTIC
XTORO

+ @ FONSECA BIOSCIENCES 0.3% N206307 001 Dec 17, 2014 Jan CAHN

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL
FINGOLIMOD HYDROCHLORIDE

AB BIOCON LTD EQ 0.5MG BASE A207979 001 Dec 04, 2019 Jan CMFD
>A> AB BIONPHARMA INC EQ 0.5MG BASE A210252 001 May 24, 2023 May NEWA

FINGOLIMOD LAURYL SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL
TASCENSO ODT

+ CYCLE EQ 0.25MG BASE N214962 001 Dec 23, 2021 Jan CAHN
+! EQ 0.5MG BASE N214962 002 Dec 09, 2022 Jan CAHN

>A> FLOTUFOLASTAT F-18 GALLIUM

>A> SOLUTION;INTRAVENOUS
>A> POSLUMA

>A> +! BLUE EARTH 50ML (8-158mCi/ML) N216023 001 May 25, 2023 May NEWA

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION
FLUDARABINE PHOSPHATE

AP2 ACTAVIS LLC 50MG/2ML (25MG/ML) A203738 001 Feb 28, 2017 Jan CTEC
AP1 AREVA PHARMS 50MG/2ML (25MG/ML) A090724 001 Sep 27, 2010 Jan CTEC
AP1 FRESENIUS KABI USA 50MG/2ML (25MG/ML) A078393 001 Oct 15, 2007 Jan CTEC
AP 50MG/2ML (25MG/ML) A078393 001 Oct 15, 2007 Jan CHRS
AP1 SAGENT PHARMS INC 50MG/2ML (25MG/ML) A076661 001 Apr 28, 2004 Jan CTEC
AP2 +! SANDOZ 50MG/2ML (25MG/ML) N022137 001 Sep 21, 2007 Jan CTEC

FLUDROCORTISONE ACETATE

TABLET;ORAL
FLUDROCORTISONE ACETATE

@ HIKMA 0.1MG A216013 001 Oct 27, 2022 Apr DISC

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL
FLUOCINOLONE ACETONIDE

@ INVATECH 0.025% A088045 001 Dec 16, 1982 Mar CAHN

SOLUTION;TOPICAL
FLUOCINOLONE ACETONIDE

>A> AT CHARTWELL RX 0.01% A209596 001 Dec 26, 2017 May CAHN
>D> AT GLASSHOUSE PHARMS 0.01% A209596 001 Dec 26, 2017 May CAHN

FLUOCINONIDE

CREAM;TOPICAL
FLUOCINONIDE

AB1 ! AMNEAL 0.05% A210554 001 Aug 21, 2018 Feb CHRS
+ @ TARO 0.05% N019117 001 Jun 26, 1984 Feb DISC

GEL;TOPICAL
FLUOCINONIDE

>D> AB PAI HOLDINGS PHARM 0.05% A209030 001 Jun 19, 2018 May DISC
>A> @ 0.05% A209030 001 Jun 19, 2018 May DISC

OINTMENT;TOPICAL
FLUOCINONIDE

AB CHARTWELL RX 0.05% A207538 001 Jul 31, 2017 Apr CAHN

SOLUTION;TOPICAL
FLUOCINONIDE

>A> AT CHARTWELL RX 0.05% A209118 001 Apr 23, 2018 May CAHN
>D> AT GLASSHOUSE PHARMS 0.05% A209118 001 Apr 23, 2018 May CAHN
>D> AT PAI HOLDINGS PHARM 0.05% A207554 001 Mar 18, 2019 May DISC
>A> @ 0.05% A207554 001 Mar 18, 2019 May DISC

FLUOROMETHOLONE

SUSPENSION/DROPS;OPHTHALMIC

FML

+! ABBVIE 0.1% N016851 002 Jul 28, 1982 Jan CAHN

FML FORTE

+! ABBVIE 0.25% N019216 001 Apr 23, 1986 Jan CAHN

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

AP ALEMBIC 2.5GM/50ML (50MG/ML) A217295 001 Mar 03, 2023 Feb NEWA

FLUOXETINE HYDROCHLORIDE

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

AA NOSTRUM LABS INC EQ 20MG BASE/5ML A075292 001 Feb 07, 2002 Mar CMFD

AA XTTRIUM LABS INC EQ 20MG BASE/5ML A075514 001 Aug 29, 2002 Jan CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

@ PIRAMAL HLTHCARE UK EQ 10MG BASE A211444 001 Sep 13, 2022 Mar DISC

@ EQ 20MG BASE A211444 002 Sep 13, 2022 Mar DISC

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION

FLUPHENAZINE DECANOATE

AO GLAND PHARMA LTD 25MG/ML A215509 001 Mar 30, 2023 Mar NEWA

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

@ PRASCO 1MG A089804 002 Aug 12, 1988 Apr DISC

@ 2.5MG A089804 003 Aug 12, 1988 Apr DISC

@ 5MG A089804 004 Aug 12, 1988 Apr DISC

@ 10MG A089804 001 Aug 12, 1988 Apr DISC

FLURANDRENOLIDE

LOTION;TOPICAL

CORDRAN

>D> AT +! ALMIRALL 0.05% N013790 001 May DISC

>A> + @ 0.05% N013790 001 May DISC

FLURANDRENOLIDE

>D> AT PADAGIS ISRAEL 0.05% A207133 001 Aug 30, 2016 May CTEC

>A> ! 0.05% A207133 001 Aug 30, 2016 May CTEC

OINTMENT;TOPICAL

CORDRAN

>D> AT +! ALMIRALL 0.05% N012806 001 May DISC

>A> + @ 0.05% N012806 001 May DISC

FLURANDRENOLIDE

>D> AT TELIGENT 0.05% A207851 001 Dec 30, 2016 May CTEC

>A> ! 0.05% A207851 001 Dec 30, 2016 May CTEC

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER;INHALATION

BREQ ELLIPTA

>A> + GLAXO GRP LTD 0.05MG/INH;EQ 0.025MG BASE/INH N204275 003 May 12, 2023 May NEWA

FLUVOXAMINE MALEATE

TABLET;ORAL

LUVOX

AB + ANI PHARMS 25MG N021519 001 Dec 20, 2007 Jan CRLD

AB + 50MG N021519 002 Dec 20, 2007 Jan CRLD

AB + 100MG N021519 003 Dec 20, 2007 Jan CRLD

FORMOTEROL FUMARATE

SOLUTION;INHALATION

FORMOTEROL FUMARATE

AN MANKIND PHARMA 0.02MG/2ML A215883 001 Mar 22, 2023 Mar NEWA

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS
FOSAPREPITANT DIMEGLUMINE

>A> AP PIRAMAL CRITICAL EQ 150MG BASE/VIAL A214683 001 May 16, 2023 May NEWA

FOSCARNET SODIUM

INJECTABLE; INJECTION
FOSCARNET SODIUM

>A> AP AVET LIFESCIENCES 2.4GM/100ML A213807 001 Jun 05, 2023 May NEWA

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION
FOSPHENYTOIN SODIUM
@ MYLAN LABS LTD

EQ 50MG PHENYTOIN NA/ML A078736 001 Jun 08, 2010 Apr DISC

FROVATRIPTAN SUCCINATE

TABLET; ORAL
FROVATRIPTAN SUCCINATE
@ MYLAN

EQ 2.5MG BASE A202931 001 Aug 28, 2014 Apr DISC

FUROSEMIDE

SOLUTION; ORAL
FUROSEMIDE
@ XTTRIUM LABS INC

10MG/ML A070655 001 Oct 02, 1987 Jan CAHN

TABLET; ORAL
FUROSEMIDE
@ CHARTWELL RX
@

20MG N018413 001 Nov 30, 1983 Mar CAHN
40MG N018413 002 Nov 30, 1983 Mar CAHN

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN

>A> AB LAURUS 100MG A217546 001 May 12, 2023 May NEWA
>A> AB 300MG A217546 002 May 12, 2023 May NEWA
>A> AB 400MG A217546 003 May 12, 2023 May NEWA

SOLUTION; ORAL
GABAPENTIN

AA RUBICON 250MG/5ML A216492 001 Jan 18, 2023 Jan NEWA

TABLET; ORAL
GABAPENTIN
@ CHARTWELL RX
@

>A> 600MG A076120 001 Jan 27, 2006 May CAHN
>A> 800MG A076120 002 Jan 27, 2006 May CAHN
AB GRANULES 600MG A217116 001 Mar 28, 2023 Mar NEWA
AB 800MG A217116 002 Mar 28, 2023 Mar NEWA
>D> @ SANDOZ 600MG A076120 001 Jan 27, 2006 May CAHN
>D> @ 800MG A076120 002 Jan 27, 2006 May CAHN

GADOBUTROL

SOLUTION; INTRAVENOUS
GADOBUTROL

AP HAINAN POLY PHARM 4.5354GM/7.5ML (604.72MG/ML) A217480 001 Mar 15, 2023 Mar NEWA
AP 9.0708GM/15ML (604.72MG/ML) A217480 002 Mar 15, 2023 Mar NEWA

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS
GADOTERATE MEGLUMINE

AP HENGRUI PHARMA 37.69GM/100ML (376.9MG/ML) A215304 005 Apr 15, 2022 Feb CMS1

GANIRELIX ACETATE

INJECTABLE; INJECTION
GANIRELIX ACETATE

AP GLAND PHARMA LTD 250MCG/0.5ML A215658 001 Feb 28, 2023 Feb NEWA
>D> AP +! ORGANON USA INC 250MCG/0.5ML N021057 001 Jul 29, 1999 May CAHN
>A> AP +! ORGANON USA ORGANON 250MCG/0.5ML N021057 001 Jul 29, 1999 May CAHN

GATIFLOXACIN

	SOLUTION/DROPS;OPHTHALMIC						
	ZYMAR						
	+ @ ALLERGAN	0.3%		N021493	001	Mar 28, 2003	Mar DISC
	ZYMAXID						
AT	+! ABBVIE	0.5%		N022548	001	May 18, 2010	Jan CAHN

GEFITINIB

	TABLET;ORAL						
	GEFITINIB						
AB	ACTAVIS LABS FL INC	250MG		A208913	001	Apr 26, 2023	Apr NEWA
>A> AB	NATCO	250MG		A212827	001	May 31, 2023	May NEWA
AB	QILU PHARM HAINAN	250MG		A211591	001	Feb 13, 2023	Feb NEWA

GEMCITABINE HYDROCHLORIDE

	INJECTABLE;INJECTION						
	GEMCITABINE HYDROCHLORIDE						
AP	HIKMA	200MG/5.26ML (38MG/ML)		A213175	001	Mar 07, 2023	Feb NEWA
AP		1GM/26.3ML (38MG/ML)		A213175	002	Mar 07, 2023	Feb NEWA
AP		2GM/52.6ML (38MG/ML)		A213175	003	Mar 07, 2023	Feb NEWA

GENTAMICIN SULFATE

	OINTMENT;OPHTHALMIC						
	GENTAMICIN SULFATE						
	@ AKORN	EQ 0.3% BASE		A064093	001	Aug 31, 1995	Feb DISC
	! FERA PHARMS LLC	EQ 0.3% BASE		A065024	001	Jul 30, 2004	Feb CTEC
AT	!	EQ 0.3% BASE		A065024	001	Jul 30, 2004	Feb CHRS
	OINTMENT;TOPICAL						
	GENTAMICIN SULFATE						
>D> AT	PAI HOLDINGS PHARM	EQ 0.1% BASE		A209233	001	Dec 31, 2018	May DISC
>A>	@	EQ 0.1% BASE		A209233	001	Dec 31, 2018	May DISC
	SOLUTION/DROPS;OPHTHALMIC						
	GENOPTIC						
	@ ALLERGAN	EQ 0.3% BASE		A062452	001	Oct 10, 1984	Feb DISC
	GENTAK						
	@ AKORN	EQ 0.3% BASE		A064163	001	Oct 12, 2001	Feb DISC
	GENTAMICIN SULFATE						
AT	! SANDOZ	EQ 0.3% BASE		A062196	001		Feb CHRS

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

	OINTMENT;OPHTHALMIC						
	PRED-G						
	+ @ ALLERGAN	EQ 0.3% BASE;0.6%		N050612	001	Dec 01, 1989	Jan DISC

GLIPIZIDE; METFORMIN HYDROCHLORIDE

	TABLET;ORAL						
	GLIPIZIDE AND METFORMIN HYDROCHLORIDE						
	@ DASH PHARMS	2.5MG;250MG		A078083	001	Apr 12, 2007	Feb CAHN
	@	2.5MG;500MG		A078083	002	Apr 12, 2007	Feb CAHN
	@	5MG;500MG		A078083	003	Apr 12, 2007	Feb CAHN

GLUCAGON

	SOLUTION;SUBCUTANEOUS						
	GVOKE KIT						
>A>	+! XERIS	1MG/0.2ML (1MG/0.2ML)		N212097	005	Aug 20, 2021	May NEWA
>A>	GVOKE PFS						
	+ @ XERIS	0.5MG/0.1ML (0.5MG/0.1ML)		N212097	001	Sep 10, 2019	Jan DISC

GLYCEROL PHENYLBUTYRATE

	LIQUID;ORAL						
	RAVICTI						
	+! HORIZON THERAP US	1.1GM/ML		N203284	001	Feb 01, 2013	Jan CAHN

GLYCOPYRROLATE

	INJECTABLE;INJECTION						
	GLYCOPYRROLATE						
	@ LUPIN LTD	0.2MG/ML		A213655	001	Feb 07, 2023	Apr DISC
AP		0.2MG/ML		A213655	001	Feb 07, 2023	Jan NEWA
AP	MANKIND PHARMA	0.2MG/ML		A217354	001	Feb 27, 2023	Feb NEWA

TABLET; ORAL

GLYCOPYRROLATE							
AA	ALEMBIC	1MG	A203657	001	Nov 30, 2018	Feb	CAHN
AA		2MG	A203657	002	Nov 30, 2018	Feb	CAHN
AA	AUROBINDO PHARMA	1MG	A202675	001	Apr 15, 2013	Jan	CAHN
AA		2MG	A202675	002	Oct 30, 2018	Jan	CAHN

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS
PREVDUO

+	SLAYBACK PHARMA LLC	0.6MG/3ML (0.2MG/ML); 3MG/3ML (1MG/ML)	N216903	001	Feb 23, 2023	Feb	NEWA
---	---------------------	--	---------	-----	--------------	-----	------

GRANISETRON HYDROCHLORIDE

TABLET; ORAL

GRANISETRON HYDROCHLORIDE							
>A>	@ AUROBINDO PHARMA USA	EQ 1MG BASE	A078725	001	Jan 30, 2008	May	CAHN
>D>	@ MYLAN	EQ 1MG BASE	A078725	001	Jan 30, 2008	May	CAHN

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE							
AB	AJANTA PHARMA LTD	EQ 1MG BASE	A217293	001	Apr 27, 2023	Apr	NEWA
AB		EQ 2MG BASE	A217293	002	Apr 27, 2023	Apr	NEWA

HALCINONIDE

CREAM; TOPICAL

HALCINONIDE							
>A>	AB CHARTWELL RX	0.1%	A214723	001	Sep 08, 2021	May	CAHN
>D>	AB GLASSHOUSE PHARMS	0.1%	A214723	001	Sep 08, 2021	May	CAHN

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE							
>D>	AB PAI HOLDINGS PHARM	0.05%	A209978	001	Mar 20, 2018	May	DISC
>A>	@	0.05%	A209978	001	Mar 20, 2018	May	DISC

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL							
	@ ACTAVIS GROUP	0.5MG	A200854	001	Jul 01, 2022	Jan	DISC
	@	1MG	A200854	002	Jul 01, 2022	Jan	DISC
	@	2MG	A200854	003	Jul 01, 2022	Jan	DISC
	@	5MG	A200854	004	Jul 01, 2022	Jan	DISC
	@	10MG	A200854	005	Jul 01, 2022	Jan	DISC
	@	20MG	A200854	006	Jul 01, 2022	Jan	DISC
AB	ZYDUS PHARMS USA	0.5MG	A077580	001	Jan 17, 2023	Jan	NEWA
AB		1MG	A077580	002	Jan 17, 2023	Jan	NEWA
AB		2MG	A077580	006	Jan 17, 2023	Jan	NEWA

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE							
>A>	AO MANKIND PHARMA	EQ 50MG BASE/ML	A216730	001	May 23, 2023	May	NEWA
>A>	AO	EQ 100MG BASE/ML	A216730	002	May 23, 2023	May	NEWA

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM							
AP	NANJING KING-FRIEND	5,000 UNITS/ML	A212061	001	Jul 15, 2020	Feb	CMFD
	HEPARIN SODIUM PRESERVATIVE FREE						
AP	NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020	Feb	CMFD

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE							
AP	EUGIA PHARMA	20MG/ML	A215147	001	Feb 13, 2023	Feb	NEWA
>D>	AP MYLAN INSTITUTIONAL	20MG/ML	A204680	001	Apr 28, 2016	May	DISC
>A>	@	20MG/ML	A204680	001	Apr 28, 2016	May	DISC

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE							
>D>	@ HERITAGE PHARMS INC	10MG	A040858	001	Feb 26, 2010	May	CMFD

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

>A>	AA		10MG	A 040858	001	Feb 26, 2010	May	CMFD
>D>		@	25MG	A 040858	002	Feb 26, 2010	May	CMFD
>A>	AA		25MG	A 040858	002	Feb 26, 2010	May	CMFD
>D>		@	50MG	A 040858	003	Feb 26, 2010	May	CMFD
>A>	AA		50MG	A 040858	003	Feb 26, 2010	May	CMFD
>D>		@	100MG	A 040858	004	Feb 26, 2010	May	CMFD
>A>	AA		100MG	A 040858	004	Feb 26, 2010	May	CMFD

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB		HERITAGE PHARMS	12.5MG	A 085182	003	May 02, 2023	Apr	NEWA
----	--	-----------------	--------	----------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

>A>	AB	MACLEODS PHARMS LTD	12.5MG;20MG	A 204801	001	Jun 01, 2023	May	NEWA
>A>	AB		12.5MG;40MG	A 204801	002	Jun 01, 2023	May	NEWA
>A>	AB		25MG;40MG	A 204801	003	Jun 01, 2023	May	NEWA
	AB	ZYDUS PHARMS	12.5MG;20MG	A 206377	001	Feb 24, 2023	Feb	NEWA
	AB		12.5MG;40MG	A 206377	002	Feb 24, 2023	Feb	NEWA
	AB		25MG;40MG	A 206377	003	Feb 24, 2023	Feb	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		APOTEX	12.5MG;EQ 10MG BASE	A 091524	001	Mar 12, 2013	Jan	CAHN
AB			12.5MG;EQ 20MG BASE	A 091524	002	Mar 12, 2013	Jan	CAHN
AB			25MG;EQ 20MG BASE	A 091524	003	Mar 12, 2013	Jan	CAHN
		@ CHARTWELL RX	12.5MG;EQ 10MG BASE	A 076374	001	Mar 31, 2004	Apr	CAHN
		@	12.5MG;EQ 20MG BASE	A 076374	002	Mar 31, 2004	Apr	CAHN
		@	25MG;EQ 20MG BASE	A 076374	003	Mar 31, 2004	Apr	CAHN

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HYDROCHLORIDE

>D>	AP	EUROHLTH INTL SARL	2MG/ML	A 202159	001	Apr 27, 2018	May	CAHN
>A>	AP	HIKMA	2MG/ML	A 202159	001	Apr 27, 2018	May	CAHN
		HOSPIRA INC	0.25MG/0.5ML	N 200403	005	Mar 03, 2023	Mar	NEWA
			4MG/ML	N 200403	003	Dec 01, 2011	Apr	CTEC

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREMYD

+	@	AKORN	1%;0.25%	N 019261	001	Jan 30, 1992	Feb	DISC
---	---	-------	----------	----------	-----	--------------	-----	------

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

>A>	AB	CHARTWELL RX	200MG	A 210543	001	Jul 06, 2018	May	CAHN
>D>	AB	LUPIN LTD	200MG	A 210543	001	Jul 06, 2018	May	CAHN

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

+	!	BAUSCH	5MG	N 018771	001		Jan	CAHN
+	!	BAUSCH AND LOMB INC	5MG	N 018771	001		Jan	CAHN

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

+	!	AM REGENT	25MG/ML	A 087408	001		Feb	CRLD
+	!		50MG/ML	A 087408	002		Feb	CRLD

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB		CHARTWELL RX	10MG	A 040804	001	Jun 30, 2008	Jan	CAHN
AB			25MG	A 040804	002	Jun 30, 2008	Jan	CAHN
AB			50MG	A 040804	003	Jun 30, 2008	Jan	CAHN

HYDROXYZINE PAMOATE

	CAPSULE;ORAL						
	HYDROXYZINE PAMOATE						
AB	HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar	CTEC
AB		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar	CTEC

ICOSAPENT ETHYL

	CAPSULE;ORAL						
	ICOSAPENT ETHYL						
AB	DR REDDYS	500MG	A209499	002	Mar 08, 2023	Feb	NEWA
AB	HIKMA	500MG	A209457	002	Mar 08, 2023	Feb	NEWA
AB	ZYDUS	500MG	A217656	001	Apr 20, 2023	Apr	NEWA
AB		1GM	A217656	002	Apr 20, 2023	Apr	NEWA

IMATINIB MESYLATE

	TABLET;ORAL						
	IMATINIB MESYLATE						
	@ BRECKENRIDGE	EQ 100MG BASE	A205990	001	Feb 08, 2019	Mar	DISC
AB	CHARTWELL RX	EQ 100MG BASE	A208429	001	Jan 17, 2019	Jan	CAHN
AB		EQ 400MG BASE	A208429	002	Jan 17, 2019	Jan	CAHN

IMIQUIMOD

	CREAM;TOPICAL						
	ALDARA						
	+ @ BAUSCH	5%	N020723	001	Feb 27, 1997	Feb	DISC
	IMIQUIMOD						
AB	! GLENMARK GENERICS	5%	A201994	001	Mar 06, 2012	Feb	CHRS

INDAPAMIDE

	TABLET;ORAL						
	INDAPAMIDE						
	@ AUROBINDO PHARMA USA	1.25MG	A075105	001	Jul 23, 1998	Apr	CAHN
	@	2.5MG	A075105	002	Jul 23, 1998	Apr	CAHN

INDOMETHACIN

	CAPSULE;ORAL						
	INDOMETHACIN						
AB	CHARTWELL MOLECULES	25MG	N018829	002	Aug 06, 1984	Feb	CMFD
AB		50MG	N018829	001	Aug 06, 1984	Feb	CMFD

INFIGRATINIB PHOSPHATE

	CAPSULE;ORAL						
	TRUSELTIQ						
	+ @ HELSINN HLTHCARE	25MG	N214622	001	May 28, 2021	Apr	DISC
	+ @	100MG	N214622	002	May 28, 2021	Apr	DISC

IOPAMIDOL

	INJECTABLE;INJECTION						
	IOPAMIDOL						
AP	HAINAN POLY	41%	A215382	001	Feb 27, 2023	Feb	NEWA
AP		61%	A215382	002	Feb 27, 2023	Feb	NEWA
	ISOVUE-M 200						
AP	+! BRACCO	41%	N018735	001	Dec 31, 1985	Feb	CTEC
	ISOVUE-M 300						
AP	+! BRACCO	61%	N018735	004	Dec 31, 1985	Feb	CTEC

IPRATROPIUM BROMIDE

	SPRAY, METERED;NASAL						
	IPRATROPIUM BROMIDE						
	@ AUROBINDO PHARMA USA	0.021MG/SPRAY	A075552	001	Mar 31, 2003	Apr	CAHN
	@	0.042MG/SPRAY	A075553	001	Mar 31, 2003	Apr	CAHN

ISONIAZID

	TABLET;ORAL						
	LANIAZID						
	@ CHARTWELL MOLECULAR	50MG	A080140	001		Feb	CAHN
	@	100MG	A080140	002		Feb	CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION
ISOPROTERENOL HYDROCHLORIDE

	@	AM REGENT	0.2MG/ML	A214775	001	Oct 19, 2022	Apr	DISC
AP		HIKMA	0.2MG/ML	A211703	001	Apr 26, 2023	Apr	NEWA
>A>	AP	PENN LIFE	0.2MG/ML	A215542	001	Sep 20, 2022	May	CAHN
>D>	AP	STI PHARMA LLC	0.2MG/ML	A215542	001	Sep 20, 2022	May	CAHN
	AP	ZYDUS PHARMS	0.2MG/ML	A215557	001	Apr 14, 2023	Apr	NEWA

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

>D>	AB	SHANDONG	120MG	A214115	001	Apr 29, 2022	May	DISC
>A>		@	120MG	A214115	001	Apr 29, 2022	May	DISC

ISOSULFAN BLUE

INJECTABLE; INJECTION
ISOSULFAN BLUE

>A>	AP	AM REGENT	1%	A210294	001	May 17, 2023	May	NEWA
-----	----	-----------	----	---------	-----	--------------	-----	------

ISOTRETINOIN

CAPSULE; ORAL
MYORISAN

>D>	AB1	DOUGLAS PHARMS	10MG	A076485	001	Jan 19, 2012	May	CAHN
>D>	AB1		20MG	A076485	002	Jan 19, 2012	May	CAHN
>D>	AB1		30MG	A076485	004	Aug 25, 2015	May	CAHN
>D>	AB1		40MG	A076485	003	Jan 19, 2012	May	CAHN
>A>	AB1	UPSHER SMITH LABS	10MG	A076485	001	Jan 19, 2012	May	CAHN
>A>	AB1		20MG	A076485	002	Jan 19, 2012	May	CAHN
>A>	AB1		30MG	A076485	004	Aug 25, 2015	May	CAHN
>A>	AB1		40MG	A076485	003	Jan 19, 2012	May	CAHN

IVACAFTOR

GRANULE; ORAL
KALYDECO

>A>	+	VERTEX PHARMS INC	5.8MG/PACKET	N207925	004	May 03, 2023	May	NEWA
>A>	+		13.4MG/PACKET	N207925	005	May 03, 2023	May	NEWA

IVERMECTIN

CREAM; TOPICAL
IVERMECTIN

	@	ZYDUS	1%	A215210	001	Aug 02, 2022	Jan	DISC
--	---	-------	----	---------	-----	--------------	-----	------

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETAMINE HYDROCHLORIDE

AP		FRESENIUS KABI USA	EQ 10MG BASE/ML	A215808	001	Jan 13, 2023	Jan	NEWA
AP			EQ 50MG BASE/ML	A215808	002	Jan 13, 2023	Jan	NEWA
AP		GLAND PHARMA LTD	EQ 50MG BASE/ML	A216809	002	Jan 24, 2023	Jan	NEWA
AP			EQ 100MG BASE/ML	A216809	003	Jan 24, 2023	Jan	NEWA

KETOCONAZOLE

TABLET; ORAL
KETOCONAZOLE

>A>		@ AUROBINDO PHARMA USA	200MG	A075597	001	Dec 23, 1999	May	CAHN
>D>		@ MYLAN	200MG	A075597	001	Dec 23, 1999	May	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

AP		CAPLIN	15MG/ML	A217789	001	May 10, 2023	Apr	NEWA
AP			30MG/ML	A217789	002	May 10, 2023	Apr	NEWA

SOLUTION/DROPS; OPHTHALMIC
ACULAR

AT	+	ABBVIE	0.5%	N019700	001	Nov 09, 1992	Jan	CAHN
		@ AKORN	0.5%	A078434	001	Nov 05, 2009	Jan	DISC

TABLET; ORAL
KETOROLAC TROMETHAMINE

AB		BIONPHARMA INC	10MG	A216759	001	Feb 23, 2023	Feb	NEWA
AB		LEADING	10MG	A215745	001	Feb 23, 2023	Feb	NEWA

>D> KETOTIFEN FUMARATE
 >D> DRUG-ELUTING CONTACT LENS;OPHTHALMIC
 >D> ACUVUE THERAVISION WITH KETOTIFEN
 >D> +! JOHNSON JOHNSON VISN EQ 19MCG BASE N022388 001 Feb 25, 2022 May DISC
 >A> + @ EQ 19MCG BASE N022388 001 Feb 25, 2022 May DISC

LACOSAMIDE

>A> CAPSULE, EXTENDED RELEASE;ORAL
 >A> MOTPOLY XR
 >A> + AUCTA 100MG N216185 001 May 04, 2023 May NEWA
 >A> + 150MG N216185 002 May 04, 2023 May NEWA
 >A> +! 200MG N216185 003 May 04, 2023 May NEWA
 SOLUTION;INTRAVENOUS
 LACOSAMIDE
 AP MSN 200MG/20ML (10MG/ML) A215979 001 Feb 09, 2023 Feb NEWA
 SOLUTION;ORAL
 LACOSAMIDE
 AA MEDLEY PHARMS 10MG/ML A216461 001 Feb 06, 2023 Jan NEWA
 TABLET;ORAL
 LACOSAMIDE
 @ ACCORD HLTHCARE 50MG A205011 001 Jul 12, 2022 Jan DISC
 @ 100MG A205011 002 Jul 12, 2022 Jan DISC
 @ 150MG A205011 003 Jul 12, 2022 Jan DISC
 @ 200MG A205011 004 Jul 12, 2022 Jan DISC
 @ APOTEX 50MG A214567 001 Sep 23, 2022 Mar DISC
 @ 100MG A214567 002 Sep 23, 2022 Mar DISC
 @ 150MG A214567 003 Sep 23, 2022 Mar DISC
 @ 200MG A214567 004 Sep 23, 2022 Mar DISC

LACTULOSE

SOLUTION;ORAL
 LACTULOSE
 AA XTTRIUM LABS INC 10GM/15ML A075911 001 Feb 21, 2002 Mar CMFD
 SOLUTION;ORAL, RECTAL
 LACTULOSE
 AA BAJAJ 10GM/15ML A076645 001 Jul 28, 2003 Feb CMFD

LAMIVUDINE

TABLET;ORAL
 LAMIVUDINE
 >A> @ AUROBINDO PHARMA USA 100MG A204002 001 Dec 31, 2014 May CAHN
 >D> @ MYLAN 100MG A204002 001 Dec 31, 2014 May CAHN

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
 TEMIXYS
 + @ CHARTWELL RX 300MG;300MG N211284 001 Nov 16, 2018 Mar CAHN

LAMOTRIGINE

TABLET;ORAL
 LAMOTRIGINE
 @ CHARTWELL MOLECULAR 25MG A077783 001 Nov 01, 2010 Jan CAHN
 @ 100MG A077783 002 Nov 01, 2010 Jan CAHN
 @ 150MG A077783 003 Nov 01, 2010 Jan CAHN
 @ 200MG A077783 004 Nov 01, 2010 Jan CAHN

LANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
 LANSOPRAZOLE
 AB AUROBINDO PHARMA LTD 15MG A207167 001 Mar 28, 2023 Mar NEWA
 AB 30MG A207167 002 Mar 28, 2023 Mar NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
 LATANOPROST
 @ AKORN 0.005% A090887 001 Jul 19, 2011 Jan DISC

LATANOPROST; NETARSUDIL DIMESYLATE

SOLUTION/DROPS;OPHTHALMIC
ROCKLATAN

>D>	+	AERIE PHARMS INC	0.005%;EQ 0.02% BASE	N208259	001	Mar 12, 2019	May CAHN
>A>	+	ALCON LABS INC	0.005%;EQ 0.02% BASE	N208259	001	Mar 12, 2019	May CAHN

LENALIDOMIDE

CAPSULE;ORAL
LENALIDOMIDE

AB		APOTEX	2.5MG	A211022	005	Mar 07, 2023	Feb NEWA
AB			20MG	A211022	006	Mar 07, 2023	Feb NEWA
AB		ARROW INTL	2.5MG	A201452	005	Mar 06, 2023	Feb NEWA
AB			20MG	A201452	006	Mar 06, 2023	Feb NEWA
AB		CIPLA	2.5MG	A214618	001	Mar 06, 2023	Feb NEWA
AB			20MG	A210435	005	Mar 06, 2023	Feb NEWA
AB		EUGIA PHARMA	2.5MG	A213885	001	Mar 06, 2023	Feb NEWA
AB			5MG	A213885	002	Mar 06, 2023	Feb NEWA
AB			10MG	A213885	003	Mar 06, 2023	Feb NEWA
AB			15MG	A213885	004	Mar 06, 2023	Feb NEWA
AB			20MG	A213885	005	Mar 06, 2023	Feb NEWA
AB			25MG	A213885	006	Mar 06, 2023	Feb NEWA
>A>	AB	HETERO LABS LTD V	2.5MG	A212414	001	May 11, 2023	May NEWA
>A>	AB		5MG	A212414	002	May 11, 2023	May NEWA
>A>	AB		10MG	A212414	003	May 11, 2023	May NEWA
>A>	AB		15MG	A212414	004	May 11, 2023	May NEWA
>A>	AB		20MG	A212414	005	May 11, 2023	May NEWA
>A>	AB		25MG	A212414	006	May 11, 2023	May NEWA
AB		LOTUS PHARM CO LTD	2.5MG	A210480	005	Mar 06, 2023	Feb NEWA
AB			20MG	A210480	006	Mar 06, 2023	Feb NEWA
AB		MYLAN	2.5MG	A213912	005	Mar 06, 2023	Feb NEWA
AB			20MG	A213912	006	Mar 06, 2023	Feb NEWA
AB		SUN PHARM	2.5MG	A211846	005	Mar 06, 2023	Feb NEWA
AB			5MG	A211846	001	Feb 08, 2023	Jan NEWA
AB			10MG	A211846	002	Feb 08, 2023	Jan NEWA
AB			15MG	A211846	003	Feb 08, 2023	Jan NEWA
AB			20MG	A211846	006	Mar 06, 2023	Feb NEWA
AB			25MG	A211846	004	Feb 08, 2023	Jan NEWA
AB		TORRENT	10MG	A213405	001	Feb 17, 2023	Feb NEWA
AB			25MG	A213405	002	Feb 17, 2023	Feb NEWA
AB		ZYDUS PHARMS	2.5MG	A210154	005	Mar 06, 2023	Feb NEWA
AB			20MG	A210154	006	Mar 06, 2023	Feb NEWA

LENIOLISIB PHOSPHATE

TABLET;ORAL
JOENJA

+	!	PHARMING	EQ 70MG BASE	N217759	001	Mar 24, 2023	Mar NEWA
---	---	----------	--------------	---------	-----	--------------	----------

LETROZOLE

TABLET;ORAL
LETROZOLE

@	CHARTWELL RX	2.5MG	A202716	001	May 16, 2013	Feb CAHN
---	--------------	-------	---------	-----	--------------	----------

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION
LEUCOVORIN CALCIUM

!	FRESENIUS KABI USA	EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Apr CHRS
		EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Apr CTEC
!		EQ 10MG BASE/ML	A207241	001	Mar 14, 2018	Apr CHRS
	LEUCOVORIN CALCIUM PRESERVATIVE FREE					
@	HIKMA	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Apr DISC

LEUPROLIDE ACETATE

POWDER;INTRAMUSCULAR
LUPRON DEPOT-PED KIT

+	!	ABBVIE ENDOCRINE INC	45MG	N020263	009	Apr 14, 2023	Apr NEWA
---	---	----------------------	------	---------	-----	--------------	----------

POWDER;SUBCUTANEOUS
ELIGARD KIT

+	!	TOLMAR	7.5MG	N021343	001	Jan 23, 2002	Feb CAHN
+	!		22.5MG	N021379	001	Jul 24, 2002	Feb CAHN
+	!		30MG	N021488	001	Feb 13, 2003	Feb CAHN
+	!		45MG	N021731	001	Dec 14, 2004	Feb CAHN

LEVETIRACETAM

		INJECTABLE; INTRAVENOUS							
		LEVETIRACETAM IN SODIUM CHLORIDE							
AP	FRESENIUS KABI USA	500MG/100ML	(5MG/ML)	A208619	001	Jan 31, 2023	Jan	NEWA	
AP		1.5GM/100ML	(15MG/ML)	A208619	003	Jan 31, 2023	Jan	NEWA	
		SOLUTION; ORAL							
		LEVETIRACETAM							
AA	ALEMBIC	100MG/ML		A203067	001	May 09, 2013	Feb	CAHN	
AA	QUAGEN	100MG/ML		A090079	001	Apr 11, 2012	Feb	CAHN	
	@ XTTRIUM LABS INC	100MG/ML		A090028	001	Mar 03, 2010	Mar	CAHN	
		TABLET; ORAL							
		LEVETIRACETAM							
	@ MYLAN	250MG		A076919	001	Nov 04, 2008	Apr	DISC	
		TABLET, EXTENDED RELEASE; ORAL							
		LEVETIRACETAM							
	@ AUROBINDO PHARMA USA	500MG		A200475	001	Dec 19, 2011	Apr	CAHN	
	@	750MG		A200475	002	Dec 19, 2011	Apr	CAHN	
	@	1GM		A200475	003	Dec 07, 2015	Apr	CAHN	
AB	OVERSEAS	500MG		A212688	002	May 05, 2023	Apr	NEWA	

LEVOFLOXACIN

		SOLUTION/DROPS; OPHTHALMIC							
		LEVOFLOXACIN							
	@ AKORN	0.5%		A090268	001	Dec 20, 2010	Jan	DISC	
!	RISING	0.5%		A077700	001	Dec 20, 2010	Jan	CTEC	

LEVOLEUCOVORIN CALCIUM

		SOLUTION; INTRAVENOUS							
		LEVOLEUCOVORIN CALCIUM							
>D>	!	GLAND PHARMA LTD	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210892	002	Sep 14, 2018	May	CTEC	
>A>	AP	!	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210892	002	Sep 14, 2018	May	CTEC	
>A>	AP	HAINAN POLY PHARM	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A217314	001	May 22, 2023	May	NEWA	
>A>	AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A217314	002	May 22, 2023	May	NEWA	

LEVOMILNACIPRAN HYDROCHLORIDE

		CAPSULE, EXTENDED RELEASE; ORAL							
		FETZIMA							
+	ABBVIE	EQ 20MG BASE		N204168	001	Jul 25, 2013	Mar	CTEC	
AB	+	EQ 20MG BASE		N204168	001	Jul 25, 2013	Jan	CAHN	
	+	EQ 40MG BASE		N204168	002	Jul 25, 2013	Mar	CTEC	
AB	+	EQ 40MG BASE		N204168	002	Jul 25, 2013	Jan	CAHN	
	+	EQ 80MG BASE		N204168	003	Jul 25, 2013	Mar	CTEC	
AB	+	EQ 80MG BASE		N204168	003	Jul 25, 2013	Jan	CAHN	
	+	EQ 120MG BASE		N204168	004	Jul 25, 2013	Mar	CTEC	
AB	+	EQ 120MG BASE		N204168	004	Jul 25, 2013	Jan	CAHN	
		LEVOMILNACIPRAN HYDROCHLORIDE							
	@ AUROBINDO PHARMA LTD	EQ 20MG BASE		A210826	001	Jan 06, 2023	Mar	DISC	
	@	EQ 40MG BASE		A210826	002	Jan 06, 2023	Mar	DISC	
	@	EQ 80MG BASE		A210826	003	Jan 06, 2023	Mar	DISC	
	@	EQ 120MG BASE		A210826	004	Jan 06, 2023	Mar	DISC	
AB	PRINSTON INC	EQ 20MG BASE		A210771	001	Mar 20, 2023	Mar	NEWA	
AB		EQ 40MG BASE		A210771	002	Mar 20, 2023	Mar	NEWA	
AB		EQ 80MG BASE		A210771	003	Mar 20, 2023	Mar	NEWA	
AB		EQ 120MG BASE		A210771	004	Mar 20, 2023	Mar	NEWA	

LEVORPHANOL TARTRATE

		TABLET; ORAL							
		LEVORPHANOL TARTRATE							
AB	HIKMA	2MG		A074278	001	Mar 31, 2000	Jan	CMFD	
AB	!	NOVITIUM PHARMA	3MG	A213479	002	Jan 12, 2021	Apr	CTEC	
AB	SUN PHARM INDS INC	3MG		A213906	002	Apr 25, 2023	Apr	NEWA	

LEVOTHYROXINE SODIUM

		CAPSULE; ORAL							
		LEVOTHYROXINE SODIUM							
>D>	AB	TEVA PHARMS USA INC	0.137MG	A211369	005	May 02, 2023	May	DISC	
>A>	@		0.137MG	A211369	005	May 02, 2023	May	DISC	
AB			0.137MG	A211369	005	May 02, 2023	Apr	NFTG	

CAPSULE;ORAL									
>D>	LEVOTHYROXINE SODIUM								
>D>	AB	0.175MG	A211369	006	May 02, 2023	May	DISC		
>A>	@	0.175MG	A211369	006	May 02, 2023	May	DISC		
	AB	0.175MG	A211369	006	May 02, 2023	Apr	NFTG		
>D>	AB	0.2MG	A211369	004	Nov 09, 2022	May	DISC		
>A>	@	0.2MG	A211369	004	Nov 09, 2022	May	DISC		
TIROSINT									
>D>	AB + INSTITUT BIOCHIMIQUE	0.137MG	N021924	009	Oct 02, 2009	May	CTEC		
>A>	+	0.137MG	N021924	009	Oct 02, 2009	May	CTEC		
	AB +	0.137MG	N021924	009	Oct 02, 2009	Apr	CFTG		
>D>	AB +	0.175MG	N021924	011	Apr 25, 2017	May	CTEC		
>A>	+	0.175MG	N021924	011	Apr 25, 2017	May	CTEC		
	AB +	0.175MG	N021924	011	Apr 25, 2017	Apr	CFTG		
>D>	AB +!	0.2MG	N021924	012	Apr 25, 2017	May	CTEC		
>A>	+!	0.2MG	N021924	012	Apr 25, 2017	May	CTEC		
POWDER;INTRAVENOUS									
LEVOTHYROXINE SODIUM									
AP	ZYDUS PHARMS	100MCG/VIAL	A217066	001	Mar 24, 2023	Mar	NEWA		
AP		200MCG/VIAL	A217066	002	Mar 24, 2023	Mar	NEWA		
AP		500MCG/VIAL	A217066	003	Mar 24, 2023	Mar	NEWA		

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL									
LEVOTHYROXINE SODIUM									
AB4	ASCENT PHARMS INC	0.025MG	A215259	001	Jan 18, 2023	Jan	NEWA		
AB4		0.05MG	A215259	002	Jan 18, 2023	Jan	NEWA		
AB4		0.075MG	A215259	003	Jan 18, 2023	Jan	NEWA		
AB4		0.088MG	A215259	004	Jan 18, 2023	Jan	NEWA		
AB4		0.1MG	A215259	005	Jan 18, 2023	Jan	NEWA		
AB4		0.112MG	A215259	006	Jan 18, 2023	Jan	NEWA		
AB4		0.125MG	A215259	007	Jan 18, 2023	Jan	NEWA		
AB4		0.137MG	A215259	008	Jan 18, 2023	Jan	NEWA		
AB4		0.15MG	A215259	009	Jan 18, 2023	Jan	NEWA		
AB4		0.175MG	A215259	010	Jan 18, 2023	Jan	NEWA		
AB4		0.2MG	A215259	011	Jan 18, 2023	Jan	NEWA		
AB4		0.3MG	A215259	012	Jan 18, 2023	Jan	NEWA		
AB2	MACLEODS PHARMS LTD	0.025MG	A211417	001	Dec 21, 2022	Jan	CTEC		
AB2		0.05MG	A211417	002	Dec 21, 2022	Jan	CTEC		
AB2		0.075MG	A211417	003	Dec 21, 2022	Jan	CTEC		
AB2		0.088MG	A211417	004	Dec 21, 2022	Jan	CTEC		
AB2		0.1MG	A211417	005	Dec 21, 2022	Jan	CTEC		
AB2		0.112MG	A211417	006	Dec 21, 2022	Jan	CTEC		
AB2		0.125MG	A211417	007	Dec 21, 2022	Jan	CTEC		
AB2		0.137MG	A211417	008	Dec 21, 2022	Jan	CTEC		
AB2		0.15MG	A211417	009	Dec 21, 2022	Jan	CTEC		
AB2		0.175MG	A211417	010	Dec 21, 2022	Jan	CTEC		
AB2		0.2MG	A211417	011	Dec 21, 2022	Jan	CTEC		
AB2		0.3MG	A211417	012	Dec 21, 2022	Jan	CTEC		

LIDOCAINE

OINTMENT;TOPICAL									
LIDOCAINE									
>D>	AT PAI HOLDINGS PHARM	5%	A205318	001	Feb 01, 2016	May	DISC		
>A>	@	5%	A205318	001	Feb 01, 2016	May	DISC		

PATCH;TOPICAL									
LIDOCAINE									
AB	INST BIOCHIMIQUE SA	5%	A209190	001	Apr 30, 2020	Apr	CAHN		

LIDOCAINE HYDROCHLORIDE

JELLY;TOPICAL									
GLYDO									
AT	! SAGENT PHARMS INC	2%	A201094	001	Apr 28, 2014	Apr	CHRS		
AT	LIDOCAINE HYDROCHLORIDE								
AT	AKORN	2%	A040433	001	Feb 12, 2003	Apr	CHRS		
SOLUTION;ORAL									
LIDOCAINE HYDROCHLORIDE									
AT	RUBICON	2%	A216780	001	Mar 28, 2023	Mar	NEWA		

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

>D>	AB	PAI HOLDINGS PHARM	2.5%;2.5%	A205887	001	Jun 29, 2018	May	DISC
>A>		@	2.5%;2.5%	A205887	001	Jun 29, 2018	May	DISC

LINACLOTIDE

CAPSULE; ORAL

LINACLOTIDE

	AB	@ AUROBINDO PHARMA	145MCG	A209611	001	Feb 07, 2023	Mar	DISC
	AB		145MCG	A209611	001	Feb 07, 2023	Jan	NEWA
		@	290MCG	A209611	002	Feb 07, 2023	Mar	DISC
	AB		290MCG	A209611	002	Feb 07, 2023	Jan	NEWA

LINZESS

		+! ABBVIE	145MCG	N202811	001	Aug 30, 2012	Mar	CTEC
		+	290MCG	N202811	002	Aug 30, 2012	Mar	CTEC
	AB	+! ALLERGAN	145MCG	N202811	001	Aug 30, 2012	Jan	CTEC
	AB	+	290MCG	N202811	002	Aug 30, 2012	Jan	CTEC

LINAGLIPTIN

TABLET; ORAL

LINAGLIPTIN

	AB	ZYDUS PHARMS	5MG	A208448	001	Mar 30, 2023	Mar	NEWA
--	----	--------------	-----	---------	-----	--------------	-----	------

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

LINAGLIPTIN AND METFORMIN HYDROCHLORIDE

	AB	ZYDUS PHARMS	2.5MG;500MG	A208449	001	Mar 30, 2023	Mar	NEWA
	AB		2.5MG;850MG	A208449	002	Mar 30, 2023	Mar	NEWA
	AB		2.5MG;1GM	A208449	003	Mar 30, 2023	Mar	NEWA

LINEZOLID

TABLET; ORAL

LINEZOLID

	AB	CHARTWELL RX	600MG	A210702	001	Apr 25, 2019	Mar	CAHN
--	----	--------------	-------	---------	-----	--------------	-----	------

LISINAPRIL

TABLET; ORAL

LISINAPRIL

	AB	HERITAGE PHARMA	2.5MG	A075752	001	Jul 01, 2002	Mar	CMFD
	AB		5MG	A075752	002	Jul 01, 2002	Mar	CMFD
	AB		10MG	A075752	003	Jul 01, 2002	Mar	CMFD
	AB		20MG	A075752	004	Jul 01, 2002	Mar	CMFD
	AB		30MG	A075752	005	Jul 01, 2002	Mar	CMFD
	AB		40MG	A075752	006	Jul 01, 2002	Mar	CMFD

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

	AB	RUBICON	2MG	A216876	001	Jan 26, 2023	Jan	NEWA
	AB	ZYDUS LIFESCIENCES	2MG	A217471	001	Mar 23, 2023	Apr	CAHN
	AB	ZYDUS PHARMS	2MG	A217471	001	Mar 23, 2023	Mar	NEWA

LORAZEPAM

TABLET; ORAL

LORAZEPAM

>D>	AB	AMNEAL PHARMS	0.5MG	A078826	001	Jun 23, 2010	May	DISC
>A>		@	0.5MG	A078826	001	Jun 23, 2010	May	DISC
>D>	AB		1MG	A078826	002	Jun 23, 2010	May	DISC
>A>		@	1MG	A078826	002	Jun 23, 2010	May	DISC
>D>	AB		2MG	A078826	003	Jun 23, 2010	May	DISC
>A>		@	2MG	A078826	003	Jun 23, 2010	May	DISC

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

	AB	GRANULES	25MG	A215959	001	Feb 23, 2023	Feb	NEWA
	AB		50MG	A215959	002	Feb 23, 2023	Feb	NEWA
	AB		100MG	A215959	003	Feb 23, 2023	Feb	NEWA

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS;OPHTHALMIC
ALREX

AB	+!	BAUSCH AND LOMB	0.2%	N020803	001	Mar 09, 1998	Mar CFTG
		LOTEPREDNOL ETABONATE					
AB		AKORN	0.2%	A215933	001	Apr 12, 2023	Mar NFTG

LOVASTATIN

TABLET;ORAL
LOVASTATIN

>A>	@	AUROBINDO PHARMA USA	10MG	A075451	001	Dec 17, 2001	May CAHN
	@		10MG	A075935	001	Dec 17, 2001	Apr CAHN
>A>	@		20MG	A075451	002	Dec 17, 2001	May CAHN
	@		20MG	A075935	002	Dec 17, 2001	Apr CAHN
>A>	@		40MG	A075451	003	Dec 17, 2001	May CAHN
	@		40MG	A075935	003	Dec 17, 2001	Apr CAHN
>D>	@	MYLAN	10MG	A075451	001	Dec 17, 2001	May CAHN
>D>	@		20MG	A075451	002	Dec 17, 2001	May CAHN
>D>	@		40MG	A075451	003	Dec 17, 2001	May CAHN

LUBIPROSTONE

CAPSULE;ORAL
LUBIPROSTONE

AB		AMNEAL	8MCG	A209450	001	Nov 30, 2021	Jan CMFD
AB			24MCG	A209450	002	Nov 30, 2021	Jan CMFD
AB		ZYDUS PHARMS	8MCG	A214131	001	Mar 23, 2023	Mar NEWA
AB			24MCG	A214131	002	Mar 23, 2023	Mar NEWA

LURASIDONE HYDROCHLORIDE

TABLET;ORAL
LURASIDONE HYDROCHLORIDE

AB		AMNEAL PHARMS CO	20MG	A208002	001	Jan 03, 2019	Feb CMFD
AB			40MG	A208002	002	Jan 03, 2019	Feb CMFD
AB			60MG	A208002	003	Jan 03, 2019	Feb CMFD
AB			80MG	A208002	004	Jan 03, 2019	Feb CMFD
AB			120MG	A208002	005	Jan 03, 2019	Feb CMFD
AB		AUROBINDO PHARMA LTD	20MG	A208045	001	Mar 10, 2023	Mar NEWA
AB			40MG	A208045	002	Mar 10, 2023	Mar NEWA
AB			60MG	A208045	003	Mar 10, 2023	Mar NEWA
AB			80MG	A208045	004	Mar 10, 2023	Mar NEWA
AB			120MG	A208045	005	Mar 10, 2023	Mar NEWA
AB	@	AVET LIFESCIENCES	120MG	A208058	005	Feb 28, 2023	Mar DISC
AB			120MG	A208058	005	Feb 28, 2023	Feb NEWA
AB		LUPIN LTD	20MG	A208031	001	Jan 03, 2019	Feb CMFD
AB			40MG	A208031	002	Jan 03, 2019	Feb CMFD
AB			60MG	A208031	003	Jan 03, 2019	Feb CMFD
AB			80MG	A208031	004	Jan 03, 2019	Feb CMFD
AB			120MG	A208031	005	Jan 03, 2019	Feb CMFD
AB		PIRAMAL HLTHCARE UK	20MG	A212091	001	Dec 28, 2020	Feb CMFD
AB			40MG	A212091	002	Dec 28, 2020	Feb CMFD
AB			60MG	A212091	003	Dec 28, 2020	Feb CMFD
AB			80MG	A212091	004	Dec 28, 2020	Feb CMFD
AB			120MG	A212091	005	Dec 28, 2020	Feb CMFD
AB		TORRENT	20MG	A208055	001	Jan 03, 2019	Feb CMFD
AB			40MG	A208055	002	Jan 03, 2019	Feb CMFD
AB			80MG	A208055	003	Jan 03, 2019	Feb CMFD
AB			120MG	A208055	004	Jan 03, 2019	Feb CMFD

>D> MACIMORELIN ACETATE

>D> FOR SOLUTION;ORAL
>D> MACRILEN

>D>	+!	NOVO	EQ 60MG BASE/POUCH	N205598	001	Dec 20, 2017	May DISC
>A>	+ @		EQ 60MG BASE/POUCH	N205598	001	Dec 20, 2017	May DISC

MACITENTAN

TABLET;ORAL
MACITENTAN

AB	@	AUROBINDO PHARMA LTD	10MG	A211198	001	Apr 18, 2023	Apr DISC
			10MG	A211198	001	Apr 18, 2023	Apr NEWA
		OPSUMIT					
	+!	ACTELION	10MG	N204410	001	Oct 18, 2013	Apr CTEC
AB	+!		10MG	N204410	001	Oct 18, 2013	Apr CFTG

MAFENIDE ACETATEFOR SOLUTION;TOPICAL
MAFENIDE ACETATE

>D>	!	NOVAST LABS	5%	A206716	001	Jul 31, 2017	May DISC
>A>	@		5%	A206716	001	Jul 31, 2017	May DISC

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

AP		FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215370	001	Jun 29, 2022	Mar CMFD
AP		FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215371	001	Jun 08, 2022	Mar CMFD
AP	+	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	001		Mar CTEC
AP	+	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	002	Nov 22, 1982	Mar CTEC

MAGNESIUM SULFATE

INJECTABLE;INJECTION

AP		AMNEAL	2GM/50ML (40MG/ML)	A216597	001	Feb 15, 2023	Feb NEWA
AP			4GM/100ML (40MG/ML)	A216597	002	Feb 15, 2023	Feb NEWA

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

>D>	AA	INDICUS PHARMA	12.5MG	A205136	001	Feb 22, 2019	May CAHN
>D>	AA		25MG	A205136	002	Feb 22, 2019	May CAHN
>D>	AA		50MG	A205136	003	Feb 22, 2019	May CAHN
>A>	AA	WILSHIRE PHARMS INC	12.5MG	A205136	001	Feb 22, 2019	May CAHN
>A>	AA		25MG	A205136	002	Feb 22, 2019	May CAHN
>A>	AA		50MG	A205136	003	Feb 22, 2019	May CAHN

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLOFENAMATE SODIUM

	@	CHARTWELL RX	EQ 50MG BASE	A072262	001	Nov 29, 1988	Jan CAHN
	@		EQ 100MG BASE	A072263	001	Nov 29, 1988	Jan CAHN

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

MEDROXYPROGESTERONE ACETATE

>A>	AB	AMNEAL	150MG/ML	A215397	001	Jun 07, 2023	May NEWA
-----	----	--------	----------	---------	-----	--------------	----------

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGESTROL ACETATE

	@	BRECKENRIDGE	125MG/ML	A204688	001	Dec 01, 2017	Jan DISC
AB		XTTRIUM LABS INC	40MG/ML	A076721	001	Nov 01, 2004	Jan CAHN

MELOXICAM

TABLET;ORAL

MELOXICAM

>A>	AB	ASCENT PHARMS INC	7.5MG	A217579	001	Jun 07, 2023	May NEWA
>A>	AB		15MG	A217579	002	Jun 07, 2023	May NEWA
AB		COREPHARMA	7.5MG	A077882	001	Jul 20, 2006	Feb CAHN
AB			15MG	A077882	002	Jul 20, 2006	Feb CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

	@	ANI PHARMS	28MG	A205365	004	Feb 28, 2020	Feb DISC
	@	XIAMEN LP PHARM CO	7MG	A213985	001	Oct 11, 2022	Apr DISC
	@		14MG	A213985	002	Oct 11, 2022	Apr DISC
	@		28MG	A213985	003	Oct 11, 2022	Apr DISC
		NAMENDA XR					
AB	+	ABBVIE	7MG	N022525	001	Jun 21, 2010	Feb CAHN
AB	+		14MG	N022525	002	Jun 21, 2010	Feb CAHN

		CAPSULE, EXTENDED RELEASE;ORAL							
		NAMENDA XR							
AB	+		21MG	N022525	003	Jun 21, 2010	Feb	CAHN	
AB	+!		28MG	N022525	004	Jun 21, 2010	Feb	CAHN	
		TABLET;ORAL							
		MEMANTINE HYDROCHLORIDE							
		@ YILING	5MG	A212947	001	Apr 03, 2020	Mar	CAHN	
		@	10MG	A212947	002	Apr 03, 2020	Mar	CAHN	
		NAMENDA							
AB	+	ABBVIE	5MG	N021487	001	Oct 16, 2003	Feb	CAHN	
AB	+!		10MG	N021487	002	Oct 16, 2003	Feb	CAHN	
		<u>MEPIVACAINE HYDROCHLORIDE</u>							
		INJECTABLE;INJECTION							
		SCANDONEST PLAIN							
>D>	AP	!	DEPROCO	A088387	001	Oct 10, 1984	May	CTEC	
>A>		!		A088387	001	Oct 10, 1984	May	CTEC	
		<u>MEROPENEM</u>							
		INJECTABLE;INJECTION							
		MEROPENEM							
		@ BROOKS STERISCIENCE	500MG/VIAL	A216154	001	Aug 18, 2022	Mar	DISC	
		@	1GM/VIAL	A216154	002	Aug 18, 2022	Mar	DISC	
		<u>MESALAMINE</u>							
		CAPSULE, DELAYED RELEASE;ORAL							
		DELZICOL							
AB	+!	ABBVIE	400MG	N204412	001	Feb 01, 2013	Feb	CAHN	
		CAPSULE, EXTENDED RELEASE;ORAL							
		MESALAMINE							
>A>	AB	AMTA	375MG	A217533	001	Jun 06, 2023	May	NEWA	
AB		AUROBINDO PHARMA LTD	375MG	A214477	001	Mar 31, 2023	Mar	NEWA	
		ENEMA;RECTAL							
		MESALAMINE							
>A>	AB	ENCUBE	4GM/60ML	A216941	001	May 30, 2023	May	NEWA	
		SUPPOSITORY;RECTAL							
		CANASA							
		@ ABBVIE	500MG	N021252	001	Jan 05, 2001	Feb	CAHN	
AB	+!		1GM	N021252	002	Nov 05, 2004	Feb	CAHN	
		TABLET, DELAYED RELEASE;ORAL							
		MESALAMINE							
>A>	AB	SINOTHERAPEUTICS INC	1.2GM	A217337	001	May 12, 2023	May	NEWA	
		<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE</u>							
		TABLET;ORAL							
		JANUMET							
		+ MSD SUB MERCK	500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007	Mar	CAHN	
		+!	1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007	Mar	CAHN	
		<u>METHIMAZOLE</u>							
		TABLET;ORAL							
		METHIMAZOLE							
>A>	AB	MACLEODS PHARMS LTD	5MG	A209827	001	May 24, 2023	May	NEWA	
>A>	AB		10MG	A209827	002	May 24, 2023	May	NEWA	
		<u>METHOCARBAMOL</u>							
		SOLUTION;IM-IV							
		METHOCARBAMOL							
		@ BAXTER HLTHCARE CORP	1GM/10ML (100MG/ML)	A215065	001	Jul 14, 2022	Feb	DISC	
		TABLET;ORAL							
		METHOCARBAMOL							
AA		AUROBINDO PHARMA LTD	500MG	A213967	002	Feb 09, 2023	Feb	NEWA	
AA			750MG	A213967	001	Aug 12, 2020	Feb	CMFD	
AA		DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Feb	CAHN	
AA			750MG	A203550	002	Feb 08, 2017	Feb	CAHN	

METHOTREXATE

>D> SOLUTION;ORAL
 >D> JYLAMVO
 >D> +! THERAKIND 2MG/ML N212479 001 Nov 29, 2022 May DISC
 >A> + @ 2MG/ML N212479 001 Nov 29, 2022 May DISC

METHSUXIMIDE

CAPSULE;ORAL
 CELONTIN
 AB +! PARKE DAVIS 300MG N010596 008 Apr CFTG
 METHSUXIMIDE
 AB NOVITIUM PHARMA 300MG A217213 001 May 01, 2023 Apr NFTG

METHYLDOPA

TABLET;ORAL
 METHYLDOPA
 >D> @ CHARTWELL RX 250MG N018934 001 Jun 29, 1984 May CMFD
 >A> 250MG N018934 001 Jun 29, 1984 May CMFD
 >D> @ 500MG N018934 002 Jun 29, 1984 May CMFD
 >A> ! 500MG N018934 002 Jun 29, 1984 May CMFD

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
 METHYLPHENIDATE HYDROCHLORIDE
 >A> AB ALKEM LABS LTD 18MG A214447 001 May 23, 2023 May NEWA
 >A> AB 27MG A214447 002 May 23, 2023 May NEWA
 >A> AB 36MG A214447 003 May 23, 2023 May NEWA
 >A> AB 54MG A214447 004 May 23, 2023 May NEWA

METHYLPREDNISOLONE

TABLET;ORAL
 MEDROL
 + PFIZER 2MG N011153 002 Apr CTEC
 METHYLPREDNISOLONE
 >A> @ CHARTWELL RX 2MG A209097 001 Feb 22, 2019 May CAHN
 >A> @ 4MG A209097 002 Feb 22, 2019 May CAHN
 >A> @ 8MG A209097 003 Feb 22, 2019 May CAHN
 >A> @ 16MG A209097 004 Feb 22, 2019 May CAHN
 >A> @ 32MG A209097 005 Feb 22, 2019 May CAHN
 >D> @ LUPIN LTD 2MG A209097 001 Feb 22, 2019 May CAHN
 >D> @ 4MG A209097 002 Feb 22, 2019 May CAHN
 >D> @ 8MG A209097 003 Feb 22, 2019 May CAHN
 >D> @ 16MG A209097 004 Feb 22, 2019 May CAHN
 >D> @ 32MG A209097 005 Feb 22, 2019 May CAHN

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION
 METHYLPREDNISOLONE ACETATE
 AB EUGIA PHARMA 40MG/ML A211930 001 Apr 13, 2023 Apr NEWA
 AB 80MG/ML A211930 002 Apr 13, 2023 Apr NEWA
 AB SLAYBACK PHARMA LLC 40MG/ML A214870 002 May 10, 2023 Apr NEWA

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL
 METOCLOPRAMIDE HYDROCHLORIDE
 AA ! XTTRIUM LABS INC EQ 5MG BASE/5ML A074703 001 Oct 31, 1997 Jan CAHN

METOLAZONE

TABLET;ORAL
 METOLAZONE
 @ AACE PHARMS 2.5MG A216216 001 Oct 25, 2022 Apr DISC
 @ 5MG A216216 002 Oct 25, 2022 Apr DISC
 @ 10MG A216216 003 Oct 25, 2022 Apr DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
 METOPROLOL SUCCINATE
 @ ACCORD HLTHCARE EQ 25MG TARTRATE A215637 001 Oct 18, 2022 Apr DISC
 @ EQ 50MG TARTRATE A215637 002 Oct 18, 2022 Apr DISC
 @ EQ 100MG TARTRATE A215637 003 Oct 18, 2022 Apr DISC
 @ EQ 200MG TARTRATE A215637 004 Oct 18, 2022 Apr DISC

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

AB	ZYDUS PHARMS	25MG	A212402	001	Apr 19, 2023	Apr	NEWA
AB		50MG	A212402	002	Apr 19, 2023	Apr	NEWA
AB		100MG	A212402	003	Apr 19, 2023	Apr	NEWA

METRONIDAZOLE

CREAM; TOPICAL

METRONIDAZOLE

AB	ZYDUS LIFESCIENCES	0.75%	A217128	001	Apr 21, 2023	Apr	NEWA
----	--------------------	-------	---------	-----	--------------	-----	------

GEL; TOPICAL

METRONIDAZOLE

AB	COSETTE	1%	A216692	001	Jan 23, 2023	Jan	NEWA
	@ TOLMAR	1%	A090903	001	Jul 22, 2011	Feb	DISC

GEL; VAGINAL

METRONIDAZOLE

@ ENCUBE

0.75%

A077264	001	Oct 31, 2006	Mar	CAHN
---------	-----	--------------	-----	------

TABLET; ORAL

METRONIDAZOLE

AB	ALEMBIC	250MG	A208681	001	Jun 20, 2017	Feb	CAHN
AB		500MG	A208681	002	Jun 20, 2017	Feb	CAHN

METRONIDAZOLE IN PLASTIC CONTAINER

INJECTABLE; INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

>A>	AP	AMNEAL	500MG/100ML	A217665	001	May 24, 2023	May	NEWA
-----	----	--------	-------------	---------	-----	--------------	-----	------

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

AB	LEADING	150MG	A215876	001	Feb 27, 2023	Feb	NEWA
AB		200MG	A215876	002	Feb 27, 2023	Feb	NEWA
AB		250MG	A215876	003	Feb 27, 2023	Feb	NEWA
AB	ZENARA	150MG	A215315	001	Aug 26, 2022	Feb	CAHN
AB		200MG	A215315	002	Aug 26, 2022	Feb	CAHN
AB		250MG	A215315	003	Aug 26, 2022	Feb	CAHN

MICAFUNGIN SODIUM

INJECTABLE; INTRAVENOUS

MICAFUNGIN SODIUM

@ ZYDUS PHARMS

EQ 50MG BASE/VIAL

A215241	001	Oct 24, 2022	Mar	DISC
---------	-----	--------------	-----	------

@

EQ 100MG BASE/VIAL

A215241	002	Oct 24, 2022	Mar	DISC
---------	-----	--------------	-----	------

MIDAZOLAM

SOLUTION; INTRAVENOUS

MIDAZOLAM IN 0.9% SODIUM CHLORIDE

AP	HIKMA	50MG/50ML (1MG/ML)	A216159	001	Apr 17, 2023	Apr	NFTG	
AP		100MG/100ML (1MG/ML)	A216159	002	Apr 17, 2023	Apr	NFTG	
AP	+!	INFORLIFE	50MG/50ML (1MG/ML)	N211844	001	Mar 22, 2021	Apr	CFTG
AP	+!		100MG/100ML (1MG/ML)	N211844	002	Mar 22, 2021	Apr	CFTG

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

+	ABBVIE	12.5MG	N022256	001	Jan 14, 2009	Jan	CAHN
+		25MG	N022256	002	Jan 14, 2009	Jan	CAHN
+		50MG	N022256	003	Jan 14, 2009	Jan	CAHN
+		100MG	N022256	004	Jan 14, 2009	Jan	CAHN

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP	SHANDONG	EQ 1MG BASE/ML	A216373	001	Jan 23, 2023	Jan	NEWA
----	----------	----------------	---------	-----	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION
MINOCIN

>D>	AP	+!	REMPEX	EQ 100MG BASE/VIAL	N050444	001		May	CTEC
>A>		+		EQ 100MG BASE/VIAL	N050444	001		May	CTEC

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL
MIRABEGRON

		@	ZYDUS PHARMS	25MG	A209488	001	Sep 29, 2022	Mar	DISC
		@		50MG	A209488	002	Sep 29, 2022	Mar	DISC

MIRTAZAPINE

TABLET; ORAL
MIRTAZAPINE

AB			PRASCO	7.5MG	A216751	001	Jan 18, 2023	Jan	NEWA
AB				15MG	A216751	002	Jan 18, 2023	Jan	NEWA
AB				30MG	A216751	003	Jan 18, 2023	Jan	NEWA
AB				45MG	A216751	004	Jan 18, 2023	Jan	NEWA

REMERON

AB		+!	ORGANON	15MG	N020415	001	Jun 14, 1996	Apr	CAHN
AB		+		30MG	N020415	002	Jun 14, 1996	Apr	CAHN
>A>	AB	+		30MG	N020415	002	Jun 14, 1996	May	CAHN
		+	@	45MG	N020415	003	Mar 17, 1997	Apr	CAHN
>A>		+	@	45MG	N020415	003	Mar 17, 1997	May	CAHN
>D>	AB	+	ORGANON USA INC	30MG	N020415	002	Jun 14, 1996	May	CAHN
>D>		+	@	45MG	N020415	003	Mar 17, 1997	May	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
REMERON SOLTAB

>D>	AB	+!	ORGANON USA INC	15MG	N021208	001	Jan 12, 2001	May	CAHN
>D>	AB	+		30MG	N021208	002	Jan 12, 2001	May	CAHN
>D>	AB	+		45MG	N021208	003	Jan 12, 2001	May	CAHN
>A>	AB	+!	ORGANON USA ORGANON	15MG	N021208	001	Jan 12, 2001	May	CAHN
>A>	AB	+		30MG	N021208	002	Jan 12, 2001	May	CAHN
>A>	AB	+		45MG	N021208	003	Jan 12, 2001	May	CAHN

MISOPROSTOL

TABLET; ORAL
MISOPROSTOL

		@	NOVEL LABS INC	0.1MG	A091667	001	Jul 25, 2012	Feb	DISC
		@		0.2MG	A091667	002	Jul 25, 2012	Feb	DISC

MOMETASONE FUROATE

LOTION; TOPICAL
ELOCON

		+	@	ORGANON	0.1%	N019796	001	Mar 30, 1989	Mar	DISC
AB		!		PADAGIS ISRAEL	0.1%	A077180	001	Apr 06, 2005	Mar	CHRS

MONTELUKAST SODIUM

TABLET, CHEWABLE; ORAL
MONTELUKAST SODIUM

AB			CHARTWELL MOLECULAR	EQ 4MG BASE	A207464	001	Dec 06, 2018	Jan	CAHN
AB				EQ 5MG BASE	A207464	002	Dec 06, 2018	Jan	CAHN

MORPHINE SULFATE

INJECTABLE; INJECTION
MORPHINE SULFATE

AP			HIKMA	2MG/ML	A211452	001	Jan 12, 2023	Jan	NFTG
AP				4MG/ML	A211452	002	Jan 12, 2023	Jan	NEWA
AP				8MG/ML	A211452	003	Jan 12, 2023	Jan	NEWA
AP				10MG/ML	A211452	004	Jan 12, 2023	Jan	NEWA
				15MG/ML	A211452	005	Jan 12, 2023	Jan	NFTG
AP		+!	HOSPIRA INC	2MG/ML	N202515	001	Nov 14, 2011	Jan	CTFG

TABLET; ORAL

MORPHINE SULFATE

		@	DR REDDYS LABS SA	15MG	A207270	001	Jan 12, 2022	Apr	CAHN
		@		30MG	A207270	002	Jan 12, 2022	Apr	CAHN
		@	MAYNE PHARMA INC	15MG	A207270	001	Jan 12, 2022	Apr	DISC
		@		30MG	A207270	002	Jan 12, 2022	Apr	DISC

TABLET, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

@	DR REDDYS LABS SA	15MG	A205386	001	Oct 28, 2016	Apr	CAHN
@		30MG	A205386	002	Oct 28, 2016	Apr	CAHN
@		60MG	A205386	003	Oct 28, 2016	Apr	CAHN
@		100MG	A205386	004	Oct 28, 2016	Apr	CAHN
@	MAYNE PHARMA INC	15MG	A205386	001	Oct 28, 2016	Apr	DISC
@		30MG	A205386	002	Oct 28, 2016	Apr	DISC
@		60MG	A205386	003	Oct 28, 2016	Apr	DISC
@		100MG	A205386	004	Oct 28, 2016	Apr	DISC

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
MOXEZA

>A>	AT2	+	HARROW EYE	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May	CAHN
>D>	AT2	+	IMPRIMIS PHARMS USA	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May	CAHN

MOXIFLOXACIN HYDROCHLORIDE

@ AKORN EQ 0.5% BASE A202916 001 Nov 09, 2017 Jan DISC

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB	CHARTWELL RX	EQ 400MG BASE	A207285	001	Feb 13, 2017	Apr	CAHN
AB	HETERO LABS LTD V	EQ 400MG BASE	A204836	001	Mar 02, 2023	Feb	NEWA
@	TORRENT	EQ 400MG BASE	A200160	001	Apr 03, 2014	Feb	DISC

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

>A>	AP		BPI LABS	500MG/VIAL	A214283	001	Jun 01, 2023	May	NEWA
-----	----	--	----------	------------	---------	-----	--------------	-----	------

NABUMETONE

TABLET;ORAL

NABUMETONE

@	AUROBINDO PHARMA USA	500MG	A090516	001	Jul 12, 2010	Apr	CAHN
@		750MG	A090516	002	Jul 12, 2010	Apr	CAHN

NADOLOL

TABLET;ORAL

NADOLOL

>A>	AB		ALEMBIC	20MG	A211763	001	Jun 02, 2023	May	NEWA
>A>	AB			40MG	A211763	002	Jun 02, 2023	May	NEWA
>A>	AB			80MG	A211763	003	Jun 02, 2023	May	NEWA

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

AP	!	EUGIA PHARMA SPECLTS	EQ 1GM BASE/VIAL	A091613	001	Dec 26, 2012	Jan	CHRS
AP	!		EQ 2GM BASE/VIAL	A091613	002	Dec 26, 2012	Jan	CHRS
AP	!		EQ 10GM BASE/VIAL	A091614	001	Dec 26, 2012	Jan	CHRS
@		SANDOZ	EQ 1GM BASE/VIAL	A062527	002	Aug 02, 1984	Jan	DISC
@			EQ 1GM BASE/VIAL	A062732	001	Dec 23, 1986	Jan	DISC
@			EQ 2GM BASE/VIAL	A062527	003	Aug 02, 1984	Jan	DISC
@			EQ 2GM BASE/VIAL	A062732	002	Dec 23, 1986	Jan	DISC
@			EQ 10GM BASE/VIAL	A062527	004	Aug 02, 1984	Jan	DISC

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL

NAFTIFINE HYDROCHLORIDE

AB		AMNEAL	2%	A206960	001	Apr 10, 2017	Feb	CAHN
----	--	--------	----	---------	-----	--------------	-----	------

GEL;TOPICAL

NAFTIFINE HYDROCHLORIDE

AB		AMNEAL	1%	A206165	001	Mar 20, 2019	Feb	CAHN
AB		TARO	2%	A208201	001	Apr 10, 2019	Mar	CMFD

NAFTIN

>D>		+	SEBELA IRELAND LTD	2%	N204286	001	Jun 27, 2013	May	CTEC
>A>	AB			2%	N204286	001	Jun 27, 2013	May	CTEC
				2%	N204286	001	Jun 27, 2013	Feb	CTEC

NALMEFENE HYDROCHLORIDE

>A> SPRAY;NASAL
 >A> OPVEE
 >A> +! OPIANT PHARMS EQ 2.7MG BASE/SPRAY N217470 001 May 22, 2023 May NEWA

NALOXEGOL OXALATE

TABLET;ORAL
 MOVANTIK
 + VALINOR EQ 12.5MG BASE N204760 001 Sep 16, 2014 Feb CAHN
 +! EQ 25MG BASE N204760 002 Sep 16, 2014 Feb CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION
 NALOXONE HYDROCHLORIDE
 @ PAR STERILE PRODUCTS 1MG/ML A215964 001 Jul 29, 2022 Jan DISC
 SPRAY, METERED;NASAL
 NALOXONE HYDROCHLORIDE
 +! AMPHASTAR PHARMS INC 4MG/SPRAY N208969 001 Mar 07, 2023 Mar NEWA

NAPROXEN

TABLET, DELAYED RELEASE;ORAL
 NAPROXEN
 @ AUROBINDO PHARMA USA 375MG A075390 001 Apr 19, 2001 Apr CAHN
 @ 500MG A075390 002 Apr 19, 2001 Apr CAHN
 >A> AB TULEX PHARMS INC 375MG A216908 001 May 31, 2023 May NEWA
 >A> AB 500MG A216908 002 May 31, 2023 May NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL
 NARATRIPTAN
 @ AUROBINDO PHARMA USA EQ 1MG BASE A202431 001 May 31, 2012 Apr CAHN
 @ EQ 2.5MG BASE A202431 002 May 31, 2012 Apr CAHN

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL
 NEBIVOLOL HYDROCHLORIDE
 AB BEXIMCO PHARMS USA EQ 2.5MG BASE A216568 001 Mar 30, 2023 Mar NEWA
 AB EQ 5MG BASE A216568 002 Mar 30, 2023 Mar NEWA
 AB EQ 10MG BASE A216568 003 Mar 30, 2023 Mar NEWA
 AB EQ 20MG BASE A216568 004 Mar 30, 2023 Mar NEWA

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL
 NEFAZODONE HYDROCHLORIDE
 @ AUROBINDO PHARMA USA 100MG A076129 002 Sep 16, 2003 Apr CAHN
 @ 150MG A076129 003 Sep 16, 2003 Apr CAHN
 @ 200MG A076129 004 Sep 16, 2003 Apr CAHN
 @ 250MG A076129 005 Sep 16, 2003 Apr CAHN

NELARABINE

INJECTABLE;INTRAVENOUS
 ARRANON
 >D> AP +! NOVARTIS 250MG/50ML (5MG/ML) N021877 001 Oct 28, 2005 May CAHN
 >A> AP +! SANDOZ 250MG/50ML (5MG/ML) N021877 001 Oct 28, 2005 May CAHN
 NELARABINE
 AP AMNEAL 250MG/50ML (5MG/ML) A216346 001 Apr 04, 2023 Mar NEWA
 >A> AP NEXUS PHARMS 250MG/50ML (5MG/ML) A215057 001 Jun 02, 2023 May NEWA
 AP SHORLA 250MG/50ML (5MG/ML) A214809 001 Mar 03, 2023 Feb NEWA

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS
 NEOSTIGMINE METHYLSULFATE
 >D> AP EUROHLTH INTL SARL 5MG/10ML (0.5MG/ML) A207042 001 Dec 28, 2015 May CAHN
 >D> AP 10MG/10ML (1MG/ML) A207042 002 Dec 28, 2015 May CAHN
 >A> AP HIKMA 5MG/10ML (0.5MG/ML) A207042 001 Dec 28, 2015 May CAHN
 >A> AP 10MG/10ML (1MG/ML) A207042 002 Dec 28, 2015 May CAHN
 AP SAGENT PHARMS INC 5MG/10ML (0.5MG/ML) A216542 001 Feb 17, 2023 Feb NEWA
 AP 10MG/10ML (1MG/ML) A216542 002 Feb 17, 2023 Feb NEWA

NEPAFENACSUSPENSION/DROPS;OPHTHALMIC
ILEVRO

>A>	+	HARROW EYE	0.3%	N203491	001	Oct 16, 2012	May CAHN
>D>	+	NOVARTIS	0.3%	N203491	001	Oct 16, 2012	May CAHN
NEVANAC							
>A>	+	HARROW EYE	0.1%	N021862	001	Aug 19, 2005	May CAHN
>D>	+	NOVARTIS	0.1%	N021862	001	Aug 19, 2005	May CAHN

NETARSUDIL MESYLATESOLUTION/DROPS;OPHTHALMIC
RHOPRESSA

>D>	+	AERIE PHARMS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017	May CAHN
>A>	+	ALCON LABS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017	May CAHN

NICARDIPINE HYDROCHLORIDECAPSULE;ORAL
NICARDIPINE HYDROCHLORIDE

AB		SQUARE PHARMS	20MG	A217555	001	May 03, 2023	Apr NEWA
AB			30MG	A217555	002	May 03, 2023	Apr NEWA

NIFEDIPINETABLET, EXTENDED RELEASE;ORAL
NIFEDIPINE

@	PHARMADAX INC	30MG	A216019	001	Nov 18, 2022	Apr DISC
@		60MG	A216019	002	Nov 18, 2022	Apr DISC

NIRAPARIB TOSYLATETABLET;ORAL
ZEJULA

+	GLAXOSMITHKLINE	EQ 100MG BASE	N214876	001	Apr 26, 2023	Apr NEWA
+		EQ 200MG BASE	N214876	002	Apr 26, 2023	Apr NEWA
+	!	EQ 300MG BASE	N214876	003	Apr 26, 2023	Apr NEWA

NIRMATRELVIR; RITONAVIR

TABLET;ORAL

PAXLOVID (COPACKAGED)

>A>	+	PFIZER	150MG;100MG	N217188	001	May 25, 2023	May NEWA
>A>	+	!	300MG;100MG	N217188	002	May 25, 2023	May NEWA

NISOLDIPINETABLET, EXTENDED RELEASE;ORAL
NISOLDIPINE

AB		AMTA	8.5MG	A216606	001	Apr 10, 2023	Mar NEWA
----	--	------	-------	---------	-----	--------------	----------

NITISINONECAPSULE;ORAL
NITISINONE

AB		MEDUNIK	20MG	A212390	004	Apr 27, 2023	Apr NEWA
>A>	AB	ZENARA	2MG	A216201	001	May 25, 2023	May NEWA
>A>	AB		5MG	A216201	002	May 25, 2023	May NEWA
>A>	AB		10MG	A216201	003	May 25, 2023	May NEWA
>A>	AB		20MG	A216201	004	May 25, 2023	May NEWA

NITRIC OXIDEGAS;INHALATION
GENOSYL

+	VERO BIOTECH INC	800PPM	N202860	001	Dec 20, 2019	Jan CAHN
---	------------------	--------	---------	-----	--------------	----------

NITROFURANTOINSUSPENSION;ORAL
NITROFURANTOIN

>A>	AB	AUROBINDO PHARMA	25MG/5ML	A212607	001	May 11, 2023	May NEWA
	AB	NOVITIUM PHARMA	25MG/5ML	A216385	001	Apr 14, 2023	Apr NEWA

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

AB	AUROBINDO PHARMA USA	50MG	A074967	001	Jul 09, 1997	Apr	CMFD
AB		100MG	A074967	002	Jul 09, 1997	Apr	CMFD
>D>	@	100MG	A077025	001	Aug 18, 2004	May	CMFD
>A>	AB	100MG	A077025	001	Aug 18, 2004	May	CMFD
AB	MANKIND PHARMA	25MG	A217272	001	Mar 21, 2023	Mar	NEWA
AB		50MG	A217272	002	Mar 21, 2023	Mar	NEWA
AB		100MG	A217272	003	Mar 21, 2023	Mar	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

	@ ALVOGEN	75MG;25MG	A215002	001	Jul 20, 2022	Jan	DISC
AB	AUROBINDO PHARMA	75MG;25MG	A209225	001	Mar 30, 2023	Mar	NEWA

NITROGLYCERIN

INJECTABLE;INJECTION

NITROGLYCERIN IN DEXTROSE 5%

>D>	AP	+	BAXTER HLTHCARE	10MG/100ML	N019970	001	Dec 29, 1989	May	CTEC
>A>				10MG/100ML	N019970	001	Dec 29, 1989	May	CTEC
>D>	AP	+		20MG/100ML	N019970	002	Dec 29, 1989	May	CTEC
>A>				20MG/100ML	N019970	002	Dec 29, 1989	May	CTEC
>D>	AP	+		40MG/100ML	N019970	003	Dec 29, 1989	May	CTEC
>A>				40MG/100ML	N019970	003	Dec 29, 1989	May	CTEC

OINTMENT;TRANSDERMAL

NITROGLYCERIN

>D>	!	FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988	May	CRLD
>A>	+		2%	A087355	001	Jul 08, 1988	May	CRLD

NOREPINEPHRINE BITARTRATE

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

>A>	+	@ LONG GROVE PHARMS	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	May	CAHN
>A>	+	@	EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	May	CAHN
>A>	+	@	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	May	CAHN
>D>	+	@ NEVAKAR INJECTABLES	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	May	CAHN
			EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	Apr	DISC
>D>	+	@	EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	May	CAHN
			EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	Apr	DISC
>D>	+	@	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	May	CAHN
			EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	Apr	DISC

NYSTATIN

OINTMENT;TOPICAL

NYSTATIN

	@ TORRENT	100,000 UNITS/GM	A211838	001	Jan 28, 2019	Mar	DISC
--	-----------	------------------	---------	-----	--------------	-----	------

SUSPENSION;ORAL

NILSTAT

	+	@ CHARTWELL MOLECULES	100,000 UNITS/ML	N050299	001		Apr	CAHN
--	---	-----------------------	------------------	---------	-----	--	-----	------

OBETICHOLIC ACID

TABLET;ORAL

OBETICHOLIC ACID

>A>	AB	APOTEX	5MG	A214862	001	May 30, 2023	May	NFTG
>A>	AB		10MG	A214862	002	May 30, 2023	May	NFTG
>A>	AB	LUPIN LTD	5MG	A214980	001	May 30, 2023	May	NFTG
>A>	AB		10MG	A214980	002	May 30, 2023	May	NFTG
>A>	AB	MSN	5MG	A215017	001	May 30, 2023	May	NFTG
>A>	AB		10MG	A215017	002	May 30, 2023	May	NFTG
		OCALIVA						
>D>	+	INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016	May	CFTG
>A>	AB	+	5MG	N207999	001	May 27, 2016	May	CFTG

	TABLET;ORAL							
	OCALIVA							
>D>	+!	10MG		N207999	002	May 27, 2016	May CFTG	
>A>	AB +!	10MG		N207999	002	May 27, 2016	May CFTG	
	<u>OLANZAPINE</u>							
	INJECTABLE;INTRAMUSCULAR							
	OLANZAPINE							
AP	ASPIRO	10MG/VIAL		A217466	001	Mar 22, 2023	Mar NEWA	
	TABLET;ORAL							
	OLANZAPINE							
AB	CADILA PHARMS LTD	2.5MG		A210022	001	Feb 24, 2023	Feb NEWA	
AB		5MG		A210022	002	Feb 24, 2023	Feb NEWA	
AB		7.5MG		A210022	003	Feb 24, 2023	Feb NEWA	
AB		10MG		A210022	004	Feb 24, 2023	Feb NEWA	
AB		15MG		A210022	005	Feb 24, 2023	Feb NEWA	
AB		20MG		A210022	006	Feb 24, 2023	Feb NEWA	
	TABLET, ORALLY DISINTEGRATING;ORAL							
	OLANZAPINE							
AB	HISUN PHARM HANGZHOU	5MG		A206892	001	Dec 31, 2020	Apr CMFD	
AB		10MG		A206892	002	Dec 31, 2020	Apr CMFD	
AB		15MG		A206892	003	Dec 31, 2020	Apr CMFD	
AB		20MG		A206892	004	Dec 31, 2020	Apr CMFD	
AB	ZYDUS PHARMS	5MG		A202889	001	Mar 09, 2023	Mar NEWA	
AB		10MG		A202889	002	Mar 09, 2023	Mar NEWA	
AB		15MG		A202889	003	Mar 09, 2023	Mar NEWA	
AB		20MG		A202889	004	Mar 09, 2023	Mar NEWA	
	<u>OLMESARTAN MEDOXOMIL</u>							
	TABLET;ORAL							
	OLMESARTAN MEDOXOMIL							
AB	MSN	5MG		A217399	001	Jan 18, 2023	Jan NEWA	
AB		20MG		A217399	002	Jan 18, 2023	Jan NEWA	
AB		40MG		A217399	003	Jan 18, 2023	Jan NEWA	
	<u>OLOPATADINE HYDROCHLORIDE</u>							
	SPRAY, METERED;NASAL							
	OLOPATADINE HYDROCHLORIDE							
>D>	AB	AMNEAL	0.665MG/SPRAY	A210901	001	Jan 28, 2020	May CHRS	
>A>	AB	!	0.665MG/SPRAY	A210901	001	Jan 28, 2020	May CHRS	
>D>	PATANASE							
>D>	AB	+!	NOVARTIS	0.665MG/SPRAY	N021861	001	Apr 15, 2008	May DISC
>A>		+ @		0.665MG/SPRAY	N021861	001	Apr 15, 2008	May DISC
	<u>OMAVELOXOLONE</u>							
	CAPSULE;ORAL							
	SKYCLARYS							
	+!	REATA PHARMS	50MG	N216718	001	Feb 28, 2023	Feb NEWA	
>D>	<u>OMIDENEPAG ISOPROPYL</u>							
>D>	SOLUTION;OPHTHALMIC							
>D>	OMLONTI							
>D>	+!	SANTEN	0.002%	N215092	001	Sep 22, 2022	May DISC	
>A>		+ @		0.002%	N215092	001	Sep 22, 2022	May DISC
	<u>ONDANSETRON</u>							
	TABLET, ORALLY DISINTEGRATING;ORAL							
	ONDANSETRON							
	!	CHARTWELL MOLECULES	16MG	A077406	001	Dec 26, 2006	Mar CHRS	
	!		24MG	A077406	002	Dec 26, 2006	Mar CHRS	
	ZOFTRAN ODT							
>D>	+ @	NOVARTIS	4MG	N020781	001	Jan 27, 1999	May CAHN	
>D>	+ @		8MG	N020781	002	Jan 27, 1999	May CAHN	
>A>	+ @	SANDOZ	4MG	N020781	001	Jan 27, 1999	May CAHN	
>A>	+ @		8MG	N020781	002	Jan 27, 1999	May CAHN	
	<u>ONDANSETRON HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	ZOFTRAN							
>D>	+ @	NOVARTIS	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	May CAHN	
>A>	+ @	SANDOZ	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	May CAHN	

INJECTABLE; INJECTION							
ZOFRAN PRESERVATIVE FREE							
>D>	+ @ NOVARTIS	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	May	CAHN
>A>	+ @ SANDOZ	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	May	CAHN
SOLUTION; ORAL							
ZOFRAN							
>D>	+ @ NOVARTIS	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	May	CAHN
>A>	+ @ SANDOZ	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	May	CAHN
TABLET; ORAL							
ONDANSETRON HYDROCHLORIDE							
!	CHARTWELL MOLECULES	EQ 24MG BASE	A077303	004	Jun 25, 2007	Feb	CTEC
ZOFRAN							
>D>	+ @ NOVARTIS	EQ 4MG BASE	N020103	001	Dec 31, 1992	May	CAHN
>D>	+ @	EQ 8MG BASE	N020103	002	Dec 31, 1992	May	CAHN
>D>	+ @	EQ 24MG BASE	N020103	003	Aug 27, 1999	May	CAHN
>A>	+ @ SANDOZ	EQ 4MG BASE	N020103	001	Dec 31, 1992	May	CAHN
>A>	+ @	EQ 8MG BASE	N020103	002	Dec 31, 1992	May	CAHN
>A>	+ @	EQ 24MG BASE	N020103	003	Aug 27, 1999	May	CAHN
<u>ORPHENADRINE CITRATE</u>							
TABLET, EXTENDED RELEASE; ORAL							
ORPHENADRINE CITRATE							
AB	RISING	100MG	A040249	001	Jan 29, 1999	Jan	CAHN
<u>OSELTAMIVIR PHOSPHATE</u>							
CAPSULE; ORAL							
OSELTAMIVIR PHOSPHATE							
@	ACCORD HLTHCARE	EQ 30MG BASE	A214726	001	Jul 25, 2022	Feb	DISC
@		EQ 45MG BASE	A214726	002	Jul 25, 2022	Feb	DISC
@		EQ 75MG BASE	A214726	003	Jul 25, 2022	Feb	DISC
FOR SUSPENSION; ORAL							
OSELTAMIVIR PHOSPHATE							
AB	EPIC PHARMA LLC	EQ 6MG BASE/ML	A215538	001	Feb 14, 2023	Feb	NEWA
<u>OXANDROLONE</u>							
TABLET; ORAL							
OXANDROLONE							
@	PAR PHARM	2.5MG	A077827	001	Jun 22, 2007	Feb	DISC
@		10MG	A077827	002	Jun 22, 2007	Feb	DISC
@	UPSHER SMITH LABS	2.5MG	A076761	001	Dec 01, 2006	Feb	DISC
@		10MG	A078033	001	Mar 22, 2007	Feb	DISC
<u>OXCARBAZEPINE</u>							
SUSPENSION; ORAL							
OXCARBAZEPINE							
>A> AB	CHARTWELL RX	300MG/5ML	A212428	001	Jun 21, 2021	May	CAHN
>D> AB	GLASSHOUSE PHARMS	300MG/5ML	A212428	001	Jun 21, 2021	May	CAHN
<u>OXYBUTYNIN CHLORIDE</u>							
GEL; TRANSDERMAL							
GELNIQUE							
+!	ABBVIE	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	Apr	CAHN
SYRUP; ORAL							
OXYBUTYNIN CHLORIDE							
AA	CHARTWELL RX	5MG/5ML	A075039	001	Jan 29, 1999	Mar	CMFD
@	XTTRIUM LABS INC	5MG/5ML	A074868	001	Feb 12, 1997	Mar	CAHN
TABLET; ORAL							
OXYBUTYNIN CHLORIDE							
!	APPCO	2.5MG	A209025	002	Feb 07, 2023	Jan	NFTG
<u>OXYCODONE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
OXYCODONE HYDROCHLORIDE							
@	DR REDDYS LABS SA	5MG	A203107	001	Jul 26, 2012	Apr	CAHN
@	MAYNE PHARMA INC	5MG	A203107	001	Jul 26, 2012	Apr	DISC
SOLUTION; ORAL							
OXYCODONE HYDROCHLORIDE							
@	DR REDDYS LABS SA	100MG/5ML	A204092	001	Jun 05, 2014	Apr	CAHN
@	MAYNE PHARMA INC	100MG/5ML	A204092	001	Jun 05, 2014	Apr	DISC

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

@ DR REDDYS LABS SA	5MG	A091313	001	Feb 18, 2011	Apr	CAHN
@	10MG	A091313	004	Apr 29, 2016	Apr	CAHN
@	15MG	A091313	002	Feb 18, 2011	Apr	CAHN
@	20MG	A091313	005	Apr 29, 2016	Apr	CAHN
@	30MG	A091313	003	Feb 18, 2011	Apr	CAHN

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

@ DASH PHARMS	6MG/ML	A091540	001	Sep 29, 2011	Feb	CAHN
---------------	--------	---------	-----	--------------	-----	------

POWDER; INTRAVENOUS

PACLITAXEL

>A> +!	AM REGENT	100MG/VIAL	N211875	001	Jul 27, 2022	Apr	CAHN
>A> +!	TEVA PHARMS INC	100MG/VIAL	N216338	001	May 11, 2023	May	NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

@ CIPLA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A206396	001	Sep 19, 2018	Feb	DISC
@ INGENUS PHARMS LLC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	Feb	DISC

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

>D>	AP	DR REDDYS	30MG/10ML (3MG/ML)	A078156	001	Aug 19, 2008	May	CTEC	
>A>	AP2		30MG/10ML (3MG/ML)	A078156	001	Aug 19, 2008	May	CTEC	
>D>	AP		90MG/10ML (9MG/ML)	A078156	003	Aug 19, 2008	May	CTEC	
>A>	AP2		90MG/10ML (9MG/ML)	A078156	003	Aug 19, 2008	May	CTEC	
>D>	AP	+!	HIKMA	30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	May	CTEC
>A>	AP1	+!		30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	May	CTEC
>D>	AP	+!		90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	May	CTEC
>A>	AP1	+!		90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	May	CTEC
>D>	AP		HOSPIRA	30MG/10ML (3MG/ML)	A075841	001	Jun 27, 2002	May	CTEC
>A>	AP2			30MG/10ML (3MG/ML)	A075841	001	Jun 27, 2002	May	CTEC
	AP			30MG/10ML (3MG/ML)	A075841	001	Jun 27, 2002	Apr	CHRS
>D>	AP			90MG/10ML (9MG/ML)	A075841	003	Jun 27, 2002	May	CTEC
>A>	AP2			90MG/10ML (9MG/ML)	A075841	003	Jun 27, 2002	May	CTEC
	AP			90MG/10ML (9MG/ML)	A075841	003	Jun 27, 2002	Apr	CHRS
>D>	AP		MYLAN LABS LTD	30MG/10ML (3MG/ML)	A078520	001	Oct 31, 2008	May	CTEC
>A>	AP2			30MG/10ML (3MG/ML)	A078520	001	Oct 31, 2008	May	CTEC
>D>	AP			90MG/10ML (9MG/ML)	A078520	002	Oct 31, 2008	May	CTEC
>A>	AP2			90MG/10ML (9MG/ML)	A078520	002	Oct 31, 2008	May	CTEC
>D>	AP		SAGENT PHARMS INC	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	May	CTEC
>A>	AP1			30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	May	CTEC
>D>	AP			90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	May	CTEC
>A>	AP1			90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	May	CTEC

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB		AJANTA PHARMA LTD	EQ 40MG BASE	A217416	001	Feb 09, 2023	Feb	NEWA
----	--	-------------------	--------------	---------	-----	--------------	-----	------

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

@ EPIC PHARMA LLC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jan	CAHN
@	EQ 25MG BASE	A213612	002	Aug 11, 2021	Jan	CAHN
@	EQ 37.5MG BASE	A213612	003	May 26, 2022	Jan	CAHN

PAROXETINE MESYLATE

>D>	TABLET; ORAL							
>D>	PEXEVA							
>D>	+	SEBELA IRELAND LTD	EQ 10MG BASE	N021299	001	Jul 03, 2003	May	DISC
>A>	+	@	EQ 10MG BASE	N021299	001	Jul 03, 2003	May	DISC
>D>	+		EQ 20MG BASE	N021299	002	Jul 03, 2003	May	DISC
>A>	+	@	EQ 20MG BASE	N021299	002	Jul 03, 2003	May	DISC
>D>	+		EQ 30MG BASE	N021299	003	Jul 03, 2003	May	DISC
>A>	+	@	EQ 30MG BASE	N021299	003	Jul 03, 2003	May	DISC

PEGCETACOPLANSOLUTION; INTRAVITREAL
SYFOVRE

+! APELLIS PHARMS 15MG/0.1ML (15MG/0.1ML) N217171 001 Feb 17, 2023 Feb NEWA

PEMETREXED DISODIUMPOWDER; INTRAVENOUS
PEMETREXED DISODIUM

AP	AMNEAL	EQ 100MG BASE/VIAL	A210047	002	May 08, 2023	Apr	NEWA
AP	MEITHEAL	EQ 100MG BASE/VIAL	A215479	001	Dec 13, 2022	Jan	CAHN
AP		EQ 500MG BASE/VIAL	A215479	002	Dec 13, 2022	Jan	CAHN
AP		EQ 750MG BASE/VIAL	A215479	003	Dec 13, 2022	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A215479	004	Dec 13, 2022	Jan	CAHN
	@ MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203628	001	Mar 10, 2023	Mar	DISC
AP		EQ 500MG BASE/VIAL	A203628	001	Mar 10, 2023	Mar	NEWA

SOLUTION; INTRAVENOUS
PEMETREXED

>A>	+!	SHILPA	EQ 100MG/10ML BASE (10MG/ML)	N215179	001	May 22, 2023	May	NEWA
>A>	+!		EQ 500MG/50ML BASE (10MG/ML)	N215179	002	May 22, 2023	May	NEWA
>A>	+!		EQ 1GM/100ML BASE (10MG/ML)	N215179	003	May 22, 2023	May	NEWA

PEMETREXED DISODIUM

	+!	SANDOZ	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214657	001	May 26, 2022	Jan	CMS1
--	----	--------	-------------------------------------	---------	-----	--------------	-----	------

PENTAMIDINE ISETHIONATEFOR SOLUTION; INHALATION
PENTAMIDINE ISETHIONATE

AN X-GEN PHARMS INC 300MG/VIAL A206983 001 Jan 20, 2023 Jan NEWA

PERAMPANELSUSPENSION; ORAL
FYCOMPA

+! CATALYST PHARMS 0.5MG/ML N208277 001 Apr 29, 2016 Feb CAHN

TABLET; ORAL
FYCOMPA

+	CATALYST PHARMS	2MG	N202834	001	Oct 22, 2012	Feb	CAHN
+		4MG	N202834	002	Oct 22, 2012	Feb	CAHN
+		6MG	N202834	003	Oct 22, 2012	Feb	CAHN
+		8MG	N202834	004	Oct 22, 2012	Feb	CAHN
+		10MG	N202834	005	Oct 22, 2012	Feb	CAHN
+		12MG	N202834	006	Oct 22, 2012	Feb	CAHN

>A> PERFLUOROHEXYLOCTANE>A> SOLUTION/DROPS; OPHTHALMIC
>A> MIEBO

>A> +! BAUSCH AND LOMB INC 1.338GM/ML N216675 001 May 18, 2023 May NEWA

PHENOXYBENZAMINE HYDROCHLORIDECAPSULE; ORAL
PHENOXYBENZAMINE HYDROCHLORIDE

AB AUROBINDO PHARMA 10MG A215600 001 May 08, 2023 Apr NEWA

PHENTERMINE HYDROCHLORIDECAPSULE; ORAL
PHENTERMINE HYDROCHLORIDE

@	LANNETT	15MG	A087022	002	Jan 20, 2012	Feb	DISC
@		30MG	A087022	001	Feb 03, 1983	Feb	DISC

PHENYLEPHRINE HYDROCHLORIDESOLUTION; INTRAVENOUS
IMMPHENTIV

>D>	+!	HIKMA	0.5MG/5ML (0.1MG/ML)	N203826	004	Mar 09, 2023	May	CAHN
>A>	+!		0.5MG/5ML (0.1MG/ML)	N203826	004	Mar 09, 2023	May	CAHN
	+!		0.5MG/5ML (0.1MG/ML)	N203826	004	Mar 09, 2023	Mar	NEWA
>D>	+!		1MG/10ML (0.1MG/ML)	N203826	005	Mar 09, 2023	May	CAHN
>A>	+!		1MG/10ML (0.1MG/ML)	N203826	005	Mar 09, 2023	May	CAHN
	+!		1MG/10ML (0.1MG/ML)	N203826	005	Mar 09, 2023	Mar	NEWA

PHENYLEPHRINE HYDROCHLORIDE

AP2	AVET LIFESCIENCES	10MG/ML (10MG/ML)	A209968	001	Feb 28, 2023	Feb	NEWA		
>D>	AP2	+!	HIKMA	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	May	CAHN
>A>	AP2	+!		10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	May	CAHN

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

>D>	AP2	+	!	50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	May	CAHN
>A>	AP2	+	!	50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	May	CAHN
>D>	AP2	+	!	100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	May	CAHN
>A>	AP2	+	!	100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	May	CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE VC PLAIN

@ XTTRIUM LABS INC 5MG/5ML;6.25MG/5ML

A088897 001 Jan 04, 1985 Jan CAHN

>A> PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE

>A> SPRAY, METERED;OPHTHALMIC

>A> MYDCOMBI

>A> +! EYENOVIA 2.5%;1% N215352 001 May 05, 2023 May NEWA

PHENYTOIN SODIUM

CAPSULE;ORAL

EXTENDED PHENYTOIN SODIUM

@ MYLAN 100MG EXTENDED

A040298 001 Dec 28, 1998 Mar DISC

@ UNICHEM 100MG EXTENDED

A213834 001 Oct 13, 2022 Apr DISC

PHYTONADIONE

TABLET;ORAL

MEPHYTON

+ @ BAUSCH 5MG

N010104 003 Feb DISC

PHYTONADIONE

AB ! ZYDUS 5MG A210189 001 Feb 20, 2019 Feb CHRS

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP SHANDONG EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL A204959 001 Aug 10, 2018 Apr CAHN

AP EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL A204959 002 Aug 10, 2018 Apr CAHN

AP EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL A204959 003 Aug 10, 2018 Apr CAHN

AP EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL A217243 001 Apr 14, 2023 Apr NEWA

ZOSYN IN PLASTIC CONTAINER

+! BAXTER HLTHCARE CORP EQ 40MG BASE/ML;EQ 5MG BASE/ML

N050750 001 Feb 24, 1998 Mar CAHN

+! EQ 60MG BASE/ML;EQ 7.5MG BASE/ML

N050750 002 Feb 24, 1998 Mar CAHN

+! EQ 4GM BASE/100ML;EQ 500MG BASE/100ML

N050750 003 Feb 24, 1998 Mar CAHN

PIRFENIDONE

TABLET;ORAL

PIRFENIDONE

>A> AB APOTEX 267MG A212709 001 May 31, 2023 May NEWA

>A> AB 801MG A212709 002 May 31, 2023 May NEWA

PIRTOBRUTINIB

TABLET;ORAL

JAYPIRCA

+ LOXO ONCOL 50MG

N216059 001 Jan 27, 2023 Jan NEWA

+! 100MG

N216059 002 Jan 27, 2023 Jan NEWA

PITAVASTATIN CALCIUM

TABLET;ORAL

PITAVASTATIN CALCIUM

AB ZYDUS PHARMS EQ 1MG BASE A206047 001 Feb 22, 2023 Feb NEWA

AB EQ 2MG BASE A206047 002 Feb 22, 2023 Feb NEWA

AB EQ 4MG BASE A206047 003 Feb 22, 2023 Feb NEWA

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

POLYTRIM

+ @ ALLERGAN 10,000 UNITS/ML;EQ 1MG BASE/ML

N050567 001 Oct 20, 1988 Feb DISC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT ! SANDOZ 10,000 UNITS/ML;EQ 1MG BASE/ML A064211 001 Apr 13, 1998 Feb CHRS

POMALIDOMIDE

CAPSULE;ORAL
POMALYST

	+	BRISTOL	1MG	N204026	001	Feb 08, 2013	Jan CAHN
	+		2MG	N204026	002	Feb 08, 2013	Jan CAHN
	+		3MG	N204026	003	Feb 08, 2013	Jan CAHN
	+	!	4MG	N204026	004	Feb 08, 2013	Jan CAHN

POSACONAZOLE

TABLET, DELAYED RELEASE;ORAL
POSACONAZOLE

>D>	AB	ACTAVIS LABS FL INC	100MG	A207355	001	Nov 30, 2022	May DISC
>A>		@	100MG	A207355	001	Nov 30, 2022	May DISC

POTASSIUM ACETATE

INJECTABLE;INJECTION
POTASSIUM ACETATE

AP		EXELA PHARMA	2MEQ/ML	A212692	001	Oct 20, 2021	Feb CMFD
----	--	--------------	---------	---------	-----	--------------	----------

POTASSIUM CHLORIDE

SOLUTION;ORAL
POTASSIUM CHLORIDE

AA		BELCHER	20MEQ/15ML	A216156	001	Mar 07, 2023	Feb NEWA
AA			40MEQ/15ML	A216156	002	Mar 07, 2023	Feb NEWA
>D>	AA	STRIDES PHARMA	40MEQ/15ML	A211665	001	Nov 17, 2022	May DISC
>A>		@	40MEQ/15ML	A211665	001	Nov 17, 2022	May DISC

TABLET, EXTENDED RELEASE;ORAL
K-TAB

	+	@	ABBVIE	10MEQ	N018279	001		Feb DISC
	+	@		20MEQ	N018279	003	Nov 25, 2013	Feb DISC
			POTASSIUM CHLORIDE					
AB3		TWI PHARMS	10MEQ	A209688	001	Jan 12, 2018	Apr CAHN	
AB3	!		20MEQ	A209688	002	Jan 12, 2018	Apr CAHN	
AB3	!	VITRUVIAS THERAP	20MEQ	A209688	002	Jan 12, 2018	Feb CHRS	

PRASUGREL HYDROCHLORIDE

TABLET;ORAL
PRASUGREL

AB		AMNEAL PHARMS	EQ 5MG BASE	A205913	001	Jun 19, 2018	Mar CTEC	
AB			EQ 10MG BASE	A205913	002	Jun 19, 2018	Mar CTEC	
		@	LUPIN LTD	EQ 5MG BASE	A205930	001	Jan 09, 2023	Feb DISC
		@		EQ 10MG BASE	A205930	002	Jan 09, 2023	Feb DISC

PRAVASTATIN SODIUM

TABLET;ORAL
PRAVASTATIN SODIUM

>A>	AB	CHARTWELL RX	10MG	A077917	001	Jan 08, 2008	May CAHN
>A>	AB		20MG	A077917	002	Jan 08, 2008	May CAHN
>A>	AB		40MG	A077917	003	Jan 08, 2008	May CAHN
>A>	AB		80MG	A077917	004	Jan 08, 2008	May CAHN
>D>	AB	LUPIN PHARMS	10MG	A077917	001	Jan 08, 2008	May CAHN
>D>	AB		20MG	A077917	002	Jan 08, 2008	May CAHN
>D>	AB		40MG	A077917	003	Jan 08, 2008	May CAHN
>D>	AB		80MG	A077917	004	Jan 08, 2008	May CAHN

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL
PRAZOSIN HYDROCHLORIDE

AB		ALEMBIC	EQ 1MG BASE	A217268	001	Mar 06, 2023	Feb NEWA
AB			EQ 2MG BASE	A217268	002	Mar 06, 2023	Feb NEWA
AB			EQ 5MG BASE	A217268	003	Mar 06, 2023	Feb NEWA
AB		AUROBINDO PHARMA LTD	EQ 1MG BASE	A213052	001	Mar 31, 2023	Mar NEWA
AB			EQ 2MG BASE	A213052	002	Mar 31, 2023	Mar NEWA
AB			EQ 5MG BASE	A213052	003	Mar 31, 2023	Mar NEWA

PREDNISOLONE

SYRUP;ORAL
PREDNISOLONE

AA		XTTRIUM LABS INC	15MG/5ML	A040313	001	Sep 10, 2003	Jan CAHN
----	--	------------------	----------	---------	-----	--------------	----------

TABLET;ORAL

PREDNISOLONE

AB	AUROBINDO PHARMA LTD	5MG	A215673	001	Mar 17, 2023	Mar	NEWA
>D>	@ CHARTWELL MOLECULAR	5MG	A080531	002		May	CMFD
>A>	BX	5MG	A080531	002		May	CMFD
AB	+! WATSON LABS	5MG	A080354	001		Mar	CTEC

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

PRED FORTE

AB	+! ABBVIE	1%	N017011	001		Jan	CAHN
	PRED MILD						
	+! ABBVIE	0.12%	N017100	001		Feb	CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA	EDENBRIDGE PHARMS	EQ 15MG BASE/5ML	A203559	003	Feb 06, 2023	Jan	NEWA
AA		EQ 15MG BASE/5ML	A203559	003	Feb 06, 2023	Jan	NEWA
AA		EQ 25MG BASE/5ML	A203559	004	Feb 06, 2023	Jan	NEWA
AA		EQ 25MG BASE/5ML	A203559	004	Feb 06, 2023	Jan	NEWA
AA	! MISSION PHARMA	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010	Jan	CTEC
AA	! XTTRIUM LABS INC	EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002	Jan	CAHN
AA	!	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Jan	CAHN

PREDNISON

SOLUTION;ORAL

PREDNISON

@ XTTRIUM LABS INC

5MG/5ML

A089726 001 Aug 02, 1988 Jan CAHN

TABLET;ORAL

PREDNISON

AB	+! HIKMA	2.5MG	A087801	001	Apr 22, 1982	Jan	CRLD
AB	+!	5MG	A080352	001		Jan	CRLD
AB	+!	50MG	A084283	001		Jan	CRLD
AB	JUBILANT CADISTA	2.5MG	A040362	004	Apr 17, 2023	Apr	NEWA
AB		50MG	A040362	005	Apr 17, 2023	Apr	NEWA

PREGABALIN

CAPSULE;ORAL

PREGABALIN

AB	ACI	25MG	A215755	001	Apr 26, 2023	Apr	NEWA
AB		50MG	A215755	002	Apr 26, 2023	Apr	NEWA
AB		75MG	A215755	003	Apr 26, 2023	Apr	NEWA
AB		100MG	A215755	004	Apr 26, 2023	Apr	NEWA
AB		150MG	A215755	005	Apr 26, 2023	Apr	NEWA
AB		200MG	A215755	006	Apr 26, 2023	Apr	NEWA
AB		225MG	A215755	007	Apr 26, 2023	Apr	NEWA
AB		300MG	A215755	008	Apr 26, 2023	Apr	NEWA
AB	AUROBINDO PHARMA	25MG	A205321	001	Mar 29, 2023	Mar	NEWA
AB		50MG	A205321	002	Mar 29, 2023	Mar	NEWA
AB		75MG	A205321	003	Mar 29, 2023	Mar	NEWA
AB		100MG	A205321	004	Mar 29, 2023	Mar	NEWA
AB		150MG	A205321	005	Mar 29, 2023	Mar	NEWA
AB		200MG	A205321	006	Mar 29, 2023	Mar	NEWA
AB		225MG	A205321	007	Mar 29, 2023	Mar	NEWA
AB		300MG	A205321	008	Mar 29, 2023	Mar	NEWA
AB	CHARTWELL RX	50MG	A212865	001	Mar 20, 2020	Mar	CAHN
AB		75MG	A212865	002	Mar 20, 2020	Mar	CAHN
AB		100MG	A212865	003	Mar 20, 2020	Mar	CAHN
AB		150MG	A212865	004	Mar 20, 2020	Mar	CAHN
AB	YILING	75MG	A210891	001	Sep 30, 2019	Mar	CAHN
AB		300MG	A210891	002	Sep 30, 2019	Mar	CAHN
>D>	AB	ZYDUS PHARMS	A206752	001	Dec 09, 2022	May	DISC
>A>	@	25MG	A206752	001	Dec 09, 2022	May	DISC
>D>	AB	50MG	A206752	002	Dec 09, 2022	May	DISC
>A>	@	50MG	A206752	002	Dec 09, 2022	May	DISC
>D>	AB	75MG	A206752	003	Dec 09, 2022	May	DISC
>A>	@	75MG	A206752	003	Dec 09, 2022	May	DISC
>D>	AB	100MG	A206752	004	Dec 09, 2022	May	DISC
>A>	@	100MG	A206752	004	Dec 09, 2022	May	DISC
>D>	AB	150MG	A206752	005	Dec 09, 2022	May	DISC
>A>	@	150MG	A206752	005	Dec 09, 2022	May	DISC
>D>	AB	200MG	A206752	006	Dec 09, 2022	May	DISC

<u>CAPSULE; ORAL</u>									
<u>PREGABALIN</u>									
>A>		@	200MG		A206752	006	Dec 09, 2022	May	DISC
>D>	AB		225MG		A206752	007	Dec 09, 2022	May	DISC
>A>		@	225MG		A206752	007	Dec 09, 2022	May	DISC
>D>	AB		300MG		A206752	008	Dec 09, 2022	May	DISC
>A>		@	300MG		A206752	008	Dec 09, 2022	May	DISC
<u>SOLUTION; ORAL</u>									
<u>PREGABALIN</u>									
AA		PATRIN	20MG/ML		A212604	001	Feb 18, 2022	Jan	CAHN
<u>TABLET, EXTENDED RELEASE; ORAL</u>									
<u>PREGABALIN</u>									
>D>	AB	SCIEGEN PHARMS INC	82.5MG		A215675	001	Sep 14, 2022	May	DISC
>A>		@	82.5MG		A215675	001	Sep 14, 2022	May	DISC
>D>	AB		165MG		A215675	002	Sep 14, 2022	May	DISC
>A>		@	165MG		A215675	002	Sep 14, 2022	May	DISC
>D>	AB		330MG		A215675	003	Sep 14, 2022	May	DISC
>A>		@	330MG		A215675	003	Sep 14, 2022	May	DISC
>A>	AB	SINOTHERAPEUTICS INC	82.5MG		A214496	001	Jun 01, 2023	May	NEWA
>A>	AB		165MG		A214496	002	Jun 01, 2023	May	NEWA
>A>	AB		330MG		A214496	003	Jun 01, 2023	May	NEWA
		@ ZYDUS PHARMS	82.5MG		A215577	001	Aug 26, 2022	Jan	DISC
		@	165MG		A215577	002	Aug 26, 2022	Jan	DISC
		@	330MG		A215577	003	Aug 26, 2022	Jan	DISC
<u>PRIMIDONE</u>									
<u>TABLET; ORAL</u>									
<u>PRIMIDONE</u>									
>D>	AB	RUBICON	125MG		A214896	003	Dec 28, 2022	May	CTEC
>A>			125MG		A214896	003	Dec 28, 2022	May	CTEC
<u>PROCAINAMIDE HYDROCHLORIDE</u>									
<u>INJECTABLE; INJECTION</u>									
<u>PROCAINAMIDE HYDROCHLORIDE</u>									
AP	!	HOSPIRA	500MG/ML		A089070	001	Feb 12, 1986	Feb	CTEC
<u>PROCHLORPERAZINE MALEATE</u>									
<u>TABLET; ORAL</u>									
<u>PROCHLORPERAZINE MALEATE</u>									
AB		AMNEAL	EQ 5MG BASE		A216598	001	Apr 17, 2023	Apr	NEWA
AB			EQ 10MG BASE		A216598	002	Apr 17, 2023	Apr	NEWA
AB		BIONPHARMA INC	EQ 5MG BASE		A217478	001	Apr 04, 2023	Mar	NEWA
AB			EQ 10MG BASE		A217478	002	Apr 04, 2023	Mar	NEWA
AB		GLENMARK PHARMS LTD	EQ 5MG BASE		A216595	001	Mar 17, 2023	Mar	NEWA
AB			EQ 10MG BASE		A216595	002	Mar 17, 2023	Mar	NEWA
<u>PROMETHAZINE HYDROCHLORIDE</u>									
<u>TABLET; ORAL</u>									
<u>PROMETHAZINE HYDROCHLORIDE</u>									
		@ AUROBINDO PHARMA USA	12.5MG		A091054	001	Aug 30, 2011	Apr	CAHN
		@	25MG		A091054	002	Aug 30, 2011	Apr	CAHN
		@	50MG		A091054	003	Aug 30, 2011	Apr	CAHN
<u>PROPAFENONE HYDROCHLORIDE</u>									
<u>CAPSULE, EXTENDED RELEASE; ORAL</u>									
<u>PROPAFENONE HYDROCHLORIDE</u>									
AB		AUROBINDO PHARMA LTD	225MG		A213096	001	Feb 21, 2023	Feb	NEWA
AB			325MG		A213096	002	Feb 21, 2023	Feb	NEWA
AB			425MG		A213096	003	Feb 21, 2023	Feb	NEWA
<u>PROPOFOL</u>									
<u>INJECTABLE; INJECTION</u>									
<u>PROPOFOL</u>									
AB		AVET LIFESCIENCES	10MG/ML		A206408	001	Oct 12, 2021	Jan	CAHN
<u>PROPYLTHIOURACIL</u>									
<u>TABLET; ORAL</u>									
<u>PROPYLTHIOURACIL</u>									
AB	+	DAVA PHARMS INC	50MG		N006188	001		Apr	CTEC
AB		MACLEODS PHARMS LTD	50MG		A208867	001	May 10, 2023	Apr	NEWA

QUININE SULFATE

CAPSULE;ORAL

QUININE SULFATE

>A>	@ AUROBINDO PHARMA USA	324MG	A202581	001	Dec 14, 2012	May	CAHN
>D>	@ MYLAN PHARMS INC	324MG	A202581	001	Dec 14, 2012	May	CAHN

RAMELTEON

TABLET;ORAL

RAMELTEON

>D>	@ INNOGENIX	8MG	A215435	001	Aug 24, 2022	May	CMFD	
>A>	AB	8MG	A215435	001	Aug 24, 2022	May	CMFD	
	@	8MG	A215435	001	Aug 24, 2022	Mar	DISC	
	AB	8MG	A215435	001	Aug 24, 2022	Jan	CAHN	
	AB	MICRO LABS	8MG	A215243	001	Feb 09, 2023	Feb	NEWA

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

AB	COREPHARMA	1.25MG	A079116	001	Jun 20, 2008	Feb	CAHN
AB		2.5MG	A079116	002	Jun 20, 2008	Feb	CAHN
AB		5MG	A079116	003	Jun 20, 2008	Feb	CAHN
AB		10MG	A079116	004	Jun 20, 2008	Feb	CAHN

RANITIDINE HYDROCHLORIDE

>D> INJECTABLE;INJECTION

>D> RANITIDINE HYDROCHLORIDE

>D>	AP	HIKMA	EQ 25MG BASE/ML	A074777	001	Mar 02, 2005	May	DISC
>A>	@		EQ 25MG BASE/ML	A074777	001	Mar 02, 2005	May	DISC
>D>	AP		EQ 25MG BASE/ML	A077458	001	Feb 16, 2006	May	DISC
>A>	@		EQ 25MG BASE/ML	A077458	001	Feb 16, 2006	May	DISC
>D>	AP	ZYDUS PHARMS USA INC	EQ 25MG BASE/ML	A091534	001	Feb 22, 2013	May	DISC
>A>	@		EQ 25MG BASE/ML	A091534	001	Feb 22, 2013	May	DISC
>D>		ZANTAC						
>D>	AP	+! PAI HOLDINGS PHARM	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	May	DISC
>A>	+ @		EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	May	DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA

	+ @	GILEAD	500MG	N021526	002	Jan 27, 2006	Jan	DISC
	+ @		1GM	N021526	001	Feb 12, 2007	Jan	DISC
		RANOLAZINE						
AB	!	SUN PHARM	1GM	A211707	002	May 28, 2019	Jan	CHRS
AB		UNICHEM	500MG	A213083	001	Mar 16, 2023	Mar	NEWA
AB			1GM	A213083	002	Mar 16, 2023	Mar	NEWA

REGADENOSON

SOLUTION;INTRAVENOUS

REGADENOSON

>A>	AP	BAXTER HLTHCARE CORP	0.4MG/5ML (0.08MG/ML)	A217455	001	May 23, 2023	May	NEWA
	AP	HIKMA	0.4MG/5ML (0.08MG/ML)	A215827	001	Feb 02, 2023	Jan	NEWA
	AP	IMS LTD	0.4MG/5ML (0.08MG/ML)	A214252	001	May 23, 2022	Apr	CMFD

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

AB		MACLEODS PHARMS LTD	0.5MG	A207209	001	Mar 22, 2023	Mar	NEWA
AB			1MG	A207209	002	Mar 22, 2023	Mar	NEWA
AB			2MG	A207209	003	Mar 22, 2023	Mar	NEWA

REZAFUNGIN ACETATE

POWDER;INTRAVENOUS

REZZAYO

	+!	CIDARA THERAPS	EQ 200MG BASE/VIAL	N217417	001	Mar 22, 2023	Mar	NEWA
--	----	----------------	--------------------	---------	-----	--------------	-----	------

RIMEGEPANT SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

NURTEC ODT

	+!	PFIZER	EQ 75MG BASE	N212728	001	Feb 27, 2020	Feb	CAHN
--	----	--------	--------------	---------	-----	--------------	-----	------

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
RYKINDO

+!	SHANDONG LUYE	12.5MG	N212849	001	Jan 13, 2023	Jan	NEWA
+!		25MG	N212849	002	Jan 13, 2023	Jan	NEWA
+!		37.5MG	N212849	003	Jan 13, 2023	Jan	NEWA
+!		50MG	N212849	004	Jan 13, 2023	Jan	NEWA

SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
UZEDY

+	TEVA	50MG/0.14ML (50MG/0.14ML)	N213586	001	Apr 28, 2023	Apr	NEWA
+		75MG/0.21ML (75MG/0.21ML)	N213586	002	Apr 28, 2023	Apr	NEWA
+		100MG/0.28ML (100MG/0.28ML)	N213586	003	Apr 28, 2023	Apr	NEWA
+		125MG/0.35ML (125MG/0.35ML)	N213586	004	Apr 28, 2023	Apr	NEWA
+		150MG/0.42ML (150MG/0.42ML)	N213586	005	Apr 28, 2023	Apr	NEWA
+		200MG/0.56ML (200MG/0.56ML)	N213586	006	Apr 28, 2023	Apr	NEWA
+!		250MG/0.7ML (250MG/0.7ML)	N213586	007	Apr 28, 2023	Apr	NEWA

TABLET;ORAL

RISPERIDONE

@	DASH PHARMS	0.25MG	A076288	001	Sep 15, 2008	Feb	CAHN
@		0.5MG	A076288	002	Sep 15, 2008	Feb	CAHN
@		1MG	A076288	003	Sep 15, 2008	Feb	CAHN
@		2MG	A076288	004	Sep 15, 2008	Feb	CAHN
@		3MG	A076288	005	Sep 15, 2008	Feb	CAHN
@		4MG	A076288	006	Sep 15, 2008	Feb	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

@	DASH PHARMS	0.25MG	A091537	006	Feb 12, 2013	Feb	CAHN
@		0.5MG	A091537	001	Mar 30, 2011	Feb	CAHN
@		1MG	A091537	002	Mar 30, 2011	Feb	CAHN
@		2MG	A091537	003	Mar 30, 2011	Feb	CAHN
@		3MG	A091537	004	Mar 30, 2011	Feb	CAHN
@		4MG	A091537	005	Mar 30, 2011	Feb	CAHN

RITONAVIR

SOLUTION;ORAL

NORVIR

+	@ ABBVIE	80MG/ML	N020659	001	Mar 01, 1996	Feb	DISC
---	----------	---------	---------	-----	--------------	-----	------

RIZATRIPTAN BENZOATE

FILM;ORAL

RIZAFILM

+!	INTELGEXX CORP	EQ 10MG BASE	N205394	001	Apr 14, 2023	Apr	NEWA
----	----------------	--------------	---------	-----	--------------	-----	------

TABLET;ORAL

RIZATRIPTAN BENZOATE

>D>	AB	CELLTRION	EQ 5MG BASE	A077526	001	Mar 26, 2013	May	CAHN
>D>	AB		EQ 10MG BASE	A077526	002	Mar 26, 2013	May	CAHN
>A>	AB	CHARTWELL RX	EQ 5MG BASE	A077526	001	Mar 26, 2013	May	CAHN
>A>	AB		EQ 10MG BASE	A077526	002	Mar 26, 2013	May	CAHN

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP		CAPLIN	50MG/5ML (10MG/ML)	A216234	001	Mar 02, 2023	Feb	NEWA
AP			100MG/10ML (10MG/ML)	A216234	002	Mar 02, 2023	Feb	NEWA
>A>	AP	HIKMA	50MG/5ML (10MG/ML)	A217034	001	May 24, 2023	May	NEWA
AP		HONG KONG	50MG/5ML (10MG/ML)	A213453	001	May 08, 2023	Apr	NEWA
AP			100MG/10ML (10MG/ML)	A213453	002	May 08, 2023	Apr	NEWA

ROFLUMILAST

TABLET;ORAL

ROFLUMILAST

AB		ALKEM LABS LTD	250MCG	A212490	001	Apr 18, 2023	Apr	NEWA
AB			500MCG	A212490	002	Apr 18, 2023	Apr	NEWA
AB		AUROBINDO PHARMA LTD	500MCG	A213298	001	Apr 17, 2023	Apr	NEWA
AB		HETERO LABS LTD III	250MCG	A208213	002	Apr 18, 2023	Apr	NEWA
AB		MICRO LABS	250MCG	A208180	002	Apr 18, 2023	Apr	NEWA
AB		ZYDUS PHARMS	250MCG	A208303	002	Apr 18, 2023	Apr	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

>D>	AB	MYLAN	EQ 0.25MG BASE	A 078881	001	May 05, 2008	May DISC
>A>		@	EQ 0.25MG BASE	A 078881	001	May 05, 2008	May DISC
>D>	AB		EQ 0.5MG BASE	A 078881	002	May 05, 2008	May DISC
>A>		@	EQ 0.5MG BASE	A 078881	002	May 05, 2008	May DISC
>D>	AB		EQ 1MG BASE	A 078881	003	May 05, 2008	May DISC
>A>		@	EQ 1MG BASE	A 078881	003	May 05, 2008	May DISC
>D>	AB		EQ 2MG BASE	A 078881	004	May 05, 2008	May DISC
>A>		@	EQ 2MG BASE	A 078881	004	May 05, 2008	May DISC
>D>	AB		EQ 3MG BASE	A 078881	005	May 05, 2008	May DISC
>A>		@	EQ 3MG BASE	A 078881	005	May 05, 2008	May DISC
>D>	AB		EQ 4MG BASE	A 078881	006	May 05, 2008	May DISC
>A>		@	EQ 4MG BASE	A 078881	006	May 05, 2008	May DISC
>A>		@	EQ 5MG BASE	A 078881	007	May 19, 2008	Mar DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

AP		AMNEAL	200MG/100ML (2MG/ML)	A 216605	001	Mar 08, 2023	Feb NEWA
AP			400MG/200ML (2MG/ML)	A 216605	002	Mar 08, 2023	Feb NEWA
AP			500MG/100ML (5MG/ML)	A 216605	003	Mar 07, 2023	Feb NEWA
AP			1GM/200ML (5MG/ML)	A 216605	004	Mar 07, 2023	Feb NEWA

RUCAPARIB CAMSYLATE

TABLET; ORAL

RUBRACA

>D>	+	CLOVIS ONCOLOGY INC	EQ 200MG BASE	N 209115	001	Dec 19, 2016	May CAHN
>D>	+		EQ 250MG BASE	N 209115	003	May 01, 2017	May CAHN
>D>	+	!	EQ 300MG BASE	N 209115	002	Dec 19, 2016	May CAHN
>A>	+	ZR PHARMA	EQ 200MG BASE	N 209115	001	Dec 19, 2016	May CAHN
>A>	+		EQ 250MG BASE	N 209115	003	May 01, 2017	May CAHN
>A>	+	!	EQ 300MG BASE	N 209115	002	Dec 19, 2016	May CAHN

RUFINAMIDE

SUSPENSION; ORAL

RUFINAMIDE

>A>	AB	CHARTWELL RX	40MG/ML	A 214009	001	Nov 07, 2022	May CAHN
>D>	AB	GLASSHOUSE PHARMS	40MG/ML	A 214009	001	Nov 07, 2022	May CAHN

TABLET; ORAL

RUFINAMIDE

>A>	AB	MICRO LABS	200MG	A 216688	001	May 15, 2023	May NEWA
>A>	AB		400MG	A 216688	002	May 15, 2023	May NEWA

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

		@ DASH PHARMS NATCO	5MG	A 074866	001	Nov 26, 1997	Mar CAHN
--	--	---------------------	-----	----------	-----	--------------	----------

SELENIUM SULFIDE

LOTION; SHAMPOO; TOPICAL

SELENIUM SULFIDE

		@ XTTRIUM LABS INC	2.5%	A 088228	001	Sep 01, 1983	Mar CAHN
--	--	--------------------	------	----------	-----	--------------	----------

SELEXIPAG

TABLET; ORAL

SELEXIPAG

>D>		ZYDUS	0.2MG	A 214302	001	Dec 21, 2022	May DISC
>A>		@	0.2MG	A 214302	001	Dec 21, 2022	May DISC
>D>	AB		0.4MG	A 214302	002	Dec 21, 2022	May DISC
>A>		@	0.4MG	A 214302	002	Dec 21, 2022	May DISC
>D>	AB		0.6MG	A 214302	003	Dec 21, 2022	May DISC
>A>		@	0.6MG	A 214302	003	Dec 21, 2022	May DISC
>D>	AB		0.8MG	A 214302	004	Dec 21, 2022	May DISC
>A>		@	0.8MG	A 214302	004	Dec 21, 2022	May DISC
>D>	AB		1MG	A 214302	005	Dec 21, 2022	May DISC
>A>		@	1MG	A 214302	005	Dec 21, 2022	May DISC
>D>	AB		1.2MG	A 214302	006	Dec 21, 2022	May DISC
>A>		@	1.2MG	A 214302	006	Dec 21, 2022	May DISC
>D>	AB		1.4MG	A 214302	007	Dec 21, 2022	May DISC

TABLET;ORAL
SELEXIPAG

>A>	@	1.4MG	A214302	007	Dec 21, 2022	May	DISC
>D>	AB	1.6MG	A214302	008	Dec 21, 2022	May	DISC
>A>	@	1.6MG	A214302	008	Dec 21, 2022	May	DISC
UPTRAVI							
>D>	AB	+ ACTELION	0.2MG	N207947	001	Dec 21, 2015	May CTEC
>A>		+	0.2MG	N207947	001	Dec 21, 2015	May CTEC
>D>	AB	+!	0.4MG	N207947	002	Dec 21, 2015	May CTEC
>A>		+!	0.4MG	N207947	002	Dec 21, 2015	May CTEC
>D>	AB	+	0.6MG	N207947	003	Dec 21, 2015	May CTEC
>A>		+	0.6MG	N207947	003	Dec 21, 2015	May CTEC
>D>	AB	+	0.8MG	N207947	004	Dec 21, 2015	May CTEC
>A>		+	0.8MG	N207947	004	Dec 21, 2015	May CTEC
>D>	AB	+	1MG	N207947	005	Dec 21, 2015	May CTEC
>A>		+	1MG	N207947	005	Dec 21, 2015	May CTEC
>D>	AB	+	1.2MG	N207947	006	Dec 21, 2015	May CTEC
>A>		+	1.2MG	N207947	006	Dec 21, 2015	May CTEC
>D>	AB	+	1.4MG	N207947	007	Dec 21, 2015	May CTEC
>A>		+	1.4MG	N207947	007	Dec 21, 2015	May CTEC
>D>	AB	+	1.6MG	N207947	008	Dec 21, 2015	May CTEC
>A>		+	1.6MG	N207947	008	Dec 21, 2015	May CTEC

SERTRALINE HYDROCHLORIDE

TABLET;ORAL
SERTRALINE HYDROCHLORIDE

>D>	@	CADILA	EQ 25MG BASE	A077106	001	Feb 06, 2007	May CAHN
>D>	@		EQ 50MG BASE	A077106	002	Feb 06, 2007	May CAHN
>D>	@		EQ 100MG BASE	A077106	003	Feb 06, 2007	May CAHN
	AB	HERITAGE PHARMA AVET	EQ 25MG BASE	A076465	001	Aug 11, 2006	Mar CMFD
	AB		EQ 50MG BASE	A076465	002	Aug 11, 2006	Mar CMFD
	AB		EQ 100MG BASE	A076465	003	Aug 11, 2006	Mar CMFD
>A>	@	ZYDUS	EQ 25MG BASE	A077106	001	Feb 06, 2007	May CAHN
>A>	@		EQ 50MG BASE	A077106	002	Feb 06, 2007	May CAHN
>A>	@		EQ 100MG BASE	A077106	003	Feb 06, 2007	May CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL
SEVELAMER CARBONATE

AB		HANGZHOU ANPRIME	800MG/PACKET	A217319	001	Mar 02, 2023	Feb NEWA
AB			2.4GM/PACKET	A217319	002	Mar 02, 2023	Feb NEWA

TABLET;ORAL
SEVELAMER CARBONATE

AB		MACLEODS PHARMS LTD	800MG	A206100	001	Apr 19, 2023	Apr NEWA
----	--	---------------------	-------	---------	-----	--------------	----------

SEVELAMER HYDROCHLORIDE

TABLET;ORAL
SEVELAMER HYDROCHLORIDE

>A>	AB	MACLEODS PHARMS LTD	400MG	A206883	001	May 26, 2023	May NEWA
>A>	AB		800MG	A206883	002	May 26, 2023	May NEWA

SILDENAFIL CITRATE

SUSPENSION;ORAL
LIQREV

+!	CMP DEV LLC	EQ 10MG BASE/ML	N214952	001	Apr 28, 2023	Apr	NEWA
----	-------------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL
SILDENAFIL CITRATE

AB		MACLEODS PHARMS LTD	EQ 25MG BASE	A202255	001	Apr 19, 2023	Apr NEWA
AB			EQ 50MG BASE	A202255	002	Apr 19, 2023	Apr NEWA
AB			EQ 100MG BASE	A202255	003	Apr 19, 2023	Apr NEWA

SILODOSIN

CAPSULE;ORAL
SILODOSIN

>D>	AB	ZYDUS PHARMS	4MG	A204816	001	Dec 08, 2022	May DISC
>A>	@		4MG	A204816	001	Dec 08, 2022	May DISC
>D>	AB		8MG	A204816	002	Dec 08, 2022	May DISC
>A>	@		8MG	A204816	002	Dec 08, 2022	May DISC

>A> SIPONIMOD
 >A> TABLET;ORAL
 >A> MAYZENT
 >A> + NOVARTIS EQ 0.25MG BASE N209884 001 Mar 26, 2019 May CAIN
 >A> + EQ 1MG BASE N209884 003 Aug 24, 2021 May CAIN
 >A> +! EQ 2MG BASE N209884 002 Mar 26, 2019 May CAIN

>D> SIPONIMOD FUMARIC ACID
 >D> TABLET;ORAL
 >D> MAYZENT
 >D> + NOVARTIS EQ 0.25MG BASE N209884 001 Mar 26, 2019 May CAIN
 >D> + EQ 1MG BASE N209884 003 Aug 24, 2021 May CAIN
 >D> +! EQ 2MG BASE N209884 002 Mar 26, 2019 May CAIN

SIROLIMUS
 SOLUTION;ORAL
 SIROLIMUS
 AA MSN 1MG/ML A216728 001 Jan 19, 2023 Jan NEWA
 TABLET;ORAL
 SIROLIMUS
 AB ZYDUS PHARMS 1MG A201676 001 Feb 15, 2023 Feb NEWA
 AB 2MG A201676 002 Feb 15, 2023 Feb NEWA

SODIUM CHLORIDE
 INJECTABLE;INJECTION
 SODIUM CHLORIDE 0.9%
 + B BRAUN 9MG/ML N019635 005 Aug 08, 2016 Mar CPOT
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 + @ LIEBEL-FLARSHEIM 450MG/50ML (9MG/ML) N021569 001 Jul 27, 2006 Mar CPOT
 + 1.125GM/125ML (9MG/ML) N021569 002 Jul 27, 2006 Mar CPOT

SODIUM OXYBATE
 >A> FOR SUSPENSION, EXTENDED RELEASE;ORAL
 >A> LUMRYZ
 >A> + AVADEL CNS 4.5GM/PACKET N214755 001 May 01, 2023 May NEWA
 >A> + 6GM/PACKET N214755 002 May 01, 2023 May NEWA
 >A> + 7.5GM/PACKET N214755 003 May 01, 2023 May NEWA
 >A> + 9GM/PACKET N214755 004 May 01, 2023 May NEWA

SODIUM PHENYLBUTYRATE
 POWDER;ORAL
 BUPHENYL
 AB +! HORIZON THERAP US 3GM/TEASPOONFUL N020573 001 Apr 30, 1996 Jan CAHN
 TABLET;ORAL
 BUPHENYL
 AB +! HORIZON THERAP US 500MG N020572 001 May 13, 1996 Jan CAHN

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
 INJECTABLE;INJECTION
 SODIUM PHOSPHATES
 AP ! FRESENIUS KABI USA 142MG/ML;276MG/ML A209997 001 Mar 30, 2022 Mar CHRS

SOLIFENACIN SUCCINATE
 TABLET;ORAL
 SOLIFENACIN SUCCINATE
 >D> AB CELLTRION 5MG A210582 001 May 20, 2019 May CAHN
 >D> AB 10MG A210582 002 May 20, 2019 May CAHN
 >A> AB CHARTWELL RX 5MG A210582 001 May 20, 2019 May CAHN
 >A> AB 10MG A210582 002 May 20, 2019 May CAHN
 >A> AB LANNETT CO INC 5MG A211622 001 Jun 06, 2023 May NEWA
 >A> AB 10MG A211622 002 Jun 06, 2023 May NEWA

SORAFENIB TOSYLATE
 TABLET;ORAL
 SORAFENIB TOSYLATE
 AB TORRENT EQ 200MG BASE A217095 001 Apr 12, 2023 Mar NEWA

>A>	<u>SOTAGLIFLOZIN</u>								
>A>	TABLET;ORAL								
>A>	INPEFA								
>A>	+	LEXICON PHARMS INC	200MG		N216203	001	May 26, 2023	May	NEWA
>A>	+	!	400MG		N216203	002	May 26, 2023	May	NEWA
	<u>SOTORASIB</u>								
	TABLET;ORAL								
	LUMAKRAS								
	+	AMGEN INC	120MG		N214665	001	May 28, 2021	Mar	CHRS
	+	!	320MG		N214665	002	Jan 20, 2023	Mar	CHRS
	+		320MG		N214665	002	Jan 20, 2023	Feb	NEWA
	<u>SPARSENTAN</u>								
	TABLET;ORAL								
	FILSPARI								
	+	TRAVERE	200MG		N216403	001	Feb 17, 2023	Feb	NEWA
	+	!	400MG		N216403	002	Feb 17, 2023	Feb	NEWA
	<u>STERILE WATER FOR INJECTION</u>								
	LIQUID;N/A								
	STERILE WATER FOR INJECTION								
AP		HIKMA	100%		A212735	001	Jan 31, 2023	Jan	NEWA
>A>	+	!	HOSPIRA 100% (5.2ML)		N018801	006	May 02, 2023	May	NEWA
	<u>SUCCINYLCHOLINE CHLORIDE</u>								
	INJECTABLE;INJECTION								
	SUCCINYLCHOLINE CHLORIDE								
	@	BRECKENRIDGE	20MG/ML		A212638	001	Oct 09, 2019	Apr	DISC
AP		MANKIND PHARMA	20MG/ML		A216127	001	Feb 02, 2023	Jan	NEWA
	<u>SUCRALFATE</u>								
	TABLET;ORAL								
	SUCRALFATE								
AB		ZYDUS LIFESCIENCES	1GM		A215705	001	May 03, 2023	Apr	NEWA
	<u>SUFENTANIL CITRATE</u>								
	TABLET;SUBLINGUAL								
	DSUVIA								
	+	!	VERTICAL PHARMS EQ 0.03MG BASE		N209128	001	Nov 02, 2018	Apr	CAHN
	<u>SULFACETAMIDE SODIUM</u>								
	SOLUTION/DROPS;OPHTHALMIC								
	SULFACETAMIDE SODIUM								
	@	AKORN	10%		A040215	001	May 25, 1999	Jan	DISC
	<u>SULINDAC</u>								
	TABLET;ORAL								
	SULINDAC								
	@	CHARTWELL RX	150MG		A072712	001	Aug 30, 1991	Jan	CAHN
	@		200MG		A072713	001	Aug 30, 1991	Jan	CAHN
	<u>TACROLIMUS</u>								
	CAPSULE;ORAL								
	TACROLIMUS								
AB		HANGZHOU ZHONGMEI	EQ 0.5MG BASE		A210929	001	Apr 17, 2023	Apr	NEWA
AB			EQ 1MG BASE		A210929	002	Apr 17, 2023	Apr	NEWA
AB			EQ 5MG BASE		A210929	003	Apr 17, 2023	Apr	NEWA
	<u>TADALAFIL</u>								
	TABLET;ORAL								
	ALYQ								
	@	TEVA PHARMS INC	20MG		A216932	001	Oct 12, 2022	Apr	DISC
	TADALAFIL								
>A>	AB2	CHARTWELL RX	20MG		A210572	001	Feb 05, 2019	May	CAHN
>D>	AB2	LUPIN LTD	20MG		A210572	001	Feb 05, 2019	May	CAHN
	AB1	NOVITIUM PHARMA	5MG		A215949	001	Mar 03, 2023	Feb	NEWA
	AB1		10MG		A215949	002	Mar 03, 2023	Feb	NEWA
	AB1		20MG		A215949	003	Mar 03, 2023	Feb	NEWA
	AB1	UNICHEM	2.5MG		A209250	001	Mar 26, 2019	Jan	CTEC
	AB1		5MG		A209250	002	Mar 26, 2019	Jan	CTEC

<u>TABLET;ORAL</u>							
TADALAFIL							
AB1		10MG		A209250	003	Mar 26, 2019	Jan CTEC
AB1		20MG		A209250	004	Mar 26, 2019	Jan CTEC
>A>	AB2	ZYDUS PHARMS	20MG	A212515	001	Jun 06, 2023	May NEWA
<u>TAMOXIFEN CITRATE</u>							
SOLUTION;ORAL							
SOLTAMOX							
	+	MAYNE PHARMA COMMRL	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005	Feb CAHN
<u>TASIMELTEON</u>							
CAPSULE;ORAL							
TASIMELTEON							
AB		APOTEX	20MG	A211607	001	Dec 20, 2022	Jan CAHN
AB		MSN	20MG	A211654	001	Jan 12, 2023	Jan NEWA
<u>TAVABOROLE</u>							
SOLUTION;TOPICAL							
TAVABOROLE							
AB		ZYDUS LIFESCIENCES	5%	A212294	001	Apr 10, 2023	Mar NEWA
<u>TAZAROTENE</u>							
GEL;TOPICAL							
TAZAROTENE							
AB		PADAGIS ISRAEL	0.05%	A213079	001	Apr 25, 2023	Apr NEWA
AB			0.1%	A213079	002	Apr 25, 2023	Apr NEWA
AB		SOLARIS PHARMA CORP	0.05%	A213644	001	Mar 20, 2023	Mar NEWA
AB			0.1%	A213644	002	Mar 20, 2023	Mar NEWA
<u>TECHNETIUM TC-99M MERTIATIDE KIT</u>							
POWDER;INTRAVENOUS							
TECHNETIUM TC 99M MERTIATIDE KIT							
	+	JUBILANT DRAXIMAGE	N/A	N216820	001	Jan 30, 2023	Jan NEWA
<u>TELMISARTAN</u>							
TABLET;ORAL							
TELMISARTAN							
>D>	AB	CELLTRION	20MG	A078710	001	Jan 08, 2014	May CAHN
>D>	AB		40MG	A078710	002	Jan 08, 2014	May CAHN
>D>	AB		80MG	A078710	003	Jan 08, 2014	May CAHN
>A>	AB	CHARTWELL RX	20MG	A078710	001	Jan 08, 2014	May CAHN
>A>	AB		40MG	A078710	002	Jan 08, 2014	May CAHN
>A>	AB		80MG	A078710	003	Jan 08, 2014	May CAHN
<u>TENOFOVIR ALAFENAMIDE FUMARATE</u>							
TABLET;ORAL							
TENOFOVIR ALAFENAMIDE							
AB		LUPIN LTD	EQ 25MG BASE	A214226	001	Mar 30, 2023	Mar NFTG
AB		VEMLIDY					
AB	+	GILEAD SCIENCES INC	EQ 25MG BASE	N208464	001	Nov 10, 2016	Mar CFTG
<u>TENOFOVIR DISOPROXIL FUMARATE</u>							
TABLET;ORAL							
TENOFOVIR DISOPROXIL FUMARATE							
AB		REYOUNG PHARM	300MG	A211337	001	Mar 02, 2023	Feb NEWA
<u>TERAZOSIN HYDROCHLORIDE</u>							
CAPSULE;ORAL							
TERAZOSIN HYDROCHLORIDE							
	@	BIONPHARMA INC	EQ 1MG BASE	A075667	001	Jul 28, 2000	Apr CAHN
	@		EQ 2MG BASE	A075667	002	Jul 28, 2000	Apr CAHN
	@		EQ 5MG BASE	A075667	003	Jul 28, 2000	Apr CAHN
	@		EQ 10MG BASE	A075667	004	Jul 28, 2000	Apr CAHN
TABLET;ORAL							
TERAZOSIN HYDROCHLORIDE							
>A>	@	CHARTWELL RX	EQ 1MG BASE	A074657	001	Apr 28, 2000	May CAHN
>A>	@		EQ 2MG BASE	A074657	002	Apr 28, 2000	May CAHN
>A>	@		EQ 5MG BASE	A074657	003	Apr 28, 2000	May CAHN
>A>	@		EQ 10MG BASE	A074657	004	Apr 28, 2000	May CAHN
>D>	@	SANDOZ	EQ 1MG BASE	A074657	001	Apr 28, 2000	May CAHN
>D>	@		EQ 2MG BASE	A074657	002	Apr 28, 2000	May CAHN

TABLET;ORAL

TERAZOSIN HYDROCHLORIDE

>D>	@	EQ 5MG BASE	A 074657	003	Apr 28, 2000	May	CAHN
>D>	@	EQ 10MG BASE	A 074657	004	Apr 28, 2000	May	CAHN

TERIFLUNOMIDE

TABLET;ORAL

TERIFLUNOMIDE

AB	AMNEAL PHARMS CO	7MG	A 209613	001	Sep 28, 2018	Feb	CMFD
AB		14MG	A 209613	002	Sep 28, 2018	Feb	CMFD
AB	APOTEX	7MG	A 209601	001	Nov 02, 2018	Jan	CMFD
AB		14MG	A 209601	002	Nov 02, 2018	Jan	CMFD
AB	AUROBINDO PHARMA	7MG	A 209638	001	Oct 26, 2018	Jan	CMFD
AB		14MG	A 209638	002	Oct 26, 2018	Jan	CMFD
AB	BIOCON PHARMA	7MG	A 209639	001	Mar 13, 2023	Mar	NEWA
AB		14MG	A 209639	002	Mar 13, 2023	Mar	NEWA
AB	HETERO LABS LTD V	7MG	A 209598	001	Mar 13, 2023	Mar	NEWA
AB		14MG	A 209598	002	Mar 13, 2023	Mar	NEWA
AB	MSN	7MG	A 209623	001	Apr 24, 2019	Feb	CMFD
AB		14MG	A 209623	002	Apr 24, 2019	Feb	CMFD
AB	MYLAN	7MG	A 209702	001	Feb 28, 2020	Feb	CMFD
AB		14MG	A 209702	002	Feb 28, 2020	Feb	CMFD
>A>	AB	NATCO	A 209555	001	May 15, 2023	May	NEWA
>A>	AB		A 209555	002	May 15, 2023	May	NEWA
AB	SOLA PHARMS	14MG	A 209677	001	Jun 17, 2020	Feb	CMFD
AB	TEVA PHARMS USA	7MG	A 209700	001	Sep 04, 2018	Feb	CMFD
AB		14MG	A 209700	002	Sep 04, 2018	Feb	CMFD
AB	ZYDUS PHARMS	7MG	A 209668	001	Nov 30, 2018	Jan	CMFD
AB		14MG	A 209668	002	Nov 30, 2018	Jan	CMFD

TESTOSTERONE

GEL, METERED;NASAL

NATESTO

+	!	ACERUS	5.5MG/0.122GM ACTUATION	N 205488	001	May 28, 2014	Jan	CHRS
+			5.5MG/0.122GM ACTUATION	N 205488	001	May 28, 2014	Jan	CRLD

GEL, METERED;TRANSDERMAL

ANDROGEL

AB	+	!	BESINS HLTHCARE	1.62% (20.25MG/1.25GM ACTUATION)	N 022309	001	Apr 29, 2011	Feb	CAHN
	+	@		12.5MG/1.25GM ACTUATION	N 021015	003	Sep 26, 2003	Feb	CAHN
AB			ENCUBE	1.62% (20.25MG/1.25GM ACTUATION)	A 208620	001	Apr 10, 2019	Jan	CAHN

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

TESTOSTERONE CYPIONATE

AO			XIROMED	100MG/ML	A 215351	001	Apr 13, 2023	Mar	NEWA
AO				200MG/ML	A 215351	002	Apr 13, 2023	Mar	NEWA

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

>A>	AB		CHARTWELL RX	12.5MG	A 210544	001	Apr 20, 2018	May	CAHN
>A>	AB			25MG	A 210544	002	Apr 20, 2018	May	CAHN
>D>	AB		LUPIN LTD	12.5MG	A 210544	001	Apr 20, 2018	May	CAHN
>D>	AB			25MG	A 210544	002	Apr 20, 2018	May	CAHN
		@	SUN PHARM	12.5MG	A 206129	001	Aug 17, 2015	Jan	DISC
		@		25MG	A 206129	002	Aug 17, 2015	Jan	DISC

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

TETRACYCLINE HYDROCHLORIDE

@		AUROBINDO PHARMA USA	250MG	A 060783	001		Apr	CAHN
@			500MG	A 060783	002		Apr	CAHN

THALIDOMIDE

CAPSULE;ORAL

THALIDOMIDE

AB			NATCO	150MG	A 213267	001	Apr 27, 2023	Apr	NFTG
AB	+		CELGENE	150MG	N 020785	004	Jan 10, 2007	Apr	CFTG

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE

AB	AMNEAL	300MG	A216276	001	Mar 20, 2023	Mar	NEWA
AB		450MG	A216276	002	Mar 20, 2023	Mar	NEWA
AB	BIONPHARMA INC	300MG	A216300	001	Apr 26, 2023	Apr	NEWA
AB		450MG	A216300	002	Apr 26, 2023	Apr	NEWA
AB	LEADING	300MG	A214950	001	Jan 30, 2023	Jan	NEWA
AB		450MG	A214950	002	Jan 30, 2023	Jan	NEWA
>A>	RHODES PHARMS	300MG	A214113	001	May 11, 2023	May	NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HYDROCHLORIDE

AP	CAPLIN	100MG/ML	A215692	001	Mar 06, 2023	Feb	NEWA
AP	DR REDDYS	100MG/ML	A080571	001		Mar	CMFD
!		200MG/ML	A080571	002		Mar	CMFD

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL
THIORIDAZINE HYDROCHLORIDE

@	CHARTWELL RX	10MG	A088131	001	Aug 30, 1983	Jan	CAHN
@		15MG	A088132	001	Aug 30, 1983	Jan	CAHN
@		25MG	A088133	001	Aug 30, 1983	Jan	CAHN
@		50MG	A088134	001	Aug 30, 1983	Jan	CAHN
@		100MG	A088135	001	Nov 20, 1984	Jan	CAHN
@		150MG	A088136	001	Sep 17, 1986	Jan	CAHN
@		200MG	A088137	001	Sep 17, 1986	Jan	CAHN

THIOTEPA

INJECTABLE; INJECTION
THIOTEPA

>A>	AP	PENN LIFE	15MG/VIAL	A208242	001	Jan 10, 2020	May	CAHN
>D>	AP	STI PHARMA LLC	15MG/VIAL	A208242	001	Jan 10, 2020	May	CAHN

THIOTHIXENE

CAPSULE;ORAL
THIOTHIXENE

AB	RISING	1MG	A071093	002	Jun 23, 1987	Feb	CAHN
AB		2MG	A071093	003	Jun 23, 1987	Feb	CAHN
AB		5MG	A071093	004	Jun 23, 1987	Feb	CAHN
AB		10MG	A071093	001	Jun 23, 1987	Feb	CAHN

TICAGRELOR

TABLET;ORAL
TICAGRELOR

AB	ALKEM LABS LTD	90MG	A208567	001	Apr 21, 2023	Apr	NEWA
----	----------------	------	---------	-----	--------------	-----	------

TIMOLOL

SOLUTION/DROPS;OPHTHALMIC
BETIMOL

+	!	THEA PHARMA	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Jan	CTEC
+	!		EQ 0.5% BASE	N020439	002	Mar 31, 1995	Jan	CTEC

TIMOLOL

@	AKORN	EQ 0.25% BASE	A205309	001	Sep 30, 2016	Jan	DISC
@		EQ 0.5% BASE	A205309	002	Sep 30, 2016	Jan	DISC

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC
TIMOLOL MALEATE

AB	EUGIA PHARMA	EQ 0.5% BASE	A213540	001	Mar 23, 2023	Mar	NEWA
AB	GLAND PHARMA LTD	EQ 0.5% BASE	A214645	002	Feb 14, 2023	Feb	NEWA

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

@	AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Jan	DISC	
>A>	AT1	MICRO LABS	EQ 0.25% BASE	A217343	001	May 26, 2023	May	NEWA
>A>	AT1		EQ 0.5% BASE	A217343	002	May 26, 2023	May	NEWA
AT3	SENTISS PHARMA	EQ 0.5% BASE	A217195	001	May 08, 2023	Apr	NEWA	

TINIDAZOLE

TABLET; ORAL		TINIDAZOLE					
AB	CHARTWELL RX	250MG		A202044	001	Apr 30, 2012	Apr CAHN
AB		500MG		A202044	002	Apr 30, 2012	Apr CAHN

TIOPRONIN

TABLET, DELAYED RELEASE; ORAL		THIOLA EC					
	+ MISSION PHARMACAL CO	100MG		N211843	001	Jun 28, 2019	Apr CTEC
AB	+	100MG		N211843	001	Jun 28, 2019	Feb CFTG
	+!	300MG		N211843	002	Jun 28, 2019	Apr CTEC
AB	+!	300MG		N211843	002	Jun 28, 2019	Feb CFTG
TIOPRONIN		@ PAR PHARM					
		100MG		A217219	001	Feb 24, 2023	Apr DISC
AB		100MG		A217219	001	Feb 24, 2023	Feb NFTG
	@	300MG		A217219	002	Feb 24, 2023	Apr DISC
AB		300MG		A217219	002	Feb 24, 2023	Feb NFTG

TIROFIBAN HYDROCHLORIDE

SOLUTION; INTRAVENOUS		AGGRASTAT					
AP	+ MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)		N020913	002	May 17, 2002	Jan CFTG
TIROFIBAN HYDROCHLORIDE		EUGIA PHARMA					
AP		EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)		A216379	001	May 01, 2023	Apr NEWA
AP		EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)		A216379	002	May 01, 2023	Apr NEWA
AP	NEXUS PHARMS	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)		A213947	001	Feb 07, 2023	Jan NFTG

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL		TIZANIDINE HYDROCHLORIDE					
	@ AUROBINDO PHARMA USA	EQ 2MG BASE		A076282	001	Dec 16, 2003	Apr CAHN
	@	EQ 4MG BASE		A076282	002	Dec 16, 2003	Apr CAHN

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC		AKTOB					
	@ AKORN	0.3%		A064096	001	Jan 31, 1996	Feb DISC

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION		TOBRAMYCIN SULFATE					
AP	HAINAN POLY	EQ 1.2GM BASE/VIAL		A217029	001	Feb 01, 2023	Jan NEWA

TOFACITINIB CITRATE

TABLET; ORAL		TOFACITINIB CITRATE					
	@ MICRO LABS	EQ 5MG BASE		A209738	001	Mar 13, 2023	Mar DISC
AB		EQ 5MG BASE		A209738	001	Mar 13, 2023	Mar NFTG
AB	ZYDUS PHARMS	EQ 5MG BASE		A209829	001	Mar 13, 2023	Mar NEWA
	XELJANZ						
AB	+ PF PRISM CV	EQ 5MG BASE		N203214	001	Nov 06, 2012	Mar CFTG

TOFERSEN

SOLUTION; INTRATHECAL		QALSODY					
	+! BIOGEN MA	100MG/15ML (6.7MG/ML)		N215887	001	Apr 25, 2023	Apr NEWA

TOLMETIN SODIUM

TABLET; ORAL		TOLMETIN SODIUM					
>D>	@ RISING	EQ 600MG BASE		A074473	001	Aug 30, 1994	May CMFD
>A>	!	EQ 600MG BASE		A074473	001	Aug 30, 1994	May CMFD

TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL
TOPIRAMATE

AB1	ACTAVIS LABS FL	25MG	A206210	001	Mar 10, 2023	Mar	NEWA
AB1		50MG	A206210	002	Mar 10, 2023	Mar	NEWA
AB1		100MG	A206210	003	Mar 10, 2023	Mar	NEWA
AB1		200MG	A206210	004	Mar 10, 2023	Mar	NEWA
AB1	PAR PHARM	25MG	A205976	002	May 04, 2023	Apr	NEWA
AB1		50MG	A205976	003	May 04, 2023	Apr	NEWA
AB1		100MG	A205976	004	May 04, 2023	Apr	NEWA
AB1		200MG	A205976	001	Mar 01, 2023	Feb	NEWA
AB1	ZYDUS	25MG	A207382	001	Nov 24, 2017	Jan	CAHN
AB2		25MG	A208949	001	Nov 29, 2022	Jan	CAHN
AB1		50MG	A207382	002	Nov 24, 2017	Jan	CAHN
AB2		50MG	A208949	002	Nov 29, 2022	Jan	CAHN
AB1		100MG	A207382	003	Nov 24, 2017	Jan	CAHN
AB2		100MG	A208949	003	Nov 29, 2022	Jan	CAHN
AB2		150MG	A208949	004	Nov 29, 2022	Jan	CAHN
AB2		200MG	A208949	005	Nov 29, 2022	Jan	CAHN
AB1	ZYDUS PHARMS TROKENDI XR	200MG	A216167	001	Feb 09, 2023	Jan	NFTG
AB1	+! SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013	Jan	CFTG

TOPOTECAN HYDROCHLORIDE

CAPSULE;ORAL
HYCAMTIN

>D>	+ NOVARTIS	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	May	CAHN
>D>	+!	EQ 1MG BASE	N020981	002	Oct 11, 2007	May	CAHN
>A>	+ SANDOZ	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	May	CAHN
>A>	+!	EQ 1MG BASE	N020981	002	Oct 11, 2007	May	CAHN

INJECTABLE;INJECTION
HYCAMTIN

>D>	AP +! NOVARTIS	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	May	CAHN
>A>	AP +! SANDOZ	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	May	CAHN

SOLUTION;INTRAVENOUS
TOPOTECAN HYDROCHLORIDE
@ DASH PHARMS

EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017	Mar	CAHN
----------------------------------	---------	-----	--------------	-----	------

TRAMETINIB DIMETHYL SULFOXIDE

SOLUTION;ORAL
MEKINIST

+! NOVARTIS	EQ 0.05MG BASE/ML	N217513	001	Mar 16, 2023	Mar	NEWA
-------------	-------------------	---------	-----	--------------	-----	------

TRAZODONE HYDROCHLORIDE

TABLET;ORAL
TRAZODONE HYDROCHLORIDE

AB	AUROBINDO PHARMA	50MG	A204852	001	Feb 05, 2020	Jan	CAHN
AB		100MG	A204852	002	Feb 05, 2020	Jan	CAHN
AB		150MG	A204852	003	Feb 05, 2020	Jan	CAHN
AB		300MG	A204852	004	Feb 05, 2020	Jan	CAHN

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS
TREPROSTINIL

AP	DR REDDYS	1MG/ML	A210214	001	May 22, 2020	Feb	CMFD
AP		2.5MG/ML	A210214	002	May 22, 2020	Feb	CMFD
AP		5MG/ML	A210214	003	May 22, 2020	Feb	CMFD
AP		10MG/ML	A210214	004	May 22, 2020	Feb	CMFD

TRETINOIN

CREAM;TOPICAL
RETIN-A

AB	+! BAUSCH	0.025%	N019049	001	Sep 16, 1988	Jan	CAHN
----	-----------	--------	---------	-----	--------------	-----	------

GEL;TOPICAL

>D>	AVITA						
>D>	BT MYLAN	0.025%	N020400	001	Jan 29, 1998	May	DISC
>A>	@	0.025%	N020400	001	Jan 29, 1998	May	DISC

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

>A>	AT	CHARTWELL RX	0.025%	A208763	001	Feb 01, 2017	May	CAHN
>A>	AT		0.1%	A208763	002	Feb 01, 2017	May	CAHN
>A>	AT		0.5%	A208763	003	Feb 01, 2017	May	CAHN
>D>	AT	LUPIN	0.025%	A208763	001	Feb 01, 2017	May	CAHN
>D>	AT		0.1%	A208763	002	Feb 01, 2017	May	CAHN
>D>	AT		0.5%	A208763	003	Feb 01, 2017	May	CAHN

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

>A>	AT	CHARTWELL RX	0.05%	A214532	001	Jan 27, 2023	May	CAHN
	AT		0.1%	A207365	001	Oct 12, 2018	Apr	CAHN
>D>	AT	GLASSHOUSE PHARMS	0.05%	A214532	001	Jan 27, 2023	May	CAHN
	AT		0.05%	A214532	001	Jan 27, 2023	Jan	NEWA

TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE

@ EYWA 50MG
@ 100MG

A214768	001	Jul 06, 2022	Jan	DISC
A214768	002	Jul 06, 2022	Jan	DISC

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

TRIENTINE HYDROCHLORIDE

AB	MSN	250MG	A211134	001	May 22, 2019	Mar	CTEC
----	-----	-------	---------	-----	--------------	-----	------

TROFINETIDE

SOLUTION;ORAL

DAYBUE

+! ACADIA PHARMS INC 200MG/ML

N217026	001	Mar 10, 2023	Mar	NEWA
---------	-----	--------------	-----	------

UBROGEPANT

TABLET;ORAL

UBRELVY

+ ABBVIE 50MG
+! 100MG

N211765	001	Dec 23, 2019	Jan	CAHN
N211765	002	Dec 23, 2019	Jan	CAHN

URSODIOL

CAPSULE;ORAL

URSODIOL

@ MYLAN 300MG
VGYAAN 300MG

AB			A090530	001	Feb 17, 2010	Jan	DISC
			A214329	001	Jul 28, 2021	Apr	CMFD

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	CHARTWELL RX	EQ 500MG BASE	A090216	001	May 24, 2010	Jan	CAHN
AB		EQ 1GM BASE	A090216	002	May 24, 2010	Jan	CAHN

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALCYTE

AB	+! CHEPLAPHARM	50MG/ML	N022257	001	Aug 28, 2009	Mar	CAHN
----	----------------	---------	---------	-----	--------------	-----	------

VALGANCICLOVIR HYDROCHLORIDE

AB	APPCO	50MG/ML	A216317	001	Apr 11, 2023	Mar	NEWA
----	-------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

VALCYTE

AB	+! CHEPLAPHARM	EQ 450MG BASE	N021304	001	Mar 29, 2001	Mar	CAHN
----	----------------	---------------	---------	-----	--------------	-----	------

VALPROIC ACID

SYRUP;ORAL

VALPROIC ACID

AA	QUAGEN	250MG/5ML	A090517	001	May 28, 2010	Apr	CAHN
	@ XTTRIUM LABS INC	250MG/5ML	A070868	001	Jul 01, 1986	Mar	CAHN

VALSARTAN

SOLUTION;ORAL
VALSARTAN

! NOVITIUM PHARMA 20MG/5ML A214102 001 Nov 02, 2021 Jan CHRS

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOMYCIN HYDROCHLORIDE

>A> AP GLAND PHARMA LTD EQ 5GM BASE/VIAL A205694 003 Jun 06, 2023 May NEWA
>A> AP EQ 10GM BASE/VIAL A205694 004 Jun 06, 2023 May NEWA
AP HIKMA EQ 1GM BASE/VIAL A203300 002 Aug 11, 2020 Jan CMFD

POWDER; INTRAVENOUS, ORAL
VANCOMYCIN HYDROCHLORIDE

+! ZHEJIANG NOVUS PHARM EQ 500MG BASE/VIAL N210274 001 Jan 20, 2023 Jan NEWA
+! EQ 1GM BASE/VIAL N210274 002 Jan 20, 2023 Jan NEWA
+! EQ 5GM BASE/VIAL N210274 003 Jan 20, 2023 Jan NEWA
+! EQ 10GM BASE/VIAL N210274 004 Jan 20, 2023 Jan NEWA

VARENICLINE TARTRATE

TABLET;ORAL
VARENICLINE TARTRATE

AB APOTEX EQ 0.5MG BASE A201962 001 Jan 25, 2023 Jan NEWA
AB EQ 1MG BASE A201962 002 Jan 25, 2023 Jan NEWA
AB PAR PHARM INC EQ 0.5MG BASE A201785 001 Aug 11, 2021 Jan CTEC
AB ! EQ 1MG BASE A201785 002 Aug 11, 2021 Jan CTEC

VASOPRESSIN

SOLUTION; INTRAVENOUS
VASOPRESSIN

>A> AP FRESENIUS KABI USA 20UNITS/ML (20UNITS/ML) A213206 001 May 26, 2023 May NEWA
VASOSTRICT
+! PAR STERILE PRODUCTS 50UNITS/50ML (1UNITS/ML) N204485 006 Apr 12, 2023 Apr NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

>A> AB GRANULES EQ 37.5MG BASE A217390 001 May 18, 2023 May NEWA
>A> AB EQ 75MG BASE A217390 002 May 18, 2023 May NEWA
>A> AB EQ 150MG BASE A217390 003 May 18, 2023 May NEWA
AB NOSTRUM PHARMS LLC EQ 37.5MG BASE A200430 001 Apr 04, 2023 Mar NEWA
AB EQ 75MG BASE A200430 002 Apr 04, 2023 Mar NEWA
AB EQ 150MG BASE A200430 003 Apr 04, 2023 Mar NEWA

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

@ CHARTWELL RX EQ 25MG BASE A077515 001 Jun 13, 2008 Jan CAHN
@ EQ 37.5MG BASE A077515 002 Jun 13, 2008 Jan CAHN
@ EQ 50MG BASE A077515 003 Jun 13, 2008 Jan CAHN
@ EQ 75MG BASE A077515 004 Jun 13, 2008 Jan CAHN
@ EQ 100MG BASE A077515 005 Jun 13, 2008 Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB AJANTA PHARMA LTD EQ 37.5MG BASE A214691 001 Apr 12, 2023 Mar NEWA
AB EQ 75MG BASE A214691 002 Apr 12, 2023 Mar NEWA
AB EQ 150MG BASE A214691 003 Apr 12, 2023 Mar NEWA
AB EQ 225MG BASE A214691 004 Apr 12, 2023 Mar NEWA

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

+ @ PFIZER 120MG N019152 003 Mar 06, 1991 Mar DISC
+ @ 240MG N019152 001 Dec 16, 1986 Mar DISC

VERAPAMIL HYDROCHLORIDE

AB CADILA PHARMS LTD 120MG A206173 003 Nov 14, 2022 Mar NEWA
AB ! GLENMARK GENERICS 120MG A090700 001 Aug 03, 2011 Mar CHRS
AB ! 240MG A078906 001 Sep 17, 2009 Mar CHRS

VIGABATRIN

FOR SOLUTION;ORAL		VIGABATRIN							
	@ ACCORD HLTHCARE	500MG/PACKET	A214425	001	Nov 13, 2020	Mar	DISC		
>A>	@ CHARTWELL RX	500MG/PACKET	A211790	001	Mar 10, 2022	May	CAHN		
>D>	@ LUPIN LTD	500MG/PACKET	A211790	001	Mar 10, 2022	May	CAHN		
AA	ZYDUS	500MG/PACKET	A214671	001	Mar 02, 2023	Feb	NEWA		
TABLET;ORAL		VIGABATRIN							
AB	PROPEL PHARMA	500MG	A215519	001	Apr 28, 2023	Apr	NEWA		

VILAZODONE HYDROCHLORIDE

TABLET;ORAL		VIIBRYD							
AB	+! ABBVIE	10MG	N022567	001	Jan 21, 2011	Jan	CAHN		
AB	+	20MG	N022567	002	Jan 21, 2011	Jan	CAHN		
AB	+	40MG	N022567	003	Jan 21, 2011	Jan	CAHN		

VORICONAZOLE

INJECTABLE;INTRAVENOUS		VORICONAZOLE							
AP	EUGIA PHARMA	200MG/VIAL	A212162	001	Feb 02, 2023	Jan	NEWA		
AP	UBI	200MG/VIAL	A211264	001	Mar 09, 2023	Mar	NEWA		
AP	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Mar	CDFR		
TABLET;ORAL		VORICONAZOLE							
AB	CHARTWELL RX	50MG	A207371	001	May 24, 2016	Apr	CAHN		
AB		200MG	A207371	002	May 24, 2016	Apr	CAHN		

VUTRISIRAN SODIUM

SOLUTION;SUBCUTANEOUS		AMVUTTRA							
	+! ALNYLAM PHARMS INC	EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML)	N215515	001	Jun 13, 2022	Feb	CPOT		
	+!	25MG/0.5ML (25MG/0.5ML)	N215515	001	Jun 13, 2022	Feb	CAIN		

WARFARIN SODIUM

TABLET;ORAL		WARFARIN SODIUM							
>A>	@ AUROBINDO PHARMA USA	1MG	A040415	001	Sep 27, 2004	May	CAHN		
>A>	@	2MG	A040415	002	Sep 27, 2004	May	CAHN		
>A>	@	2.5MG	A040415	003	Sep 29, 2004	May	CAHN		
>A>	@	3MG	A040415	004	Sep 27, 2004	May	CAHN		
>A>	@	4MG	A040415	005	Sep 27, 2004	May	CAHN		
>A>	@	5MG	A040415	006	Sep 27, 2004	May	CAHN		
>A>	@	6MG	A040415	007	Sep 27, 2004	May	CAHN		
>A>	@	7.5MG	A040415	008	Sep 27, 2004	May	CAHN		
>A>	@	10MG	A040415	009	Sep 27, 2004	May	CAHN		
>D>	@ MYLAN	1MG	A040415	001	Sep 27, 2004	May	CAHN		
>D>	@	2MG	A040415	002	Sep 27, 2004	May	CAHN		
>D>	@	2.5MG	A040415	003	Sep 29, 2004	May	CAHN		
>D>	@	3MG	A040415	004	Sep 27, 2004	May	CAHN		
>D>	@	4MG	A040415	005	Sep 27, 2004	May	CAHN		
>D>	@	5MG	A040415	006	Sep 27, 2004	May	CAHN		
>D>	@	6MG	A040415	007	Sep 27, 2004	May	CAHN		
>D>	@	7.5MG	A040415	008	Sep 27, 2004	May	CAHN		
>D>	@	10MG	A040415	009	Sep 27, 2004	May	CAHN		

XENON XE-129 HYPERPOLARIZED

GAS;INHALATION		XENOVIEW							
	+! POLAREAN	N/A	N214375	001	Dec 23, 2022	Jan	NEWA		

ZAVEGEPANT HYDROCHLORIDE

SPRAY, METERED;NASAL		ZAVZPRET							
	+! PFIZER	EQ 10MG BASE/SPRAY	N216386	001	Mar 09, 2023	Mar	NEWA		

ZILEUTON

TABLET, EXTENDED RELEASE;ORAL

ZILEUTON

AB	!	RISING	600MG	A204929	001	Mar 17, 2017	Jan	CHRS
		ZYFLO CR						
	+	@ CHIESI	600MG	N022052	001	May 30, 2007	Jan	DISC

>A> ZINC SULFATE

>A> SOLUTION;INTRAVENOUS

>A> ZINC SULFATE

>A>	AP	FRESENIUS KABI USA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A216145	001	Dec 27, 2022	May	CAIN
>A>	AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A216145	002	Dec 27, 2022	May	CAIN
>A>	AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A216145	003	Dec 27, 2022	May	CAIN

>D> ZINC SULFATE MONOHYDRATE

>D> SOLUTION;INTRAVENOUS

>D> ZINC SULFATE

>D>	AP	FRESENIUS KABI USA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A216145	001	Dec 27, 2022	May	CAIN
>D>	AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A216145	002	Dec 27, 2022	May	CAIN
>D>	AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A216145	003	Dec 27, 2022	May	CAIN

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS

RECLAST

>D>	AP	+	NOVARTIS	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	May	CAHN
>A>	AP	+	SANDOZ	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	May	CAHN
			ZOLEDRONIC ACID						
>A>	AP		HONG KONG	EQ 5MG BASE/100ML	A213371	001	Jun 05, 2023	May	NEWA

ZOLMITRIPTAN

SPRAY;NASAL

ZOMIG

AB	+	AMNEAL	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Jan	CAHN
AB	+	!	5MG/SPRAY	N021450	004	Sep 30, 2003	Jan	CAHN

ZOLPIDEM TARTRATE

CAPSULE;ORAL

ZOLPIDEM TARTRATE

>A>		+	ALMATICA	7.5MG	N215721	001	May 09, 2023	May	NEWA
-----	--	---	----------	-------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL

ZOLPIDEM TARTRATE

>D>	AB		ANCHEN PHARMS	6.25MG	A078148	002	Apr 14, 2011	May	DISC
>A>			@	6.25MG	A078148	002	Apr 14, 2011	May	DISC
>D>	AB			12.5MG	A078148	001	Dec 03, 2010	May	DISC
>A>			@	12.5MG	A078148	001	Dec 03, 2010	May	DISC

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

EXCEDRIN (MIGRAINE RELIEF)

+! GLAXOSMITHKLINE CONS 250MG;250MG;65MG

N020802 001 Jan 14, 1998 Apr CTNA

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ACETAMINOPHEN AND IBUPROFEN

L FERRIGO CO 250MG;125MG

A214836 001 Feb 28, 2023 Feb NEWA

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 5MG;120MG

A212409 001 Mar 08, 2023 Feb NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION;TOPICAL

SOLUPREP S

+! 3M HEALTH CARE 2%;70%

N208288 001 Aug 08, 2018 Mar CTNA

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

COREPHARMA 25MG;220MG

A211830 001 Aug 22, 2019 Feb CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

GUARDIAN DRUG EQ 20MG BASE

A216149 001 Mar 15, 2023 Mar NEWA

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

MARKSANS PHARMA 10MG

A217543 001 Mar 08, 2023 Feb NEWA

20MG

A217543 002 Mar 08, 2023 Feb NEWA

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

FEXOFENADINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 30MG/5ML

A213466 001 May 23, 2023 May NEWA

TABLET;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA USA 30MG

A202039 001 Nov 19, 2014 Apr CAHN

FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA USA 60MG

A202039 002 Nov 19, 2014 Apr CAHN

180MG

A202039 003 Nov 19, 2014 Apr CAHN

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ GRANULES 600MG;60MG

A216082 001 Aug 22, 2022 Feb DISC

@ 1.2GM;120MG

A216082 002 Aug 22, 2022 Feb DISC

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET;ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 200MG;30MG

A213565 001 Mar 10, 2023 Mar NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

@ GRANULES 2MG;125MG

A215981 001 Aug 29, 2022 Feb DISC

LORATADINE

CAPSULE;ORAL

LORATADINE

AUROBINDO PHARMA 10MG

A211900 001 Mar 24, 2023 Mar NEWA

>A>

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL
NARCAN

+!	EMERGENT	4MG/SPRAY	N208411	001	Nov 18, 2015	Mar	CMKT
----	----------	-----------	---------	-----	--------------	-----	------

NAPROXEN SODIUM

CAPSULE;ORAL
NAPROXEN SODIUM

@	STRIDES PHARMA	EQ 200MG BASE	A215472	001	Aug 17, 2022	Feb	DISC
---	----------------	---------------	---------	-----	--------------	-----	------

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

@	AKORN	EQ 0.1% BASE	A204532	001	Jan 10, 2017	Jan	DISC
@		EQ 0.2% BASE	A204723	001	Dec 05, 2017	Jan	DISC

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL
OMEPRAZOLE MAGNESIUM

	AUROBINDO PHARMA LTD	EQ 20MG BASE	A213201	001	Apr 28, 2023	Apr	NEWA
--	----------------------	--------------	---------	-----	--------------	-----	------

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

>A>	ZYDUS	20MG;1.1GM	A203345	001	Mar 16, 2018	May	CAHN
>D>	ZYDUS PHARMS	20MG;1.1GM	A203345	001	Mar 16, 2018	May	CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 5 MAY 2023

NO MAY 2023 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2023 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	8748382	Oct 03, 2027	U-2009		I-907	Dec 19, 2025
	8748382	Oct 03, 2027	U-3543			
	RE49444	Apr 28, 2031	U-2009			
	RE49444	Apr 28, 2031	U-3543			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			
<u>ABROCITINIB - CIBINOO</u>						
N 213871 001					NPP	Feb 09, 2026
<u>ABROCITINIB - CIBINOO</u>						
N 213871 002					NPP	Feb 09, 2026
<u>ABROCITINIB - CIBINOO</u>						
N 213871 003					NPP	Feb 09, 2026
<u>ACETAMINOPHEN; IBUPROFEN - COMBOGESIC</u>						
N 209471 001	10532036	Sep 22, 2025	U-3553		>A> NP	Mar 01, 2026
	11197830	Feb 27, 2039	DP U-3553			
	11534407	Feb 27, 2039	DP U-3553			
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001					NCE ODE-352	Dec 12, 2027 Dec 12, 2029
<u>ALBUTEROL SULFATE; BUDESONIDE - AIRSUPRA</u>						
N 214070 001	9415009	May 28, 2030	U-3509		NP	Jan 10, 2026
<u>ALENDRONATE SODIUM - ALENDRONATE SODIUM</u>						
A 214512 001					>A> CGT	Nov 20, 2023
<u>ALPELISIB - VIJOICE</u>						
N 215039 001					ODE-396	Apr 05, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALPELISIB - VIJOICE</u>						
N 215039	002				ODE-396	Apr 05, 2029
<u>ALPELISIB - VIJOICE</u>						
N 215039	003				ODE-396	Apr 05, 2029
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081	001	11540981	Feb 07, 2028	DP		
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANA VEL XR</u>						
N 208147	001	11590228	Sep 07, 2036	DP U-3538		
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANA VEL XR 5</u>						
N 210526	001	11590081	Sep 24, 2038	DP U-3538		
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANA VEL XR 10</u>						
N 210526	002	11590081	Sep 24, 2038	DP U-3538		
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANA VEL XR 15</u>						
N 210526	003	11590081	Sep 24, 2038	DP U-3538		
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANA VEL XR 20</u>						
N 210526	004	11590081	Sep 24, 2038	DP U-3538		
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	001	11559559	Dec 18, 2034	U-3514		
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	002	11559559	Dec 18, 2034	U-3514		
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	003	11559559	Dec 18, 2034	U-3514		
<u>APALUTAMIDE - ERLEADA</u>						
N 210951	001	10052314	Sep 23, 2033	U-2381	Y	
		10052314	Sep 23, 2033	U-2382	Y	
		9481663	Jun 04, 2033	DS DP U-2237		
		9481663	Jun 04, 2033	DS DP U-2624		
		RE49353	Sep 23, 2033	U-2381		
<u>APALUTAMIDE - ERLEADA</u>						
N 210951	002	10702508	Apr 30, 2038	U-3012		
		10849888	Sep 23, 2033	U-3013		
		8445507	Sep 15, 2030	DS DP U-2237		
		8445507	Sep 15, 2030	DS DP U-2624		
		8802689	Mar 27, 2027	U-2237		
		8802689	Mar 27, 2027	U-2624		
		9388159	Mar 27, 2027	DS DP		
		9481663	Jun 04, 2033	DS DP U-2237		
		9481663	Jun 04, 2033	DS DP U-2624		
		9884054	Sep 23, 2033	U-2237		
		9987261	Mar 27, 2027	DP		
		RE49353	Sep 23, 2033	U-2381		
<u>ARIPIPIRAZOLE - ABILIFY ASIMTUFI</u>						
N 217006	001	>A> 10517951	Apr 23, 2033	DP U-3245		
		>A> 10517951	Apr 23, 2033	DP U-814		
		>A> 11097007	Apr 23, 2033	DP U-3245		
		>A> 11097007	Apr 23, 2033	DP U-814		
		>A> 11638757	Apr 23, 2033	DP U-3245		
		>A> 11638757	Apr 23, 2033	DP U-814		
		>A> 8338427	Mar 15, 2025	DP U-1530		
		>A> 8338428	Aug 06, 2023	DP U-1530		
		>A> 8399469	Jun 29, 2025	DS		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY ASIMTUFIN</u>						
N 217006 001	>A> 8759351	Aug 06, 2023	DP U-1530			
<u>ARIPRAZOLE - ABILIFY ASIMTUFIN</u>						
N 217006 002	>A> 10517951	Apr 23, 2033	DP U-3245			
	>A> 10517951	Apr 23, 2033	DP U-814			
	>A> 11097007	Apr 23, 2033	DP U-3245			
	>A> 11097007	Apr 23, 2033	DP U-814			
	>A> 11638757	Apr 23, 2033	DP U-3245			
	>A> 11638757	Apr 23, 2033	DP U-814			
	>A> 8338427	Mar 15, 2025	DP U-1530			
	>A> 8338428	Aug 06, 2023	DP U-1530			
	>A> 8399469	Jun 29, 2025	DS			
	>A> 8759351	Aug 06, 2023	DP U-1530			
<u>ASPIRIN - VAZALORE</u>						
N 203697 001	10646431	Sep 29, 2032	DP			
	10786444	Sep 29, 2032	U-3559			
<u>ASPIRIN - VAZALORE</u>						
N 203697 002	10646431	Sep 29, 2032	DP			
	10786444	Sep 29, 2032	U-3559			
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 001	>A> 8754096	Jul 19, 2032	DS DP U-3534		>A> I-909	Apr 17, 2026
	>A> 9499545	Nov 10, 2031	DS DP U-3534			
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 002	>A> 8754096	Jul 19, 2032	DS DP U-3534		>A> I-909	Apr 17, 2026
	>A> 9499545	Nov 10, 2031	DS DP U-3534			
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 003	>A> 8754096	Jul 19, 2032	DS DP U-3534		>A> I-909	Apr 17, 2026
	>A> 9499545	Nov 10, 2031	DS DP U-3534			
<u>ATORVASTATIN CALCIUM - ATORVALIO</u>						
N 213260 001	11369567	Jun 07, 2037	DP			
	>A> 11654106	Jun 07, 2037	DP U-3612			
	>A> 11654106	Jun 07, 2037	DP U-3613			
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	11603356	May 29, 2041	DS DP U-3558			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001					NPP	Dec 20, 2025
<u>AZACITIDINE - VIDAZA</u>						
N 050794 001					ODE-399	May 20, 2029
<u>AZACITIDINE - ONUREG</u>						
N 214120 001	11571436	May 14, 2029	DP			
<u>AZACITIDINE - ONUREG</u>						
N 214120 002	11571436	May 14, 2029	DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	9737469	Nov 02, 2031	U-3500			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	9737469	Nov 02, 2031	U-3500			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	9737469	Nov 02, 2031	U-3500			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	11559637	Jul 21, 2039	DP			
	11583643	Aug 19, 2041	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	11559637	Jul 21, 2039	DP			
	11583643	Aug 19, 2041	DP			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	11613511	Jun 19, 2040	DS			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	11613511	Jun 19, 2040	DS			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
	9533955*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
	9533955*PED	Sep 26, 2029				
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11541026	Feb 19, 2040	U-3356			
	>A> 11628155	Dec 27, 2040	U-3356			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	11618733	Nov 01, 2039	U-3300			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	11618733	Nov 01, 2039	U-3300			
<u>BEXAGLIFLOZIN - BRENZAVVY</u>						
N 214373 001	10533032	Jul 03, 2031	U-2214		NCE	Jan 20, 2028
	10981942	Jun 13, 2031	DS DP			
	7838499	Jan 30, 2029	DS DP U-2214			
	8106021	Aug 22, 2028	U-2214			
	8802637	Aug 22, 2028	DS DP U-2214			
	8987323	May 14, 2032	DS DP			
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	11590209	Apr 29, 2041	U-3539			
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001	11596600	Jul 27, 2029	U-2222			
<u>BUDESONIDE - BUDESONIDE</u>						
A 215328 001					CGT	Oct 24, 2023
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001					ODE-389	Dec 15, 2028
<u>BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT AEROSPHERE</u>						
N 216579 001	>A> 10716753	May 28, 2030	DP U-3203			
	>A> 9415009	May 28, 2030	U-3203			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 001	>A> 10912772	Jul 26, 2032	U-3617			
	>A> 11110084	Jul 26, 2032	DP U-3616			
	>A> 11135215	Jul 26, 2032	DP			
	>A> 8236292	Jan 10, 2027	DP U-3619			
	>A> 8236755	Jul 31, 2026	DP U-3620			
	>A> 8545832	Jun 06, 2025	DP U-3619			
	>A> 9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 002	>A> 10912772	Jul 26, 2032	U-3617			
	>A> 11110084	Jul 26, 2032	DP U-3616			
	>A> 11135215	Jul 26, 2032	DP			
	>A> 8236292	Jan 10, 2027	DP U-3619			
	>A> 8236755	Jul 31, 2026	DP U-3620			
	>A> 8545832	Jun 06, 2025	DP U-3619			
	>A> 9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 003	>A> 10912772	Jul 26, 2032	U-3617			
	>A> 11110084	Jul 26, 2032	DP U-3616			
	>A> 11135215	Jul 26, 2032	DP			
	>A> 8236292	Jan 10, 2027	DP U-3619			
	>A> 8236755	Jul 31, 2026	DP U-3620			
	>A> 8545832	Jun 06, 2025	DP U-3619			
	>A> 9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 004	>A> 10912772	Jul 26, 2032	U-3617			
	>A> 11110084	Jul 26, 2032	DP U-3616			
	>A> 11135215	Jul 26, 2032	DP			
	>A> 8236292	Jan 10, 2027	DP U-3619			
	>A> 8236755	Jul 31, 2026	DP U-3620			
	>A> 8545832	Jun 06, 2025	DP U-3619			
	>A> 9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 005	>A> 10912772	Jul 26, 2032	U-3617			
	>A> 11110084	Jul 26, 2032	DP U-3616			
	>A> 11135215	Jul 26, 2032	DP			
	>A> 8236292	Jan 10, 2027	DP U-3619			
	>A> 8236755	Jul 31, 2026	DP U-3620			
	>A> 8545832	Jun 06, 2025	DP U-3619			
	>A> 9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 006	>A> 10912772	Jul 26, 2032	U-3617			
	>A> 11110084	Jul 26, 2032	DP U-3616			
	>A> 11135215	Jul 26, 2032	DP			
	>A> 8236292	Jan 10, 2027	DP U-3619			
	>A> 8236755	Jul 31, 2026	DP U-3620			
	>A> 8545832	Jun 06, 2025	DP U-3619			
	>A> 9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 007	>A> 10912772	Jul 26, 2032	U-3617			
	>A> 11110084	Jul 26, 2032	DP U-3616			
	>A> 11135215	Jul 26, 2032	DP			
	>A> 8236292	Jan 10, 2027	DP U-3619			
	>A> 8236755	Jul 31, 2026	DP U-3620			
	>A> 8545832	Jun 06, 2025	DP U-3619			
	>A> 9937164	Jul 26, 2032	DP U-3618			
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11534414	Nov 05, 2034	DP U-3419			
	11541021	Nov 05, 2034	U-3419			
	11541048	Nov 05, 2034	U-3419			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11596627	Nov 05, 2034	U-3419			
	11617728	Nov 05, 2034	U-3419			
	11617747	Nov 05, 2034	U-3563			
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	11554102	Jan 11, 2033	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	11576894	Jul 06, 2030	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	11576894	Jul 06, 2030	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	11576894	Jul 06, 2030	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	11576894	Jul 06, 2030	DP			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	>A> 11633369	Jun 17, 2035	DP U-2780			
	>A> 11633369	Jun 17, 2035	DP U-2781			
	>A> 11633369	Jun 17, 2035	DP U-3071			
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030 001	11529357	Jan 31, 2040	DP			
<u>CARBIDOPA; LEVODOPA - DHIVY</u>						
N 214869 001	11439613	Mar 28, 2039	U-3557			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Sep 17, 2029	DS DP U-1750		I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Sep 17, 2029	DS DP U-1750		I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Sep 17, 2029	DS DP U-1750		I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	RE49302	Jul 16, 2029	U-2543		I-904	Dec 16, 2025
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	RE49302	Jul 16, 2029	U-2543		I-904	Dec 16, 2025
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 001 >A>	11654133	Jun 16, 2039	U-3610			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 002 >A>	11654133	Jun 16, 2039	U-3610			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 003 >A>	11654133	Jun 16, 2039	U-3610			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 004 >A>	11654133	Jun 16, 2039	U-3610			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 005 >A>	11654133	Jun 16, 2039	U-3610			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 006 >A>	11654133	Jun 16, 2039	U-3610			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - SOLUPREP S</u>						
N 208288 001					M-292	Jan 20, 2026
<u>CHLOROPROCAINE HYDROCHLORIDE - IHEEZO</u>						
N 216227 001					NP	Sep 27, 2025
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001 >A>	6706276	Sep 06, 2023	DP			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	8143240	Jan 12, 2024	U-2942			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 001	11541002	Jan 31, 2040	DP U-724			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 002	11541002	Jan 31, 2040	DP U-724			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 003	11541002	Jan 31, 2040	DP U-724			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	11597699	Oct 05, 2026	U-3554		ODE-416	Oct 28, 2029
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					ODE-407	Jul 14, 2029
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					ODE-407	Jul 14, 2029
<u>CYCLOSPORINE - VERKAZIA</u>						
N 214965 001	11612658	Jan 27, 2026	U-3560		NP	Jun 23, 2024
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	>A> 11642370	Jan 15, 2039	DP			
	>A> 11648262	Jan 15, 2039	DP			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	11510941	Mar 02, 2039	DP			
	11510942	Jan 15, 2039	DP U-2752			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912	Oct 15, 2032	DP U-3149			
	10028912	Oct 15, 2032	DP U-3150			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	10869869	Aug 30, 2033	U-3185		I-894	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296		ODE-428	Mar 16, 2030
	7994185*PED	Jul 20, 2030			PED	Dec 22, 2024
	8415345	Jan 20, 2030	DS DP U-1406		PED	Oct 30, 2025
	8415345	Jan 20, 2030	DS DP U-2031		PED	Nov 04, 2025
	8415345	Jan 20, 2030	DS DP U-2032		PED	Dec 22, 2025
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	10869869	Aug 30, 2033	U-3185		I-894	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296		ODE-428	Mar 16, 2030
	7994185*PED	Jul 20, 2030			PED	Dec 22, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	8415345	Jan 20, 2030	DS DP U-1406		PED	Oct 30, 2025
	8415345	Jan 20, 2030	DS DP U-2031		PED	Nov 04, 2025
	8415345	Jan 20, 2030	DS DP U-2032		PED	Dec 22, 2025
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 217514 001	>A> 11504333	Jun 29, 2038	DP		NP	Mar 16, 2026
	>A> 7994185	Jan 20, 2030	DS DP		ODE-428	Mar 16, 2030
	>A> 8415345	Jan 20, 2030	DS DP			
	>A> 8703781	Oct 15, 2030	DS DP U-3565			
	8835443	Jun 10, 2025	U-3565			
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001	6900175	May 23, 2028	U-3499			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 001	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	>A> 11643397	Jun 27, 2023	DS U-3535			
	>A> 11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 002	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	>A> 11643397	Jun 27, 2023	DS U-3535			
	>A> 11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 003	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	>A> 11643397	Jun 27, 2023	DS U-3535			
	>A> 11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 004	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	>A> 11643397	Jun 27, 2023	DS U-3535			
	>A> 11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 005	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	>A> 11643397	Jun 27, 2023	DS U-3535			
	>A> 11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	8975254	Mar 25, 2033	DS DP U-2605			
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001					ODE-417	Apr 30, 2028
					ODE-420	Apr 30, 2028
					ODE-421	Apr 30, 2028
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 002					ODE-417	Apr 30, 2028
					ODE-420	Apr 30, 2028
					ODE-421	Apr 30, 2028
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 001					ODE-417	Apr 30, 2028
					ODE-418	Apr 30, 2028
					ODE-419	Apr 30, 2028
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 002					ODE-417	Apr 30, 2028
					ODE-418	Apr 30, 2028
					ODE-419	Apr 30, 2028
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001					ODE-417	Apr 30, 2028
					ODE-420	Apr 30, 2028
					ODE-421	Apr 30, 2028
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	>A> 11446291	Mar 07, 2036	U-1995			
	>A> 11446291*PED	Sep 07, 2036				
	>A> 11564917	Mar 07, 2036	U-1995			
	>A> 11564917*PED	Sep 07, 2036				
	>A> 11648244	Mar 07, 2036	U-1995			
	>A> 11648244*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	>A> 11446291	Mar 07, 2036	U-1995			
	>A> 11446291*PED	Sep 07, 2036				
	>A> 11564917	Mar 07, 2036	U-1995			
	>A> 11564917*PED	Sep 07, 2036				
	>A> 11648244	Mar 07, 2036	U-1995			
	>A> 11648244*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	>A> 11446291	Mar 07, 2036	U-1995			
	>A> 11446291*PED	Sep 07, 2036				
	>A> 11564917	Mar 07, 2036	U-1995			
	>A> 11564917*PED	Sep 07, 2036				
	>A> 11648244	Mar 07, 2036	U-1995			
	>A> 11648244*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 001	>A> 10959996	Mar 07, 2036	U-3055			
	>A> 10959996*PED	Sep 07, 2036				
	>A> 11179386	Mar 15, 2038	DP U-1995			
	>A> 11179386	Mar 15, 2038	DP U-3055			
	>A> 11179386*PED	Sep 15, 2038				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 001	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	>A> 11357772	Mar 07, 2036	U-1995			
	>A> 11357772	Mar 07, 2036	U-3055			
	>A> 11357772*PED	Sep 07, 2036				
	>A> 11446291	Mar 07, 2036	U-1995			
	>A> 11446291*PED	Sep 07, 2036				
	>A> 11564917	Mar 07, 2036	U-1995			
	>A> 11564917*PED	Sep 07, 2036				
	>A> 11648244	Mar 07, 2036	U-1995			
	>A> 11648244*PED	Sep 07, 2036				
	>A> 8524733	Apr 03, 2031	DS DP			
	>A> 8524733*PED	Oct 03, 2031				
	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
	>A> 9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 002	>A> 10959996	Mar 07, 2036	U-3055			
	>A> 10959996*PED	Sep 07, 2036				
	>A> 11179386	Mar 15, 2038	DP U-1995			
	>A> 11179386	Mar 15, 2038	DP U-3055			
	>A> 11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	>A> 11357772	Mar 07, 2036	U-1995			
	>A> 11357772	Mar 07, 2036	U-3055			
	>A> 11357772*PED	Sep 07, 2036				
	>A> 11446291	Mar 07, 2036	U-1995			
	>A> 11446291*PED	Sep 07, 2036				
	>A> 11564917	Mar 07, 2036	U-1995			
	>A> 11564917*PED	Sep 07, 2036				
	>A> 11648244	Mar 07, 2036	U-1995			
	>A> 11648244*PED	Sep 07, 2036				
	>A> 8524733	Apr 03, 2031	DS DP			
	>A> 8524733*PED	Oct 03, 2031				
	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
	>A> 9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 003	>A> 10959996	Mar 07, 2036	U-3055			
	>A> 10959996*PED	Sep 07, 2036				
	>A> 11179386	Mar 15, 2038	DP U-1995			
	>A> 11179386	Mar 15, 2038	DP U-3055			
	>A> 11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	>A> 11357772	Mar 07, 2036	U-1995			
	>A> 11357772	Mar 07, 2036	U-3055			
	>A> 11357772*PED	Sep 07, 2036				
	>A> 11446291	Mar 07, 2036	U-1995			
	>A> 11446291*PED	Sep 07, 2036				
	>A> 11564917	Mar 07, 2036	U-1995			
	>A> 11564917*PED	Sep 07, 2036				
	>A> 11648244	Mar 07, 2036	U-1995			
	>A> 11648244*PED	Sep 07, 2036				
	>A> 8524733	Apr 03, 2031	DS DP			
	>A> 8524733*PED	Oct 03, 2031				
	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
	>A> 9550780*PED	Mar 18, 2034				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001						

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	002				NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	003				NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	004				NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	005				NPP	Dec 16, 2025
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401	001	11559501	Jan 06, 2042	DP		
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401	002	11559501	Jan 06, 2042	DP		
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401	003	11559501	Jan 06, 2042	DP		
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401	004	11559501	Jan 06, 2042	DP		
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304	001	>A> 11648214	Sep 23, 2037	DP U-3334		
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304	002	>A> 11648214	Sep 23, 2037	DP U-3334		
<u>DOXEPIN HYDROCHLORIDE - DOXEPIN HYDROCHLORIDE</u>						
A 215408	001				CGT	Aug 16, 2023
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532	001	>A> 11617751	Jul 17, 2030	DP U-1		
		>A> 11617751	Jul 17, 2030	DP U-3572		
		>A> 11617751	Jul 17, 2030	DP U-3573		
		>A> 11617751	Jul 17, 2030	DP U-3574		
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574	001	>A> 11617751	Jul 17, 2030	DP U-1		
		>A> 11617751	Jul 17, 2030	DP U-3572		
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639	001	10071066	Oct 10, 2034	U-3524	NCE	Jan 27, 2028
		10385008	Jan 05, 2038	DS DP		
		10420734	Oct 10, 2034	U-3524		
		10745343	Jan 05, 2038	U-3523		
		7612114	Aug 18, 2026	DS DP U-3523		
		8399520	Dec 25, 2023	DS DP U-3523		
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639	002	10071066	Oct 10, 2034	U-3524	NCE	Jan 27, 2028
		10385008	Jan 05, 2038	DS DP		
		10420734	Oct 10, 2034	U-3524		
		10745343	Jan 05, 2038	U-3523		
		7612114	Aug 18, 2026	DS DP U-3523		
		8399520	Dec 25, 2023	DS DP U-3523		
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450	001	11542239	Jul 23, 2039	DS DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	11542239	Jul 23, 2039	DS DP			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	11542239	Jul 23, 2039	DS DP			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	11564916	Aug 13, 2029	U-3525			
	11578062	Mar 25, 2031	DP U-3544			
	>A> 11639347	Apr 09, 2027	DS DP U-3587			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	11564916	Aug 13, 2029	U-3525			
	11578062	Mar 25, 2031	DP U-3544			
	>A> 11639347	Apr 09, 2027	DS DP U-3587			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 001	>A> 10022352	Apr 09, 2027	DP U-3596		>A> NCE	Oct 21, 2024
	>A> 10081621	Mar 25, 2031	DP U-3600		>A> NP	Apr 26, 2026
	>A> 10239867	Apr 09, 2027	DS DP U-3590			
	>A> 10272046	Feb 27, 2033	DP U-3599			
	>A> 10646481	Aug 13, 2029	DP			
	>A> 10758534	Oct 06, 2035	DS DP U-3589			
	>A> 10793547	Dec 08, 2037	DS DP U-3588			
	>A> 11147770	Feb 27, 2033	DP U-3598			
	>A> 11179367	Dec 08, 2037	DP U-3597			
	>A> 11426407	Oct 06, 2035	DS DP U-3595			
	>A> 11453655	Dec 08, 2037	DS DP			
	>A> 11517564	Dec 08, 2037	DP U-3586			
	>A> 11564916	Aug 13, 2029	U-3585			
	>A> 11578062	Mar 25, 2031	DP U-3584			
	>A> 11639347	Apr 09, 2027	DS DP U-3583			
	>A> 7495103	May 20, 2027	DS DP			
	>A> 7645789	May 01, 2027	DS DP			
	>A> 7776905	Jun 03, 2027	DS DP			
	>A> 8324242	Aug 05, 2027	U-3589			
	>A> 8354427	Jul 06, 2026	U-3593			
	>A> 8410274	Dec 28, 2026	DP			
	>A> 8415387	Nov 12, 2027	U-3589			
	>A> 8598181	May 01, 2027	U-3589			
	>A> 8623905	May 01, 2027	DS DP			
	>A> 8629162	Jun 24, 2025	U-3592			
	>A> 8754224	Dec 28, 2026	DS DP			
	>A> 8883206	Feb 27, 2033	DP			
	>A> 9670163	Dec 28, 2026	DP U-3591			
	>A> 9931334	Dec 28, 2026	DP U-3591			
	>A> 9974781	Apr 09, 2027	DP U-3589			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	>A> 10022352	Apr 09, 2027	DP U-3596		>A> NCE	Oct 21, 2024
	>A> 10081621	Mar 25, 2031	DP U-3600		>A> NP	Apr 26, 2026
	>A> 10239867	Apr 09, 2027	DS DP U-3590			
	>A> 10272046	Feb 27, 2033	DP U-3599			
	>A> 10646481	Aug 13, 2029	DP			
	>A> 10758534	Oct 06, 2035	DS DP U-3589			
	>A> 10793547	Dec 08, 2037	DS DP U-3588			
	>A> 11147770	Feb 27, 2033	DP U-3598			
	>A> 11179367	Dec 08, 2037	DP U-3597			
	>A> 11426407	Oct 06, 2035	DS DP U-3595			
	>A> 11453655	Dec 08, 2037	DS DP			
	>A> 11517564	Dec 08, 2037	DP U-3586			
	>A> 11564916	Aug 13, 2029	U-3585			
	>A> 11578062	Mar 25, 2031	DP U-3584			
	>A> 11639347	Apr 09, 2027	DS DP U-3583			
	>A> 7495103	May 20, 2027	DS DP			
	>A> 7645789	May 01, 2027	DS DP			
	>A> 7776905	Jun 03, 2027	DS DP			
	>A> 8324242	Aug 05, 2027	U-3589			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	>A> 8354427	Jul 06, 2026	U-3593			
	>A> 8410274	Dec 28, 2026	DP			
	>A> 8415387	Nov 12, 2027	U-3589			
	>A> 8598181	May 01, 2027	U-3589			
	>A> 8623905	May 01, 2027	DS DP			
	>A> 8629162	Jun 24, 2025	U-3592			
	>A> 8754224	Dec 28, 2026	DS DP			
	>A> 8883206	Feb 27, 2033	DP			
	>A> 9670163	Dec 28, 2026	DP U-3591			
	>A> 9931334	Dec 28, 2026	DP U-3591			
	>A> 9974781	Apr 09, 2027	DP U-3589			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	11564886	Mar 07, 2032	DP U-3531			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	11564886	Mar 07, 2032	DP U-3531			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	11564886	Mar 07, 2032	DP U-3531			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	8501758	Aug 27, 2030	DS DP			
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 001	11571398	May 16, 2040	U-3183			
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 002	11464752	May 16, 2040	DP			
	11571398	May 16, 2040	U-3183			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	11590286	Dec 12, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	11590286	Dec 12, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	11590286	Dec 12, 2026	DP			
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 001	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 002	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 003	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 004	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 005	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVAL</u>						
N 211109 001	11578044	Oct 19, 2037	DS			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVAL</u>						
N 211109 002	11578044	Oct 19, 2037	DS			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001					M-289	Jan 27, 2026
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001					ODE-393 PED	Mar 25, 2029 Sep 25, 2029
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 001	>A> 11633489	Jun 22, 2036			U-3594	
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 002	>A> 11633489	Jun 22, 2036			U-3594	
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 003	>A> 11633489	Jun 22, 2036			U-3594	
<u>FEZOLINETANT - VEOZAH</u>						
N 216578 001	>A> 10836768	Mar 28, 2034			U-3621	
	>A> 8871761	Apr 04, 2031	DS			
	>A> 9422299	Mar 28, 2034	DS DP		U-3622	
	>A> 9987274	Mar 28, 2034			U-3622	
<u>FLOTUFOLASTAT F-18 GALLIUM - POSLUMA</u>						
N 216023 001	>A> 11413360	Nov 22, 2038	DS		U-3614	
	>A> 11413360	Nov 22, 2038	DS		U-3615	
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	>A> 8113199	Oct 23, 2027	DP			
	>A> 8113199*PED	Apr 23, 2028				
	>A> 8161968	Feb 05, 2028	DP			
	>A> 8161968*PED	Aug 05, 2028				
	>A> 8534281	Mar 08, 2030	DP			
	>A> 8534281*PED	Sep 08, 2030				
	>A> 8746242	Oct 11, 2030	DP			
	>A> 8746242*PED	Apr 11, 2031				
	>A> 9333310	Oct 02, 2027	DP			
	>A> 9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	>A> 8113199	Oct 23, 2027	DP			
	>A> 8113199*PED	Apr 23, 2028				
	>A> 8161968	Feb 05, 2028	DP			
	>A> 8161968*PED	Aug 05, 2028				
	>A> 8534281	Mar 08, 2030	DP			
	>A> 8534281*PED	Sep 08, 2030				
	>A> 8746242	Oct 11, 2030	DP			
	>A> 8746242*PED	Apr 11, 2031				
	>A> 9333310	Oct 02, 2027	DP			
	>A> 9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 003	>A> 8113199	Oct 23, 2027	DP		M-290	Mar 01, 2026
	>A> 8113199*PED	Apr 23, 2028				
	>A> 8161968	Feb 05, 2028	DP			
	>A> 8161968*PED	Aug 05, 2028				
	>A> 8534281	Mar 08, 2030	DP			
	>A> 8534281*PED	Sep 08, 2030				
	>A> 8746242	Oct 11, 2030	DP			
	>A> 8746242*PED	Apr 11, 2031				
	>A> 9333310	Oct 02, 2027	DP			
	>A> 9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	>A> 11116721	Feb 26, 2029	DP U-1401		>A> NPP	May 13, 2026
	>A> 11116721	Feb 26, 2029	DP U-1691			
	>A> 11116721*PED	Aug 26, 2029				
	>A> 7439393	May 21, 2025	DS DP U-1401			
	>A> 7439393	May 21, 2025	DS DP U-1691			
	>A> 7439393	May 21, 2025	DS DP U-2099			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	>A> 7439393	May 21, 2025	DS DP U-2100			
	>A> 7439393*PED	Nov 21, 2025				
	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	>A> 8511304	Jun 14, 2027	DP U-1424			
	>A> 8511304	Jun 14, 2027	DP U-1691			
	>A> 8511304*PED	Dec 14, 2027				
	>A> 8534281	Mar 08, 2030	DP			
	>A> 8534281*PED	Sep 08, 2030				
	>A> 8746242	Oct 11, 2030	DP			
	>A> 8746242*PED	Apr 11, 2031				
	>A> 9333310	Oct 02, 2027	DP			
	>A> 9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	>A> 11116721	Feb 26, 2029	DP U-1691			
	>A> 11116721*PED	Aug 26, 2029				
	>A> 7439393	May 21, 2025	DS DP U-1691			
	>A> 7439393	May 21, 2025	DS DP U-2099			
	>A> 7439393	May 21, 2025	DS DP U-2100			
	>A> 7439393*PED	Nov 21, 2025				
	>A> 8113199	Oct 23, 2027	DP			
	>A> 8113199*PED	Apr 23, 2028				
	>A> 8161968	Feb 05, 2028	DP			
	>A> 8161968*PED	Aug 05, 2028				
	>A> 8511304	Jun 14, 2027	DP U-1691			
	>A> 8511304*PED	Dec 14, 2027				
	>A> 8534281	Mar 08, 2030	DP			
	>A> 8534281*PED	Sep 08, 2030				
	>A> 8746242	Oct 11, 2030	DP			
	>A> 8746242*PED	Apr 11, 2031				
	>A> 9333310	Oct 02, 2027	DP			
	>A> 9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 003				>A> NS		May 13, 2026
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	11554229	Feb 23, 2036	U-2133			
	11602603	Oct 27, 2028	DP U-2133			
	8327844	Oct 24, 2023	U-2133			
	8522778	Apr 20, 2024	DP			
<u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u>						
N 214018 001					M-286	Oct 27, 2025
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	11529362	Jun 02, 2037	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	11529362	Jun 02, 2037	DP			
<u>FUTIBATINIB - LYTGOBI</u>						
N 214801 001					ODE-410	Sep 30, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 001	>A> 11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 002	>A> 11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 003	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 004	>A> 11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 005	>A> 11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 006	>A> 11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 007	>A> 11590246	Jan 17, 2040	DP			
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001					ODE-395	Jun 01, 2029
<u>GIVOSIRAN SODIUM - GIVLAARI</u>						
N 212194 001	>A> 9133461	Nov 30, 2033	DS DP U-2672			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 001	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 002	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYOPEN</u>						
N 212097 003	11590205	Apr 22, 2036	DP U-2742			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLUCAGON - GVOKE HYOPEN</u>						
N 212097 004	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE KIT</u>						
N 212097 005 >A>	11590205	Apr 22, 2036	DP U-2742			
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903 001	10456354	Oct 25, 2038	DP			
	11110054	Oct 25, 2038	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 006 >A>	9248229	Mar 12, 2034	DP			
	>A> 9731082	Apr 23, 2032	DP			
<u>IBREXAFUNGERP CITRATE - BREXAFEMME</u>						
N 214900 001	11534433	Jun 10, 2039	U-3159		I-903	Nov 30, 2025
	11534433	Jun 10, 2039	U-3508			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001					ODE-109	Mar 04, 2023
					ODE-117	May 06, 2023
					ODE-128	Jan 18, 2024
					ODE-152	Aug 02, 2024
					ODE-405	Aug 24, 2029
					PED	Jul 18, 2024
					PED	Feb 02, 2025
					PED	Feb 24, 2030
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002					ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Jan 18, 2024
					ODE*	Aug 02, 2024
					ODE-405	Aug 24, 2029
					PED	Feb 24, 2030
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001					ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Jan 18, 2024
					ODE*	Aug 02, 2024
					ODE-405	Aug 24, 2029
					PED	Feb 24, 2030
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002					ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Jan 18, 2024
					ODE*	Aug 02, 2024
					ODE-405	Aug 24, 2029
					PED	Feb 24, 2030
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003					ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Jan 18, 2024
					ODE*	Aug 02, 2024
					ODE-405	Aug 24, 2029
					PED	Feb 24, 2030
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004					ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Jan 18, 2024
					ODE*	Aug 02, 2024
					ODE-405	Aug 24, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	004				PED	Feb 24, 2030
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003	001	10106548	Jun 03, 2033	DS DP	ODE-405	Aug 24, 2029
		10106548*PED	Dec 03, 2033		PED	Feb 24, 2030
		10125140	Jun 03, 2033	DS DP		
		10125140*PED	Dec 03, 2033			
		10478439	Jun 03, 2031		U-3422	
		10478439*PED	Dec 03, 2031			
		10961251	Jun 03, 2033	DP		
		10961251*PED	Dec 03, 2033			
		7514444	Dec 28, 2026	DS DP		
		7514444*PED	Jun 28, 2027			
		8008309	Nov 13, 2027	DS DP		
		8008309*PED	May 13, 2028			
		8497277	Dec 28, 2026		U-3422	
		8497277*PED	Jun 28, 2027			
		8697711	Dec 28, 2026	DS DP		
		8697711*PED	Jun 28, 2027			
		8735403	Dec 28, 2026	DS DP		
		8735403*PED	Jun 28, 2027			
		8754091	Dec 28, 2026	DP		
		8754091*PED	Jun 28, 2027			
		8957079	Dec 28, 2026	DS DP		
		8957079*PED	Jun 28, 2027			
		9181257	Dec 28, 2026	DS		
		9181257*PED	Jun 28, 2027			
		9296753	Oct 30, 2033	DS		
		9296753*PED	Apr 30, 2034			
		9725455	Jun 03, 2033	DS		
		9725455*PED	Dec 03, 2033			
		9795604	Oct 24, 2034		U-3422	
		9795604*PED	Apr 24, 2035			
<u>IVACAFTOR - KALYDECO</u>						
N 203188	001	11564916	Aug 13, 2029		U-3530	
<u>IVACAFTOR - KALYDECO</u>						
N 207925	001	11564916	Aug 13, 2029		U-3528	
<u>IVACAFTOR - KALYDECO</u>						
N 207925	002	11564916	Aug 13, 2029		U-3528	
<u>IVACAFTOR - KALYDECO</u>						
N 207925	003	11564916	Aug 13, 2029		U-3528	
<u>IVACAFTOR - KALYDECO</u>						
N 207925	004	>A> 10272046	Feb 27, 2033	DP	U-3605	
		>A> 10646481	Aug 13, 2029	DP		
		>A> 11147770	Feb 27, 2033	DP	U-3604	
		>A> 11564916	Aug 13, 2029		U-3603	
		>A> 7495103	May 20, 2027	DS DP		
		>A> 8324242	Aug 05, 2027		U-3609	
		>A> 8354427	Jul 06, 2026		U-3608	
		>A> 8410274	Dec 28, 2026	DP		
		>A> 8629162	Jun 24, 2025		U-3607	
		>A> 8754224	Dec 28, 2026	DS DP		
		>A> 8883206	Feb 27, 2033	DP		
		>A> 9670163	Dec 28, 2026	DP	U-3606	
<u>IVACAFTOR - KALYDECO</u>						
N 207925	005	>A> 10272046	Feb 27, 2033	DP	U-3605	
		>A> 10646481	Aug 13, 2029	DP		
		>A> 11147770	Feb 27, 2033	DP	U-3604	
		>A> 11564916	Aug 13, 2029		U-3603	
		>A> 7495103	May 20, 2027	DS DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 005	>A> 8324242	Aug 05, 2027	U-3609			
	>A> 8354427	Jul 06, 2026	U-3608			
	>A> 8410274	Dec 28, 2026	DP			
	>A> 8629162	Jun 24, 2025	U-3607			
	>A> 8754224	Dec 28, 2026	DS DP			
	>A> 8883206	Feb 27, 2033	DP			
	>A> 9670163	Dec 28, 2026	DP U-3606			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	11564916	Aug 13, 2029	U-3527			
	11578062	Mar 25, 2031	DP U-3545			
	>A> 11639347	Apr 09, 2027	DS DP U-2569			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	11564916	Aug 13, 2029	U-3527			
	11578062	Mar 25, 2031	DP U-3545			
	>A> 11639347	Apr 09, 2027	DS DP U-2569			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	11564916	Aug 13, 2029	U-3529			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	11564916	Aug 13, 2029	U-3529			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	11191766	Apr 04, 2037	U-2471			
	11484535	Apr 04, 2037	U-2470			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	7423050	Mar 27, 2024	DS DP U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	7423050	Mar 27, 2024	DS DP U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 003	7423050	Mar 27, 2024	DS DP U-1719			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	11618748	Jan 27, 2030	U-1524			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001					ODE*	Aug 28, 2026
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 002					ODE*	Apr 07, 2024
					ODE*	Aug 28, 2026
					PED	Oct 07, 2024
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 001					>A> M-293	Apr 20, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028	002				>A> M-293	Apr 20, 2026
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215973	001	10071985	Aug 17, 2037	DS DP	NCE	Dec 22, 2027
		10654827	Aug 17, 2037	U-3507		
		11267799	Aug 16, 2038	DS		
		9951043	Feb 28, 2034	DS DP U-3507		
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215974	001	10071985	Aug 17, 2037	DS DP	NCE	Dec 22, 2027
		10654827	Aug 17, 2037	U-3507		
		11267799	Aug 16, 2038	DS		
		9951043	Feb 28, 2034	DS DP U-3507		
<u>LENIOLISIB PHOSPHATE - JOENJA</u>						
N 217759	001	8653092	Feb 19, 2032	DS DP	NCE ODE-430	Mar 24, 2028 Mar 24, 2030
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947	001	11090386	Feb 23, 2036	U-3519		
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947	002	11090386	Feb 23, 2036	U-3519		
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED KIT</u>						
N 020263	009	>A> 8921326	Feb 05, 2031	DP	>A> NS	Apr 14, 2026
		>A> 9617303	Mar 22, 2028	U-3611		
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133	001				ODE-385	Dec 30, 2028
<u>LEVOLEUCOVORIN - KHAPZORY</u>						
N 211226	001	11541012	Mar 25, 2039	DP		
<u>LEVOLEUCOVORIN - KHAPZORY</u>						
N 211226	002	11541012	Mar 25, 2039	DP		
<u>LEVONORGESTREL - LILETTA</u>						
N 206229	001	11571328	Sep 07, 2040	DP		
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219	001	11534395	Jan 26, 2036	DP U-2764		
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565	001	>A> 11642317	May 03, 2033	DP		
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933	001	11596599	May 03, 2033	U-2985		
		>A> 11642317	May 03, 2033	DP		
<u>LUMASIRAN SODIUM - OXLUMO</u>						
N 214103	001				ODE-415	Oct 06, 2029
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	001	9907794	May 26, 2026	DP		
		9907794*PED	Nov 26, 2026			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	002	9907794	May 26, 2026	DP		
		9907794*PED	Nov 26, 2026			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
<u>MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB</u>						
N 213135 001 >A>	11638697	Aug 04, 2037	DP			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001					NPP ODE-429	Mar 13, 2026 Mar 13, 2030
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001					ODE-388	Nov 23, 2028
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 001					ODE-398	Apr 28, 2029
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 002					ODE-398	Apr 28, 2029
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 003					ODE-398	Apr 28, 2029
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 004					ODE-398	Apr 28, 2029
<u>METHSUXIMIDE - METHSUXIMIDE</u>						
A 217213 001					CGT	Oct 28, 2023
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	11633389	Aug 14, 2033	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	11633389	Aug 14, 2033	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	11633389	Aug 14, 2033	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	11628150	Dec 22, 2029	DP U-2843			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	11612593	May 30, 2038	DS			
	11612594	May 30, 2038	DS			
	>A> 11622962	Mar 17, 2039	DS			
	>A> 11633387	May 30, 2038	DS			
	>A> 11633388	Mar 25, 2039		U-2371		
	>A> 11642334	Feb 20, 2039		U-2371		
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001					ODE-392	Feb 17, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196	002				ODE-392	Feb 17, 2029
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196	003				ODE-392	Feb 17, 2029
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296	001	11590095	Mar 18, 2036	U-1384		
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787	001	11590286	Dec 12, 2026	DP		
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE</u>						
N 208969	001				>A> NP	Mar 07, 2026
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862	001	11590286	Dec 12, 2026	DP		
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045	001	11617713	Aug 26, 2034	DP U-3110		
		11628139	Aug 26, 2034	DP U-3110		
<u>NALOXONE HYDROCHLORIDE - ZIMHI</u>						
N 212854	001	11571518	Jun 14, 2041	DP U-3515		
		11571518	Jun 14, 2041	DP U-3516		
		11571518	Jun 14, 2041	DP U-3517		
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)</u>						
N 215457	001	11590286	Dec 12, 2026	DP		
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254	001	11618748	Jan 27, 2030	U-1524		
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718	001	11559523	Nov 18, 2030	DP U-3522		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734	002	11547758	Apr 18, 2027	U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734	003	11547758	Apr 18, 2027	U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734	004	11547758	Apr 18, 2027	U-1029		
<u>NIMODIPINE - NYMALIZE</u>						
N 203340	002	11517563	Apr 16, 2038	DP	Y	
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832	001	10154990	Jan 08, 2026	U-2620		
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832	002	10154990	Jan 08, 2026	U-2620		
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876	001	>A> 11091459	Mar 27, 2038	DP		
		>A> 8071579	Aug 12, 2027	U-2655		
		>A> 8071623	Mar 27, 2031	DS DP		
		>A> 8143241	Aug 12, 2027	U-2655		
		>A> 8436185	Apr 24, 2029	DS		
		>A> 8859562	Aug 04, 2031	U-2655		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 002	>A> 11091459	Mar 27, 2038	DP			
	>A> 8071579	Aug 12, 2027	U-2655			
	>A> 8071623	Mar 27, 2031	DS DP			
	>A> 8143241	Aug 12, 2027	U-2655			
	>A> 8436185	Apr 24, 2029	DS			
	>A> 8859562	Aug 04, 2031	U-2655			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 003	>A> 11091459	Mar 27, 2038	DP			
	>A> 8071579	Aug 12, 2027	U-2655			
	>A> 8071623	Mar 27, 2031	DS DP			
	>A> 8143241	Aug 12, 2027	U-2655			
	>A> 8436185	Apr 24, 2029	DS			
	>A> 8859562	Aug 04, 2031	U-2655			
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	11511252	Sep 21, 2029	DP			
	11554241	Aug 18, 2025	U-3037			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 001	11602508	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 002	11602508	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 003	11602508	Jan 30, 2038	DP			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	11583539	Nov 12, 2041	U-3186			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	11583539	Nov 12, 2041	U-3186			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	11583539	Nov 12, 2041	U-3186			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	11583539	Nov 12, 2041	U-3186			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	>A> 11633396	Oct 07, 2029	DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	>A> 11633396	Oct 07, 2029	DP			
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001					NCE ODE-413	Dec 01, 2027 Dec 01, 2029
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	7553828	Jun 02, 2024	DS			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	7553828	Jun 02, 2024	DS			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001	11091430	Apr 20, 2029	U-3552		NCE	Feb 28, 2028
	8124799	Dec 03, 2029	DS		ODE-427	Feb 28, 2030
	8440854	Apr 20, 2029	DP			
	8993640	Apr 24, 2033	DS DP			
	9670147	Apr 20, 2029	DS			
	9701709	Apr 24, 2033	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001	11091430	Apr 20, 2029	U-3552		NCE	Feb 28, 2028
	8124799	Dec 03, 2029	DS		ODE-427	Feb 28, 2030
	8440854	Apr 20, 2029	DP			
	8993640	Apr 24, 2033	DS DP			
	9670147	Apr 20, 2029	DS			
	9701709	Apr 24, 2033	DS DP			
<u>OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEF</u>						
N 213593 001 >A>	11633478	Jul 16, 2039	DP			
<u>PACRITINIB CITRATE - VONJO</u>						
N 208712 001					ODE-397	Feb 28, 2029
<u>PAFOLACIANINE SODIUM - CYTALUX</u>						
N 214907 001					I-905 ODE-390	Dec 16, 2025 Nov 29, 2028
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001					M-288	Feb 08, 2026
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	10035822	Nov 15, 2033	DS		NCE	May 14, 2026
	10125171	Aug 02, 2033	DS		NP	Feb 22, 2026
	10875893	Nov 15, 2033	DS U-3540			
	11292815	Nov 15, 2033	DS DP U-3540			
	7888323	Dec 04, 2027	DS			
	7989589	Dec 04, 2027	DS			
	8168584	Apr 07, 2027	U-3540			
	8168584	Apr 07, 2027	U-3542			
	9056076	Oct 25, 2026	U-3540			
	9169307	Nov 18, 2027	DS U-3541			
<u>PEMETREXED DISODIUM - PEMETREXED</u>						
N 215179 001 >A>	11147817	Mar 26, 2035	DP			
<u>PEMETREXED DISODIUM - PEMETREXED</u>						
N 215179 002 >A>	11147817	Mar 26, 2035	DP			
<u>PEMETREXED DISODIUM - PEMETREXED</u>						
N 215179 003 >A>	11147817	Mar 26, 2035	DP			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001 >A>	11628162	Aug 30, 2040	U-3568		ODE-404	Aug 26, 2029
	>A> 11628162	Aug 30, 2040	U-3569			
	>A> 11628162	Aug 30, 2040	U-3570			
	>A> 11628162	Aug 30, 2040	U-3571			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002 >A>	11628162	Aug 30, 2040	U-3568		ODE-404	Aug 26, 2029
	>A> 11628162	Aug 30, 2040	U-3569			
	>A> 11628162	Aug 30, 2040	U-3570			
	>A> 11628162	Aug 30, 2040	U-3571			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003 >A>	11628162	Aug 30, 2040	U-3568		ODE-404	Aug 26, 2029
	>A> 11628162	Aug 30, 2040	U-3569			
	>A> 11628162	Aug 30, 2040	U-3570			
	>A> 11628162	Aug 30, 2040	U-3571			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001 >A>	6949571	Jun 08, 2024	DS DP U-106			
	>A> 6949571	Jun 08, 2024	DS DP U-2088			
	>A> 6949571	Jun 08, 2024	DS DP U-2089			
	>A> 6949571	Jun 08, 2024	DS DP U-2428			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	>A> 6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	>A> 6949571	Jun 08, 2024	DS DP U-106			
	>A> 6949571	Jun 08, 2024	DS DP U-2088			
	>A> 6949571	Jun 08, 2024	DS DP U-2089			
	>A> 6949571	Jun 08, 2024	DS DP U-2428			
	>A> 6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	>A> 6949571	Jun 08, 2024	DS DP U-106			
	>A> 6949571	Jun 08, 2024	DS DP U-2088			
	>A> 6949571	Jun 08, 2024	DS DP U-2089			
	>A> 6949571	Jun 08, 2024	DS DP U-2428			
	>A> 6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	>A> 6949571	Jun 08, 2024	DS DP U-106			
	>A> 6949571	Jun 08, 2024	DS DP U-2088			
	>A> 6949571	Jun 08, 2024	DS DP U-2089			
	>A> 6949571	Jun 08, 2024	DS DP U-2428			
	>A> 6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	>A> 6949571	Jun 08, 2024	DS DP U-106			
	>A> 6949571	Jun 08, 2024	DS DP U-2088			
	>A> 6949571	Jun 08, 2024	DS DP U-2089			
	>A> 6949571	Jun 08, 2024	DS DP U-2428			
	>A> 6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	>A> 6949571	Jun 08, 2024	DS DP U-106			
	>A> 6949571	Jun 08, 2024	DS DP U-2088			
	>A> 6949571	Jun 08, 2024	DS DP U-2089			
	>A> 6949571	Jun 08, 2024	DS DP U-2428			
	>A> 6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	>A> 6949571	Jun 08, 2024	DS DP U-106			
	>A> 6949571	Jun 08, 2024	DS DP U-2088			
	>A> 6949571	Jun 08, 2024	DS DP U-2089			
	>A> 6949571	Jun 08, 2024	DS DP U-2428			
	>A> 6949571	Jun 08, 2024	DS DP U-2429			
<u>PHENOBARBITAL SODIUM - SEZABY</u>						
N 215910 001					ODE-414	Nov 17, 2029
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001	7229630	Jul 31, 2023	DP			
	7575757	Jul 31, 2023	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
A 216496 001					CGT	Jul 17, 2023
<u>PHENYLEPHRINE HYDROCHLORIDE - IMPHENTIV</u>						
N 203826 004	11213480	Sep 26, 2036	DP			
	11471400	Aug 05, 2036	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - IMPHENTIV</u>						
N 203826 005	11213480	Sep 26, 2036	DP			
	11471400	Aug 05, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PILOCARPINE HYDROCHLORIDE - VUITY</u>						
N 214028 001	10610518	Apr 24, 2039	U-3252		D-187	Mar 28, 2026
	10610518	Apr 24, 2039	U-3561			
	10610518	Apr 24, 2039	U-3562			
	11285134	Apr 24, 2039	U-3252			
	11285134	Apr 24, 2039	U-3561			
	11285134	Apr 24, 2039	U-3562			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	10464905	Dec 16, 2036	U-3518		ODE-424	Jan 27, 2030
	10695323	Dec 16, 2036	DS DP U-3518			
	10918622	Dec 16, 2036	U-3518			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	10464905	Dec 16, 2036	U-3518		ODE-424	Jan 27, 2030
	10695323	Dec 16, 2036	DS DP U-3518			
	10918622	Dec 16, 2036	U-3518			
<u>PREDNISOLONE - PREDNISOLONE</u>						
A 215673 001					>A> CGT	Nov 18, 2023
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145 001	8771733	Jun 02, 2030	DS DP U-257			
	8852632	Jan 28, 2028	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145 002	8771733	Jun 02, 2030	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 002	8771733	Jun 02, 2030	DS DP U-257			
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	11583526	Sep 29, 2037	U-3020			
<u>REZAFUNGIN ACETATE - REZZAYO</u>						
N 217417 001	10702573	Mar 14, 2033	DS DP U-3566		NCE	Mar 22, 2028
	11197909	Jul 14, 2038	DS DP U-3566		ODE-426	Mar 22, 2030
	8722619	Mar 02, 2032	DS DP U-3566		GAIN	Mar 22, 2033
	9526835	Mar 14, 2033	DS DP U-3566		GAIN	Mar 22, 2035
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	11564912	Feb 26, 2029	U-3511			
	11564912	Feb 26, 2029	U-3512			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	11529336	Aug 12, 2040	U-3382			
	11534432	Aug 12, 2040	U-3442			
	11576903	Dec 30, 2040	DP			
	11576904	Aug 12, 2040	U-3537			
	11612591	Dec 30, 2040	DP			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001	11534444	Oct 04, 2038	U-1943		ODE-400	May 27, 2029
<u>RISPERIDONE - RYKINDO</u>						
N 212849 001	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RYKINDO</u>						
N 212849 002	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
<u>RISPERIDONE - RYKINDO</u>						
N 212849 003	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
<u>RISPERIDONE - RYKINDO</u>						
N 212849 004	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
<u>RISPERIDONE - UZEDY</u>						
N 213586 001	10736965	Jan 12, 2025	DP			
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
>A>	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
<u>RISPERIDONE - UZEDY</u>						
N 213586 002	10736965	Jan 12, 2025	DP			
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
>A>	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
<u>RISPERIDONE - UZEDY</u>						
N 213586 003	10736965	Jan 12, 2025	DP			
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
>A>	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
<u>RISPERIDONE - UZEDY</u>						
N 213586 004	10736965	Jan 12, 2025	DP			
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
>A>	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - UZEDY</u>						
N 213586 005	10736965	Jan 12, 2025	DP			
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
>A>	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
<u>RISPERIDONE - UZEDY</u>						
N 213586 006	10736965	Jan 12, 2025	DP			
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
>A>	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
<u>RISPERIDONE - UZEDY</u>						
N 213586 007	10736965	Jan 12, 2025	DP			
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
>A>	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	11510923	Sep 04, 2040	U-3505			
	11571425	May 20, 2031	DP			
	11590136	May 20, 2031	U-3229			
	11590136	May 20, 2031	U-3404			
	11590137	Sep 04, 2040	U-3505			
	11590138	Jun 10, 2040	U-3551			
	11602536	May 05, 2041	U-3550			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	11602522	Sep 04, 2035	DP U-3169			
	11602522	Sep 04, 2035	DP U-3302			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMO</u>						
N 213246	001				ODE-409 ODE-412	Sep 21, 2029 Sep 21, 2029
<u>SELPERCATINIB - RETEVMO</u>						
N 213246	002				ODE-409 ODE-412	Sep 21, 2029 Sep 21, 2029
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756	001	7425637	Mar 13, 2024	DS		
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756	002	7425637	Mar 13, 2024	DS		
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256	001				NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256	002				NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256	003				NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256	004				NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256	005				NPP	Dec 23, 2025
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793	001				ODE-402	Jun 16, 2029
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845	001				M-287	Jan 31, 2026
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473	001				M-287	Jan 31, 2026
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109	001				M-287	Jan 31, 2026
<u>SILDENAFIL CITRATE - LIOREV</u>						
N 214952	001	>A> 11337979	Dec 24, 2038	DP U-3582		
		>A> 11464778	Dec 24, 2038	DP U-3582		
<u>SIROLIMUS - FYARRO</u>						
N 213312	001				ODE-386	Nov 22, 2028
<u>SIROLIMUS - HYFTOR</u>						
N 213478	001				ODE-391	Mar 22, 2029
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755	001	>A> 10272062	Jul 21, 2037	DP	>A> NP	May 01, 2026
		>A> 10736866	Jul 21, 2037	DP	ODE-431	May 01, 2030
		>A> 10925844	Feb 28, 2040	DP		
		>A> 10952986	Jul 21, 2037	U-3601		
		>A> 10973795	Jul 21, 2037	DP		
		>A> 11000498	Jul 21, 2037	DP U-3580		
		>A> 11052061	Jul 21, 2037	DP		
		>A> 11065224	Jul 21, 2037	DP		
		>A> 11400065	Jul 21, 2037	U-3579		
		>A> 11504347	Jul 21, 2037	DP		
		>A> 11583510	Feb 07, 2042	U-3578		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	>A> 11602512	Jul 21, 2037	U-3577			
	>A> 11602513	Jul 21, 2037	U-3576			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	>A> 10272062	Jul 21, 2037	DP		>A> NP	May 01, 2026
	>A> 10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	>A> 10925844	Feb 28, 2040	DP			
	>A> 10952986	Jul 21, 2037	U-3601			
	>A> 10973795	Jul 21, 2037	DP			
	>A> 11000498	Jul 21, 2037	DP U-3580			
	>A> 11052061	Jul 21, 2037	DP			
	>A> 11065224	Jul 21, 2037	DP			
	>A> 11400065	Jul 21, 2037	U-3579			
	>A> 11504347	Jul 21, 2037	DP			
	>A> 11583510	Feb 07, 2042	U-3578			
	>A> 11602512	Jul 21, 2037	U-3577			
	>A> 11602513	Jul 21, 2037	U-3576			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	>A> 10272062	Jul 21, 2037	DP		>A> NP	May 01, 2026
	>A> 10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	>A> 10925844	Feb 28, 2040	DP			
	>A> 10952986	Jul 21, 2037	U-3601			
	>A> 10973795	Jul 21, 2037	DP			
	>A> 11000498	Jul 21, 2037	DP U-3580			
	>A> 11052061	Jul 21, 2037	DP			
	>A> 11065224	Jul 21, 2037	DP			
	>A> 11400065	Jul 21, 2037	U-3579			
	>A> 11504347	Jul 21, 2037	DP			
	>A> 11583510	Feb 07, 2042	U-3578			
	>A> 11602512	Jul 21, 2037	U-3577			
	>A> 11602513	Jul 21, 2037	U-3576			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	>A> 10272062	Jul 21, 2037	DP		>A> NP	May 01, 2026
	>A> 10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	>A> 10925844	Feb 28, 2040	DP			
	>A> 10952986	Jul 21, 2037	U-3601			
	>A> 10973795	Jul 21, 2037	DP			
	>A> 11000498	Jul 21, 2037	DP U-3580			
	>A> 11052061	Jul 21, 2037	DP			
	>A> 11065224	Jul 21, 2037	DP			
	>A> 11400065	Jul 21, 2037	U-3579			
	>A> 11504347	Jul 21, 2037	DP			
	>A> 11583510	Feb 07, 2042	U-3578			
	>A> 11602512	Jul 21, 2037	U-3577			
	>A> 11602513	Jul 21, 2037	U-3576			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 001	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 002	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 003	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 004	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 004	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 005	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 006	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE; TAURURSODIOL - RELYVRIO</u>						
N 216660 001	11583542	Jul 27, 2040	DP		ODE-411	Sep 29, 2029
<u>SODIUM THIOSULFATE - PEDMARK</u>						
N 212937 001	11617793	Jul 01, 2039	DP		ODE-384	Sep 20, 2029
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	11160779	Mar 19, 2040	U-3521			
	11439597	Sep 05, 2037	DP			
	11560354	Mar 06, 2039	DP U-3520			
	>A> 11648232	Jun 01, 2038	U-3602			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11160779	Mar 19, 2040	U-3521			
	11439597	Sep 05, 2037	DP			
	11560354	Mar 06, 2039	DP U-3520			
	>A> 11648232	Jun 01, 2038	U-3602			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	10512620	Aug 18, 2038	U-2769			
	10512620	Aug 18, 2038	U-3547			
	10799138	Apr 05, 2039	U-3125			
	10799138	Apr 05, 2039	U-3549			
	11583216	Aug 21, 2039	U-3549			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001 >A>	11426404	Sep 15, 2040	U-3306			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 002	10519146	May 21, 2038	DS DP		NCE	May 28, 2026
	11236091	May 20, 2040	DS DP U-3306		ODE-352	May 28, 2028
	>A> 11426404	Sep 15, 2040	U-3306			
<u>SPARSENTAN - FILSPARI</u>						
N 216403 001	9993461	Mar 29, 2030	U-3269		NCE	Feb 17, 2028
					ODE-389	Feb 17, 2030
<u>SPARSENTAN - FILSPARI</u>						
N 216403 002	9993461	Mar 29, 2030	U-3269		NCE	Feb 17, 2028
					ODE-389	Feb 17, 2030
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 001					ODE-403	Jul 14, 2029
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 002					ODE-403	Jul 14, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223	001				ODE-403	Jul 14, 2029
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223	002				ODE-403	Jul 14, 2029
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225	001				M-291	Jan 22, 2024
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225	002				M-291	Jan 22, 2024
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099	001	>A> 11571531	Feb 23, 2026		U-1809	
<u>TAPINAROF - VTAMA</u>						
N 215272	001	11590088	Nov 13, 2039		U-2625	
		11597692	Nov 13, 2038	DS DP		
		11612573	May 19, 2036		U-2625	
		11617724	May 19, 2036	DP		
		11622945	May 19, 2036	DP		
<u>TASIMELTEON - HETLIOZ</u>						
N 205677	001	11566011	Feb 12, 2035	DS DP		
		11633377	Jan 25, 2033		U-2149	
		11633377	Jan 25, 2033		U-3003	
<u>TASIMELTEON - HETLIOZ LQ</u>						
N 214517	001	11566011	Feb 12, 2035	DS DP		
		11633377	Jan 25, 2033		U-3003	
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723	001	8410088	Jan 23, 2034	DS DP		
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209549	001				PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209549	002				PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209601	001				PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209601	002				PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209613	001				PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209613	002				PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209638	001				PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209638	002				PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209663	001				PC	Sep 08, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209663 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209668 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209668 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209690 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209690 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209700 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209700 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209710 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209710 002					PC	Sep 08, 2023
<u>TERLIPRESSIN ACETATE - TERLIVAZ</u> N 022231 001					ODE-406	Sep 14, 2029
<u>TESTOSTERONE CYPIONATE - TESTOSTERONE CYPIONATE</u> N 216318 001 >A> 11642355		Mar 25, 2039	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u> N 206089 001 11564933		Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u> N 206089 002 11564933		Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u> N 206089 003 11564933		Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - TLANDO</u> N 208088 001 11559530		Nov 28, 2037	U-1500			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u> N 213953 001 >A> 11590146 >A> 11617758		Dec 31, 2030 Mar 15, 2033	DP DP U-2506			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u> N 213953 002 >A> 11590146 >A> 11617758		Dec 31, 2030 Mar 15, 2033	DP DP U-2506			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u> N 213953 003 >A> 11590146 >A> 11617758		Dec 31, 2030 Mar 15, 2033	DP DP U-2506			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u> N 212904 001 6821987		Apr 26, 2024	DS DP U-3100			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2024	DS DP U-3100			
<u>TOFERSEN - QALSODY</u>						
N 215887 001	>A> 10385341	Apr 01, 2035	DS DP		>A> NCE	Apr 25, 2028
	>A> 10669546	Apr 01, 2035		U-3575	>A> ODE-432	Apr 25, 2030
	>A> 10968453	Apr 01, 2035		U-3575		
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	11633374	Aug 21, 2040	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	10869869	Aug 30, 2033		U-3184	I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032		DP	ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025		U-1581		
	8835443	Jun 10, 2025		U-1582		
	8835443	Jun 10, 2025		U-2020		
	8835443	Jun 10, 2025		U-2037		
	8835443	Jun 10, 2025		U-2302		
	8835443	Jun 10, 2025		U-2305		
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030		U-2020		
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032		DP		
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032		DP		
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032		DP		
	9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	10869869	Aug 30, 2033		U-3184	I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032		DP	ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025		U-1581		
	8835443	Jun 10, 2025		U-1582		
	8835443	Jun 10, 2025		U-2020		
	8835443	Jun 10, 2025		U-2037		
	8835443	Jun 10, 2025		U-2302		
	8835443	Jun 10, 2025		U-2305		
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030		U-2020		
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032		DP		
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032		DP		
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032		DP		
	9399021*PED	Jul 28, 2032				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 217513 001	7378423	May 29, 2027	DS DP		NP	Mar 16, 2026
	>A> 8703781	Oct 15, 2030	DS DP U-3564		ODE-428	Mar 16, 2030
	8835443	Jun 10, 2025	U-3564			
<u>TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR</u>						
N 215760 001					ODE-401	Apr 28, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRIFAROTENE - AKLIEE</u>						
N 211527 001 >A>	7807708	Jul 19, 2031	DS DP			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	11529352	Jul 23, 2039	U-3504			
<u>TROFINETIDE - DAYBUE</u>						
N 217026 001	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	9212204	Jan 27, 2032	U-3556		ODE-425	Mar 10, 2030
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11207324	Apr 27, 2038	U-3510		I-906	Jan 19, 2026
					ODE-422	Jan 19, 2030
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324	Apr 27, 2038	U-3510		I-906	Jan 19, 2026
					ODE-422	Jan 19, 2030
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	11524964	Oct 17, 2036	U-3371			
	11535624	Oct 17, 2036	U-3255			
	11535625	Oct 17, 2036	U-3298			
	11607411	Mar 09, 2038	U-3341			
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	11535626	Oct 17, 2036	U-3298			
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	11607411	Mar 09, 2038	U-3341			
<u>VANCOMYCIN - VANCOMYCIN</u>						
N 213895 001	11517609	Nov 06, 2035	U-282			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001	11638692	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002	11638692	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 005	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 006	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 007	11628200	Nov 06, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 006	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	11590128	Sep 06, 2033	U-3548			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	11590128	Sep 06, 2033	U-3548			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	11590128	Sep 06, 2033	U-3548			
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	11622991	Dec 07, 2037	U-3056			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001					ODE-387	Nov 19, 2028
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002					ODE-387	Nov 19, 2028
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003					ODE-387	Nov 19, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001					ODE-394	Dec 17, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002					ODE-394	Dec 17, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001					ODE-394	Dec 17, 2028
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001					ODE-212	Jun 13, 2029
<u>XENON XE-129 HYPERPOLARIZED - XENOVIEW</u>						
N 214375 001	10583205	Feb 20, 2035	DP		NCE	Dec 23, 2027
	11052161	Dec 29, 2035	DP			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-817	Jan 19, 2026
	10570139	Apr 22, 2034	U-2145		ODE-274	Jan 19, 2030
	10570139	Apr 22, 2034	U-2537			
	10570139	Apr 22, 2034	U-2666			
	10570139	Apr 22, 2034	U-3063			
	10570139	Apr 22, 2034	U-3486			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11591340	Aug 15, 2037	U-1745			
	11591340	Aug 15, 2037	U-2145			
	11591340	Aug 15, 2037	U-2537			
	11591340	Aug 15, 2037	U-2666			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	11591340	Aug 15, 2037	U-3063			
	11591340	Aug 15, 2037	U-3486			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
<u>ZAVEGEPANT HYDROCHLORIDE - ZAVZPRET</u>						
N 216386 001	7220862	Jan 21, 2024	DS DP		NCE	Mar 09, 2028
	7314883	Dec 05, 2023	U-3555			
	8481546	Oct 07, 2031	DS DP U-3555			
<u>ZINC SULFATE - ZINC SULFATE</u>						
A 216145 001					CGT	Aug 14, 2023

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 43rd Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm